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Stellingen 
1. Op basis van de hoge homologie tussen prokaryote pyruvaat dehydrogenases (Elp) uit 
pyruvaat dehydrogenase multienzym complex kan geextrapoleerd worden dat prokaryoot 
Elp bindt aan de centrale component (E2p) via een N-terminaal bindingsdomein. 
Dit proefschrift 
2. Op basis van de voorgestelde wijze van binding voor heterotetrameer Elb zijn er zeer 
grote verschillen tussen de wijze van binding van El aan kubisch E2 (homodimeren aan 
een 24-meer) en aan dodecaedrisch E2 (heterotetrameren aan een 60-meer), de 
voorgestelde wijze van binding van heterotetrameer El behoeft echter meer experimentele 
ondersteuning. 
Dit proefschrift & Mvarsson, A., Seger, K., Turley, S., Sokatch, JR. and Hoi, W.G.J.: Crystal structure of 2-
oxoisovalerate and dehydrogenase and the architecture of2-oxo acid dehydrogenase multienzyme 
complexes (1999) Nat. Struct. Biol. 6, 785-792 
3. De overgang van enzymologie naar farmacologie is vooral moeilijk omdat er in 
verschillende "talen" over dezelfde zaken wordt gediscussieerd. 
4. Eiwit homologie modelling zonder experimentele validatie is niet meer dan speculeren 
over de structuur van een eiwit. Om deze reden zou er altijd een nauwe samenwerking 
moeten zijn tussen theoretici en experimentele biochemici / biofysici. 
5. Alhoewel het ophelderen van de structuur van rhodopsine een enorme bijdrage heeft 
geleverd aan inzicht in het mechanisme van G-eiwit gekoppelde receptoren moet 
voorzichtigheid in acht worden genomen bij het extrapoleren van deze structuur naar 
andere G-eiwit gekoppelde receptoren. 
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, J., Teller, D. 
C, Okada, T., Stenkamp, R. E., Yamamoto, M., Miyano, M.: Crystal Structure of Rhodopsin: A G Protein-
Coupled Receptor (2000) Science 289, 739 
6. Het beter om in een goed milieu te leven dan om uit een goed milieu te komen. 
7. Omdat het krijgen van een kind altijd slecht uitkomt binnen een wetenschappelijke 
carriere, is dit geen reden om het krijgen van kinderen uit te stellen. 
8. Elke plant is een waterplant. 
Stellingen behorende bij het proefschrift 
'Pyruvate dehydrogenase. Its structure, function and interactions within the pyruvate 
dehydrogenase multienzyme complex.' 
Annechien F. Hengeveld 
Wageningen, 24 april 2002 
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Abbreviations and symbols 
AD Alzheimer's disease 
ADHC Acetoin dehydrogenase complex 
BCAA Branched-chain amino acid 
BCDC Branched-chain oxoacid dehydrogenase complex 
BCKA Branched- chain a-ketoacid 
CAT Chloramphenicol acetyltransferase 
Cblnd 2,6-dichlorophenol-indophenol 
El a-ketoacid dehydrogenase component 
Elb Branched-chain a-ketoacid dehydrogenase (EC 1.2.1.25) 
Elo 2-oxoglutarate dehydrogenase (EC 1.2.4.2) 
Elp Pyruvate dehydrogenase (EC 1.2.4.1) 
E2 Dihydrolipoyl acyltransferase component 
E2p Dihydrolipoyl transacetylase (EC 2.3.1.12) 
E3 Dihydrolipoamide dehydrogenase component (EC 1.8.1.4) 
E3BP E3 binding protein (protein X) 
GDHC Glycine dehydrogenase complex 
LS Leigh's syndrome 
MP-8 Microperoxidase 8 
MSUD Maple Syrup Urine Disease 
NOE Nuclear Overhauser effect 
Nterm-Elp Peptide representing amino acid 4 to 45 of Elp from Azotobacter vinelandii 
OGDC Oxoglutarate dehydrogenase complex 
PDC Pyruvate decarboxylase 
PDHC Pyruvate dehydrogenase multienzyme complex 
PFOR Pyruvate ferredoxin oxidoreductase 
POX Pyruvate dehydrogenase 
ThDP Thiamin diphosphate 
TK transketolase 
TPPI time proportional phase incrementation 
1 Introduction 
Pyruvate dehydrogenase multi-enzyme complex (PDHC) is member of a family of multi-
enzyme complexes that catalyse the irreversible decarboxylation of various 2-oxoacid 
substrates to their corresponding acyl-CoA derivatives, NADH and CO2. PDHC, like the other 
members of this family, consists of an assembly of non-covalently attached proteins that 
catalyse successive steps in a reaction sequence. The combined catalytic activity of the 
enzymes in the assembly is greatly enhanced through the coupling of the successive reactions 
of the complex. Covalent attachment of reaction intermediates forces them to complete the 
reaction sequence and prevents "scavenging" by competing enzymes. Additionally, active site 
coupling and substrate channelling limit the diffusion of the substrates and degradation of 
unstable reaction intermediates. The coupling of the successive reaction steps finally results in 
a very effective regulation of the overall reaction sequence that can occur on all participating 
enzymes [Reed, 1974; Hammes, 1981]. 
2-oxoacid dehydrogenase complexes hold key points in primary energy metabolism (figure 1): 
PDHC at the branch-point of glycolysis and citric acid cycle, the oxoglutarate dehydrogenase 
complex (OGDC) in the citric acid cycle, the branched-chain oxoacid dehydrogenase complex 
(BCDC) in amino acid catabolism, the glycine dehydrogenase complex (GDHC) in the glycine 
cleavage system and in the photosynthetic carbon cycle and acetoin dehydrogenase complex 
(ADHC) in acetoin metabolism. Malfunctioning of any of these complexes in man leads to a 
broad variety of clinical manifestations [Wynn et al., 1996; Indo & Matsuda, 1996; Kerr et al., 
1996; Danner & McKean, 1996; Chuang & Shih 1995; Robinson, 1995; Kerr & Zinn 1995; 
Dahl, 1995; Patel & Harris 1995; Roche & Patel, 1989; Kish, 1997; Mizuno et al., 1994]. 
Consequently, there is a broad interest in the functioning of these complexes on a molecular 
level. This thesis describes the studies on the pyruvate dehydrogenase (Elp) component of the 
PDHC from Azotobacter vinelandii, a gram-negative bacterium. PDHC from Azotobacter 
vinelandii is of special interest as it is the smallest and simplest know 2-oxoacid 
dehydrogenase. Consequently, in this introduction I will mainly focus on the structure and 
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Figure 1. Metabolic location of 2-oxoacid dehydrogenase complexes [Olson, 1989]. 
function of PDHC from gram-negative bacteria. The functioning and dysfunctioning of human 
2-oxoacid dehydrogenase multi-enzyme complexes and their involvement in metabolic 
disease is reviewed in chapter 7. 
Reaction mechanism and architecture 
Five 2-oxoacid dehydrogenase complexes are found in gram-negative bacteria: PDHC, 
OGDC, BCDC, GDHC and ADHC. All, except GDHC [Douce et al., 2001], share a common 
architecture. The complexes consist of multiple copies of three enzymes: 2-oxoacid 
dehydrogenase or El-component, dihydrolipoyl acyltransferase (E2) and dihydrolipoamide 
dehydrogenase (E3). Mammalian and yeast PDHC contain a so-called E3-binding protein 
(E3BP, formerly called protein X) [de Marcucci & Lindsay, 1985; Lawson et al., 1991; 
Neagle & Lindsay, 1991] that is involved in the binding of E3 to the complex. Eukaryotic 
PDHC and BCDC in addition, contain specific regulatory proteins (El-kinase and El 
phosphatase) [Linn et al., 1969; Patel & Roche, 1990]. E2 forms the central core of the 
complex with either octahedral (24 subunits) or icosahedral (60 subunits) symmetry. Multiple 
Introduction 
copies of the peripheral components El and E3 are non-covalently attached to this core. The 
resulting multi-enzyme complexes are of such an enormous size (-5-14 MDa) that complexes 
R-C-COOH 
El 
PDHC: R=CH3 
OGDC: R = HOOC-CHz-CHz 
BCDC: R = CHrCH-CHj 
CH, 
Figure 2. Reaction mechanism of 2-
oxoacid dehydrogenase complexes. A 2-
oxo acid dehydrogenase (Elp, Elb or 
Elo) uses thiamin diphosphate (ThDP) 
to carry out the oxidative 
decarboxylation of the substrate, forming 
an acylated lipoic acid, covalently 
attached to the acyltransferase 
component (E2p, E2b or E2o) and C02. 
The E2-component catalyses the transfer 
of the acyl group to coenzyme A (CoA). 
The resulting dihydrolipoyl group is then 
reoxidised by the dihydrolipoamide 
dehydrogenase component (E3) using 
NAD+, forming NADH. 
of octahedral and of icosahedral symmetry can be distinguished by electron microscopy 
[Oliver & reed, 1982]. As an exception, the E2p core (the subscript "p" denotes the origin of 
the E2 component: "p" for PDHC, "o" for OGDC and "b" for BCDC) of Azotobacter 
vinelandii dissociates into trimers upon binding of the peripheral Elp or E3 component, 
resulting in a complex of only 700 kDa [Schulze et al., 1991]. The same phenomenon occurs 
as a result of the expression of the Escherichia coli E2o catalytic domain with a C-terminal 
(his)^ tag [Knapp et al., 2000]. The C-terminus of the trimeric form is rotated 37° compared to 
the cubic form, disrupting the two-fold interface. No effects however were observed in the 
active site. 
PDHC irreversibly catalyses the oxidative decarboxylation of pyruvate, generating acetyl-
CoA, NADH and CO2 (figure 2). In this reaction three prosthetic groups (thiamin 
diphosphate, lipoic acid and flavin adenine dinucleotide) and two cofactors (CoA and NAD ) 
are involved. Elp utilises thiamin diphosphate (ThDP) to catalyse the oxidative 
decarboxylation of pyruvate and to subsequently reductively acetylate the lipoic acid that is 
attached to E2p. This lipoic acid, which is covalently attached to a lysine on E2p forming the 
Chapter 1 
•fr 
E2: 
E3BP: 
K + P E1orE1+E3 
• f r 
•£ 
E3 
Catalytic domain 
L J 
Lipoyl domain 
L J L J 
Lipoyl domain Binding domain C-terminal domain 
Figure 3. The domain structure of E2. The separately folding domains are connected by flexible 
linker sequences shown in wavy lines. An asterisk indicates the lipoic acid that is covalently 
attached to the lipoyl domain. 
lipoyl-group, is involved in all three steps of the reaction mechanism and visits the active sites 
of all three enzymes. E2p catalyses the transfer of the acetyl group from the lipoyl group to 
CoA, forming and releasing acetyl CoA. Finally, the reduced lipoyl group is reoxidised by E3 
utilising flavin adenine dinucleotide (FAD) and transferring the reduction equivalents to 
NAD , forming NADH. Unlike eukaryotic PDHC gram-negative PDHC does not contain 
additional regulatory enzymes, but is regulated via allosteric mechanisms. 
The acyltransferase component (E2) and dihydrolipoamide dehydrogenase (E3) 
This introduction mainly focuses on the El component of 2-oxoacid dehydrogenase 
complexes. For a better understanding however, the most important features of the other 
components of the complex will be discussed in this section [for reviews see Perham, 1991; 
Mattevi et al., 1992a; Berg & de Kok, 1997; de Kok et al., 1998; Perham, 2001]. 
Limited proteolysis studies revealed that E2 has a multi-domain structure that contains three 
independent folding units that are separated by linker sequences of about 20-50 amino acids 
(Figure 3) [Bleile et al., 1979; Bleile et al., 1981; Packman et al., 1984a; Packman et al., 
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1984b; Packman & Perham, 1987; Chuang, 1985; Hanemaaijer et al., 1987]. From N- to C-
terminus it contains two or three lipoyl domains (dependent on the type and source of the 
complex), an E1/E3 binding domain and a catalytic domain. NMR experiments indicate that 
the linker sequences are extended and highly flexible [Perham et al., 1981; Duckworth et al., 
1982; Hanemaaijer et al., 1988; Texter et al., 1988]. This flexibility is essential for the 
mechanism of active site coupling, by which the substrate, covalently attached to the lipoyl 
domain, is transferred between the active sites of El, E2 and E3 (figure 2) [Miles et al., 1988; 
Turner et al., 1993; Schulze et al., 1993]. 
The role of the lipoyl domain and its role in active site coupling was extensively reviewed 
recently by [Berg & de Kok, 1997] and [Perham, 2000]. 3-dimensional structures of lipoyl 
domains of several sources have been solved [Dardel et al., 1993; Green et al., 1995; Berg et 
al., 1996; Berg et al., 1997; Ricaud et al., 1996]. All show a very similar overall fold: two 
four-stranded P-sheets packed in a sandwich like manner. A conserved lysine residue is 
exposed in a P-turn at the far end of the domain. A lipoic acid prosthetic group is attached to 
this residue. An exposed loop close to the lipoylated lysine residue was shown to be involved 
in the species specific recognition of El, it has become clear however, that recognition of the 
lipoyl domain by its partner El is a complex process and can not be attributed to a single 
determinant on the lipoyl domain [Jones et al., 2000; Jones et al., 2001; Howard et al., 2000; 
Gong etal., 2000]. 
The peripheral E1/E3 binding domain (-35 amino acid residues) is one of the smallest 
proteins that has a stable globular fold in the absence of disulphide bridges or prosthetic 
groups [Brocklehurst et al., 1994]. The structure of the binding domain of E. coli E2o and 
Bacillus stearothermophilus E2p were solved by NMR [Robien et al., 1992; Kalia et al., 
1993] and additionally, the structure of the binding domain of B. stearothermophilus E2p in 
complex with E3 was solved by X-ray crystallography [Mande et al., 1996]. In accord with the 
substantial sequence homology for the binding domains of different complex type and of 
different sources, the solved structures of the binding domain were very similar. The global 
fold comprises two parallel a-helices, separated by a short loop, a short helix and a longer 
disordered loop. 
The C-terminal catalytic domain of E2 harbours the acyltransferase active site and in addition 
the sites responsible for the formation of the octahedral or icosahedral core. Crystal structures 
are now at hand for both the 24-meric cubic structure and the 60-meric dodecahedral structure 
[Mattevi et al., 1992; 1993a; 1993b; Knapp et al., 1998; Izard et al., 1999]. Both have a 
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hollow interior and contain large pores at their faces. Trimeric E2-units form the building 
blocks of these aggregates, with extensive and strong interactions. The inter-trimer 
interactions are much weaker. The active site of E2 is located at each interface of 2 E2-
subunits in a trimer; a 3 nm long channel is formed, with two entrances. Lipoamide enters this 
channel from the outside, whereas CoA enters from the inside of the hollow core. A conserved 
histidine and serine/threonine residue are involved in the reaction mechanism, as was shown 
by extensive mutagenesis/X-ray crystallography studies [Mattevi et al., 1993c; Hendle et al., 
1995]. More extensive reviews on E2 can be read in [de Kok et al., 1998; Berg & de Kok, 
1997; Perham 1991]. 
E3 is an FAD-linked homodimer that reoxidises the reduced lipoamide, forming NADH 
[Williams, 1992]. Several 3D structures have been solved by X-ray crystallography [Mattevi 
et al., 1991; 1992b; 1993b; de la Sierra et al., 1997]. The two identical subunits of E3 are 
composed of four distinct domains: an FAD binding domain, an NAD binding domain, a 
central domain and an interface domain. The catalytic side of the enzyme is located at the 
dimer interface. The catalytic mechanism of E3 has been extensively investigated: the final 
production of NADH involves the transfer of reducing equivalents from the E2-linked 
lipoamide via the FAD cofactor and a redox-active cysteine disulphide pair [Hopkins & 
Williams, 1995]. 
The 2-oxoacid dehydrogenase component (El) 
History 
The El component catalyses the rate limiting step in the overall complex reaction; the 
reductive acylation of the lipoyl groups [Cate et al., 1980]. Until quite recently it was by far 
the least characterised component of the complex. This lack of (structural) information was 
largely due to the lack of a stable form of the enzyme: when resolved from the complex, El is 
unstable. At the start of this project only the recombinant expression of two functional 
heterotetrameric El [Wynn et al., 1992b; Lessard & Perham, 1994] had been reported, 
whereas no stable homodimeric El was available. 
In this chapter I will review the structural and functional data that are now at hand for El. To 
put this thesis in its right perspective, the reader should keep in mind however, that most of 
this information has only come available very recently. 
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The El-component exists either as a homodimer (012) or heterotetramer (ct2P2)> depending on 
the type and source of the complex [Perham, 1991]. 2-oxoglutarate dehydrogenase (Elo) and 
pyruvate dehydrogenase (Elp) from gram-negative sources are homodimeric enzymes with 
subunits of-100 kDa. Branched-chain 2-oxoacid dehydrogenase (Elb) and Elp from other 
sources exist as heterotetramers with subunits of -36 kDa and ~ 41 kDa. Exceptional El 
components were found in Z. mobilis (a tetrameric Elp that contains an N-terminal domain in 
its P-subunit) [Neveling et al., 1999] and Alcaligenes eutrophus that possesses two Elp 
components {Hein & Steinbiichel, 1996]. There is strikingly little sequence similarity between 
homodimeric and heterotetrameric El or even between Elo and homodimeric Elp. An 
exception to this is the so-called "Thiamin diphosphate-binding motif, that has so far been 
found in all known thiamin diphosphate (ThDP) dependent enzymes [Hawkins et al., 1989]. 
ThDF'-dependent enzymes 
El is a member of the family of ThDP dependent enzymes. In this paragraph, I will briefly 
describe some of the other members of this family, as much of the mechanistic information on 
El is extrapolated from these enzymes. 
In all ThDP dependent enzymes the diphosphorylated state of thiamin (vitamin Bl) (Figure 4) 
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functions as a cofactor, along with a metal ion such as Mg or Ca , in many reactions where 
a C-C bond adjacent to a carbonyl group is cleaved. The chemical steps that occur during non-
enzymatic ThDP catalysis are well known and have been reviewed in detail [Kluger, 1987; 
Schellenberger, 1998]. With the structural information at an atomic level available for a 
number of ThDP dependent enzymes (pyruvate decarboxylase (PDC) [Dyda et al., 1993], 
pyruvate oxidase (POX) [Muller & Schulz, 1993], transketolase (TK) [Lindqvist et al., 1992] 
and pyruvate ferredoxin oxidoreductase (PFOR) [Chabriere et al., 1999] significant advances 
have been made in the understanding of the enzyme-catalysed mechanism. 
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TK catalyses the transfer of a dihydroxyethyl group between a ketose and an aldose sugar 
phosphate (figure 5) [Sundstrom et al., 1993]. TK is found in the non-oxidative branch of the 
pentose phosphate pathway where it, together with transaldose, creates a link to glycolysis. 
— o o = o o Figure 5. The general 
HO — + x — OH < , HO — + -
) - 0 H „ / ) - 0 H / 
transketolase. 
TK is a homodimer, with subunits of 74 kDa. The determination of the 3D structure of yeast 
TK by X-ray crystallography revealed for the first time the fold of a ThDP dependent enzyme 
and provided the first insights into the structural basis for ThDP binding and catalysis 
[Lindqvist & Schneider, 1993]. TK has three domains: i) a pyrophosphate (pp) binding 
domain, ii) the pyrimidine (pyr) binding domain and iii) the C-terminal domain. ThDP is 
bound at the interface between the pp-domain of one subunit and the pyr-domain of the other 
subunit. Of all ThDP dependent enzymes TK is the most homologous to the homodimeric Elp 
(see also chapter 6 of this thesis). 
POX catalyses the oxidative decarboxylation of pyruvate in the presence of phosphate and 02 
during the formation of acetylphosphate and hydrogen peroxide [Sedewitz et al., 1984a; 
1984b]. The enzyme uses FAD as a second cofactor. The X-ray structure of tetrameric POX 
from Lactobacillus plantarum was solved [Muller & Schulz, 1993]. The enzyme consists of 
three domains: i) the pyrimidine (pyr) binding domain, ii) an FAD binding domain and iii) a 
pyrophosphate (pp) binding domain. Analogous to TK, ThDP is bound at the interface of the 
pyr-domain and the pp-domain originating from different subunits. 
PDC is a key enzyme in alcoholic fermentation that catalyses the conversion of pyruvate to 
acetaldehyde: 
CH3COCOO" + H20 -> CH3CHO + OH" + C02 
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The catalytic mechanisms of PDC from yeast [Lobell & Crout, 1996] and Zymomonas mobilis 
[Sun et al., 1995] have been investigated in detail. Yeast PDC is allosterically regulated via 
substrate activation. 3D high-resolution structures were solved for PDC from yeast [Dyda et 
al., 1993] and from Z. mobilis [Dobritzsch et al., 1998]. Both exist as homotetramers in the 
native state with subunits of- 60 kDa. The overall domain structure of PDC is very similar to 
that of POX, despite the fact that the overall sequence identity is less than 20% [Lindqvist & 
Schneider, 1993]. 
PFOR is utilised by anaerobic bacteria and archaea and can be regarded as the precursor of 
PDHC [Witzmann & Bisswanger, 1998]. It catalyses the decarboxylation of pyruvate, forming 
acetyl-CoA. The surplus reducing equivalents are transferred via ferredoxin to cytochrome C 
[Charon et al., 1999]. Unlike PDHC, PFOR can also perform the reverse reaction; that is, the 
formation of pyruvate from C02 and acetyl-CoA. The structure of PFOR from Desulfovibrio 
africanus was solved by X-ray crystallography [Chabriere et al., 1999]. It is a homodimer of 
266 kDa, each subunit contains one ThDP, two ferredoxin type [4Fe-4S] clusters and one 
[4Fe-4S] cluster coordinated by an atypical cysteine-containing motif. In contrast with other 
ThDP dependent enzymes the two domains that bind ThDP (the pp- and the pyr-domain) 
originate from one subunit. 
In addition to the above-described enzymes, the structure of benzoyl formate decarboxylase 
was solved [Hasson et al., 1998], that also shows the same general ThDP-binding fold. 
Reaction mechanism of El 
ThDP catalyses numerous reactions that all are initiated by the deprotonation of the catalytic 
centre of the coenzyme (the C2-atom of the thiazolium moiety) (figure 6, step 1). The 
dissociation rate of the C2-H is enhanced about four orders of magnitude through the action of 
a conserved glutamine, via the Nf and N4' groups of the pyrimidine moiety of ThDP [Kern et 
al., 1997]. In all known structures of ThDP dependent enzymes, ThDP has a highly 
constrained, protein induced V-shaped conformation [Muller et al., 1993; Shin et al., 1977], 
which prevents the simultaneous protonation of the thiazole C2 and the pyrimidine N4' atom. 
The formed C2-carbanion carries out a nucleophilic attack on the substrate (figure 6, step 2). 
This activation mechanism has been confirmed by C-NMR for PDC, TK [Kern et al., 1997], 
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addition of an electrophile, such as a proton, via a general acid catalyst located on El to one 
of the sulphur atoms of the lipoic acid, thereby shifting the equilibrium to the products 
[Jordan, 1999]. 
For further detail on ThDP-chemistry and ThDP enzymes the reader is referred to excellent 
reviews published in a special issue of Biochimica et Biophysica Acta [Schellenberger, 
1998a] and [Charon et al., 1999]. 
Regulation of El 
El catalyses the rate limiting step of the overall complex reaction and is therefore an ideal 
target for complex regulation. In prokaryotic complexes many effectors influence the activity 
of PDHC in a positive or negative manner. Metabolic inhibitors of PDHC include NADH, 
acetyl-CoA and GTP [Bremer, 1969; Schwartz et al., 1968; Schwartz & Reed, 1970; 
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Figure 6 The catalytic mechanism 
of ThDP enzymes. A description of 
the mechanism is given in the 
section "reaction mechanism of El". 
Bisswanger & Henning, 1971; Bosma, 1984], additionally, regulation of Elp occurs by its 
substrate pyruvate. Mammalian Elp is regulated in a more complex fashion by 
phosphorylation/dephosphorylation of the a-subunit [Patel & Roche, 1990; Patel et al., 1996; 
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Kolobova et al., 2001; Korotchkina & Patel, 2001]. El is the target of (synthetic) substrate 
analogues and ThDP-analogues [Lowe et al., 1983; Gutowski & Lienhard, 1976]. 
Fluoropyruvate [Leung & Frey, 1978; Bisswanger, 1980; 1981; Flourney & Frey, 1989] and 
phosphonate [Kluger & Pike 1977] and phosphonate analogues of pyruvate [Schonbrunn-
Hanebeck et al., 1990] act as competitive inhibitors, whereas bromopyruvate [Maldonado et 
al., 1972; Apfel et al., 1984; Lowe & Perham, 1984] and 2-oxo-3-alkynoic acids [Brown et al., 
1997] act as suicide inhibitors. In addition, PDHC activity is very sensitive for ionic strength 
and pH [Pawelczyk et al., 1992; Rodriguez-Zavala et al., 2000]. 
The mechanism of regulation of A. vinelandii E lo by its substrate and by structural substrate 
analogs can be represented by a scheme that considers the formation of a pre-catalytic 
complex "SE" between the substrate and the enzyme, before the catalytic complex "ES" is 
formed. In the catalytic complex the ThDP bound enamine/C2a-carbanion intermediate is 
formed. The incorrect orientation of the substrate in the pre-catalytic complex, or the 
occupation of this site by a substrate analog, causes the substrate or substrate analog inhibition 
[Bunik et al., 2000]. Evidence of a precatalytic complex was found in the X-ray structure of 
PFOR [Chabriere et al., 1999], where one of the carboxyl oxygen atoms of pyruvate, instead 
of the carbonyl oxygen, interacts with the N 4 ' of ThDP. In P. putida E lb LEvarsson, 1999] 
the substrate analog a-chloroisocaproate binds in a similar fashion. Therefore, the precatalytic 
binding of 2-oxoacid substrates could be a general step in ThDP catalysis. 
Hennig and co-workers [Hennig et al., 1997] investigated the mechanism of the regulation of 
E. coli Elp by pyruvate by testing the influence of pyruvate on the interaction of El with 
several ThDP-analogs. Pyruvate enhances the binding of ThDP and coenzymatically active 
ThDP-analogs, which point to an increased binding affinity of the reaction intermediate-ThDP 
complex to E1. Lowering of the pyruvate concentration has an opposite effect: it enhances the 
dissociation of ThDP. At physiological ThDP concentrations ThDP binding and dissociation 
are slow compared to the catalytic activity, and therefore El can efficiently be regulated 
through this pyruvate-mediated effect. 
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3D structure of El 
The crystal structures of human and P. putida Elb (an (X2P2 tetramer) [iEvarsson et al., 1999; 
jEvarsson et al., 2000] reveal a tightly packed arrangement of the four subunits, with the P2-
Figure 7. Overall structure of human heterotetrameric Elb [/Evarsson et al., 2000]. 
dimer held between the jaws of a 'vise' formed by the rx2-dimer (figure 7). The a-subunit is 
composed of three domains: an extended N-terminal tail, a large domain and a small C-
terminal domain. The P-subunit consists of two domains. Each subunit in the tetramers 
interacts with all three other subunits through extensive surface contacts (even though the 
interactions are mainly between the domains of the a-subunit and the N-terminal domain of 
the P-subunit). The structures of human and P. putida Elb are very similar: both have a 
topology that is again very similar to that of TK from yeast: residues from both the a- and P-
subunit form a core that is also found in PDC, POX, TK, PFOR and BFD [Muller et al., 1993; 
Lindqvist & Schneider, 1993]. The a-subunit of Elb corresponds to the N-terminal half of 
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TK, the P-subunit to the C-terminal half (Chapter 7 in this thesis compares heterotetrameric 
El and TK in more detail). Most likely, homodimeric El has the same principle structure as 
heterodimeric El (see chapter 6 for a more detailed comparison of homodimeric and 
heterotetrameric El). 
A 20A long hydrophobic channel suitable to accommodate the E2-lipoyl-lysine arm leads to 
the active site of Elb. Two ThDP-binding pockets are formed at the interface between the a-
and P'-subunit and visa versa. The a-subunit binds the phosphate end of ThDP and the P'-
subunit binds the pyrimidine end of ThDP (figure 8). In a nutshell the following residues are 
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Figure 8: Conserved thiamin diphosphate (ThDP) protein interactions in the active site of from top 
to bottom, transketolase (TK), P. putida E l b and human E lb . 
of importance in the active site of Elb: residues from the so-called "ThDP-binding motif 
(GDG-X(25_30)-N) [Hawkins et al., 1989] interact with the phosphate moiety of ThDP, 
whereas the characteristic V-conformation of the cofactor is formed through the action of 
hydrophobic residues in the p-subunit. A glutamate of the P-subunit (E62p in P. putida Elb) 
has an important role in cofactor activation, as was confirmed by mutagenesis [Wynn et al. 
2001]. The protonation potential of this glutamate is increased by a second glutamate from the 
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a-subunit (E218a in P. putida). Two histidines are oriented towards the reactive C2 of ThDP 
and are most likely involved in substrate recognition and binding. The hydrophobic channel 
positions the disulphide exactly between these two residues. Possibly one of these histidine 
residues acts as a proton donor in the reduction of the disulphide bond. The importance of the 
corresponding active site residues in E. coli Elp was confirmed by site directed mutagenesis 
[Russell et al., 1992; Yi et al., 1996]. For more detail on the structural properties of El and its 
role in the dysfunctioning of the complexes the reader is referred to chapter 7 of this thesis. 
Assembly 
As was already described in an earlier section, the structural core of the 2-oxoacid 
dehydrogenase complexes is formed by aggregates of E2. E2p from gram-negative bacteria, 
E2o and most E2b's form a cubic assembly of 24-subunits [Perham, 1991]. All other E2's 
form a core of 60 subunits with icosahedral symmetry. The non-covalent binding of the 
peripheral components El and E3 results in huge complexes of 5-14 MDa [Oliver & Reed, 
1982]. E. coli E2p is able to bind up to 24 Elp dimers or 24 E3 dimers [Reed et al., 1975], but 
in the isolated complex the stochiometry varies [Hale & Perham, 1979]. Optimal stochiometry 
for E. coli PDHC is 12 Elp dimers and 6 E3 dimers bound to the 24-meric cubic core (Elp to 
the edges and E3 to the faces of the cube) [Reed et al., 1975]. PDHC from A. vinelandii forms 
the smallest known complex: only 700 kDa [Schulze 1992]. It exists of a functional E2p 
trimer, two Elp dimers and one E3 dimer. In vitro, 2-oxoacid dehydrogenase complexes are 
self-assembling: they can be reconstituted from their individual components [Bates et al., 
1977; Bosma, 1984; Domingo et al., 1999]. As an exception, human BCDC requires 
chaperones for in vitro reassociation [Wynn et al., 2000; Chuang et al., 1999]. 
The binding of El and E3 to E2 is competitive: an excess of either component can displace 
the other component [Bosma, 1984;Reed et al, 1975; Lessard et al., 1996]. For B. 
stearothermophilus E2p it was shown that Elp and E3 couldn't bind simultaneously to the 
same binding domain [Lessard & Perham, 1995]. Mutagenesis experiments of A. vinelandii 
E2p identified separate binding regions on the binding domain for Elp and E3 [Schulze et al., 
1993]. The elucidation of the X-ray structure of the isolated binding domain of B. 
stearothermophilus in complex with E3 revealed that an E3 dimer binds to the N-terminal 
helix of the binding domain of E2p, mainly via electrostatic interactions [Mande et al., 1996]. 
The subunit interface of E3 is involved in the binding as was shown in the E3 - binding 
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domain structure and as was shown by the stabilisation of the subunit interactions upon 
binding to E2p [Westphal et al., 1995]. Based on the stochiometry of binding and on the fact 
that the dissociation of El requires monomerisation (high pH), it seemed likely that Elp also 
binds at its subunit interface. In contrast, mutagenesis experiments of A. vinelandii E2p show 
that Elp requires binding sites on both the binding- and catalytic-domain of E2p [Schulze et 
al., 1991c; 1992; 1993], suggesting two binding sites on Elp. In this thesis, we identified the 
extended N-terminal domain of A. vinelandii Elp as the domain that is necessary for the 
binding of Elp to E2p [Hengeveld 1997, 1999] (chapters 2-4). For efficient binding two N-
terminal binding domains are required (see chapter 3) and it seems likely that one N-terminal 
domain of Elp binds to the binding domain of E2p whereas the second N-terminal domain of 
Elp binds to the catalytic domain of E2p. Therefore, Cryo electron microscopy of frozen-
hydrated complexes [Wagenknecht et al., 1990; 1992] shows that E. coli Elp and E3 are 
separated from the E2p core by 3-5 nm. This suggests a flexible mode of attachment of Elp 
and E3 to the E2p core, by the flexible linker sequences that connect the binding domain to 
the catalytic domain. Alternatively, for Elp, the distance might be bridged by an extended N-
terminal domain (see chapters 2, 3 and 4 of this thesis). The advantage of flexible binding of 
El is that it does not impose constraints that could prevent allosteric transitions in Elp. 
Recently, a size variation of 40 A was demonstrated for B. stearothermophilus PDHC, 
emphasising the dynamic character of the complexes [Zhou et al., 2001]. 
Outline of this thesis 
To obtain a better insight into the structure and functioning of the El-component of the 
pyruvate dehydrogenase multi-enzyme complex from A. vinelandii a PhD project was started 
in 1995. The results of this project are presented in this thesis. 
Much was known about the multienzyme complexes at the start of this project, but very little 
of this knowledge concerned El. The enzyme had not been cloned or sequenced and the wild 
type Elp was unstable when separated from the complex. Chapter 2 describes for the first 
time the over-expression and purification of a stable homodimeric Elp. In addition, limited 
proteolysis indicates that the N-terminal region of the enzyme is involved in the binding of 
Elp to E2p. Chapter 2 and 3 illustrate the importance of this N-terminal region of Elp. N-
terminal deletion mutants were constructed to investigate the role of the N-terminal region of 
Elp in more detail (chapter 3). In Chapter 4 we describe in detail the properties of a synthetic 
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peptide representing this region using advanced spectroscopic techniques. In chapter 5 point 
mutations reveal the specific binding residues in this region. 
Detailed structural information on a heterotetrameric El has come available in the final stages 
of this project. Chapter 6 highlights the similarities between the homodimeric and 
heterotetrameric El's and we propose a model for the homodimeric Elp. Finally, in chapter 7 
the structural basis of the dysfunctioning of the 2-oxo acid dehydrogenase complexes is 
reviewed. 
2 Expression and characterisation of the homodimeric El-component of the Azotobacter vinelandii pyruvate 
dehydrogenase complex. 
This chapter is a modified version of Hengeveld, A.F.; Westphal, A.H. & de Kok, A. (1997): 
"Expression and characterisation of the homodimeric El component of the Azotobacter vinelandii 
pyruvate dehydrogenase complex" Eur. J. Biochem. 250 , 260-268. 
Abstract 
We have cloned and sequenced the gene encoding the homodimeric pyruvate dehydrogenase component (Elp) of 
the pyruvate dehydrogenase complex from Azotobacter vinelandii and expressed and purified the Elp component 
in Escherichia coli. 
The cloned Elp can be used to fully reconstitute complex activity. The enzyme is stable in high ionic strength 
buffers, but is irreversibly inactivated when incubated at high pH, which presumably is caused by its inability to 
redimerize correctly. This explains the previously found low stability of the wild-type Elp component after 
resolution from the complex at high pH. 
The cloned Elp shows a kinetic behaviour exactly as the wild-type complex-bound enzyme with respect to its 
substrate (pyruvate), its allosteric properties and its effectors. These experiments show that acetyl coenzyme A 
acts as a feedback inhibitor by binding to the Elp component. 
Limited proteolysis experiments show that the N-terminal region of Elp is easily removed. The resulting protein 
fragment is still active with artificial electron acceptors but has lost its ability to bind to the core component 
(E2p) and thus reconstitute complex activity. Elp is protected against proteolysis by E2p. The allosteric effector 
pyruvate changes E1 p into a conformation which is more resistant to proteolysis. 
Introduction 
The pyruvate dehydrogenase complex (PDHC) from Azotobacter vinelandii catalyses the 
oxidative decarboxylation of pyruvate and the subsequent acetylation of coenzyme A (Co A) to 
acetyl-CoA (for recent reviews see (Perham, 1991; Mattevi, De Kok, & Perham, 1992a; Berg, 
& De Kok, 1997). The complex is composed of multiple copies of three different components: 
pyruvate dehydrogenase (Elp), dihydrolipoyl acyltransferase (E2p), and lipoamide 
dehydrogenase (E3). The E2p component plays a central role in the functioning of the 
complex. It has a multidomain structure: the N-terminal part contains three lipoyl domains 
each carrying a lipoamide moiety covalently attached to a specific lysyl residue, following 
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there is an Elp/E3 binding domain, and at the C-terminus there is a catalytic domain 
containing the acyltransferase catalytic site, which also forms the structural core of the 
complex. The different E2p domains are linked by proline-alanine-rich spacer sequences that 
are highly flexible and which are essential for the PDHC activity (Perham, Duckworth, & 
Roberts, 1981). 
Because the crystallisation of the entire complex is most likely prohibited by the flexibility of 
the lipoyl domains caused by its flexible linker regions, the structures of the several different 
components of the A. vinelandii PDHC complex were solved. Todate crystal structures of the 
24-meric octahedral catalytic domain of A. vinelandii E2p (Mattevi et al., 1992c; Mattevi et 
al., 1993a) and of E3 (Mattevi et al., 1991) were solved. The solution structure of the E2p 
lipoyl domain (Berg, Vervoort & De Kok, 1997) was solved by NMR spectroscopy. The 
binding mode of E3 to the binding domain has been solved by X-ray crystallography for the 
PDHC from B. stearothermophilus (Mande et al., 1996). As yet no structural information on 
the El component is available. 
The El component can be a homodimer (a2) or a heterotetramer (a2p2). Homodimeric El 
with a molecular mass of approximately 100 kDa is found in all 2-oxoglutarate 
dehydrogenases (Elo) and in pyruvate dehydrogenases (Elp) from gram-negative bacteria. 
The heterotetramer with subunits of approximately 41 and 36 kDa is found in branched-chain 
2-oxoacid dehydrogenases (Elb) and in Elp from eukaryotes and gram-positive bacteria. It is 
striking how little sequence similarity is observed between the homodimeric and the 
heterotetrameric El components or even between the homodimeric Elp and Elo (Matuda et 
al., 1991). One common motif was identified in all El components: a putative thiamin 
diphosphate-binding motif (Hawkins et al., 1989). This motif was found in all known thiamin 
diphosphate-dependent enzymes and is predicted to be involved in the thiamin diphosphate 
binding (ThDP). Recent three-dimensional structure determinations of several ThDP-
dependent enzymes (Lindqvist & Schneider, 1993) - transketolase (TK) (Lindqvist et al., 
1992), pyruvate oxidase (POX) (Muller & Schulz, 1993) and pyruvate decarboxylase (PDC) 
(Dyda et al., 1993) - have shown that the motif is indeed involved in binding the metal ion and 
the diphosphate group of ThDP. Mutagenesis experiments have also proven that these 
residues are involved in the binding of the metal ion and ThDP (Russell et al., 1992; 
Diefenbach et al., 1992). 
Several heterotetrameric El's were previously cloned and expressed in E. coli. Genes 
expressing the El a and the Eip subunit of the mammalian branched-chain 2-oxoacid 
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dehydrogenase complex were overexpressed in E. coli (Wynn et al., 1992a; Wynn et al., 
1992b; Davie et al., 1992). Coexpression of the Ela subunit fused to a maltose-binding 
protein (MBP) and the Eip subunit resulted in an active Elb (a2(32), but mixing in vitro did 
not (Davie et al., 1992). In contrast, the Ela and Eip subunits of the Elp component of the 
PDHC from B. stearothermophilus were produced separately in E. coli (Lessard & Perham, 
1994) and a functional Elp (a2p2) was produced by in vitro mixing of the individual subunits 
with one subunit in excess. In addition, the genes encoding the Ela and El(3 subunits of the 
mammalian PDHC were co-expressed, producing a functional Elp-component (Jeng et al., 
1994). Likewise, the active Elb component of P. putida was overexpressed in both P. putida 
and in E. coli (Hester et al., 1995) and a functional Elb of Streptomyces avermitilis was 
produced in E. coli (Skinner et al., 1995). 
The homodimeric Elp component has, until now, resisted most attempts to characterisation. 
No procedure for the expression of Elp has been described sofar. The main problem in 
characterising the homodimeric Elp has been its instability when resolved from the complex. 
The A. vinelandii Elp is dissociated from the complex by binding the complex on a Thiol-
Sepharose matrix and eluting the El component at pH 9.4, a procedure which incubates the 
components at alkaline pH for a short time only (De Graaf-Hess & De Kok, 1982). The 
dissociation of the complex is thought to be caused by the monomerisation of the El 
component if incubated at alkaline pH (Reed & Oliver, 1968b). 
This paper describes the cloning and expression of an active and stable homodimeric Elp and 
its characterisation. 
Experimental procedures 
Materials 
Restriction endonucleases and T4-DNA-ligase were purchased from Bethesda Research 
Laboratory (BRL). The Wizard Miniprep DNA purification system and the Wizard DNA 
clean-up system were purchased from Promega corporation BNL. Pefabloc SC (4-(2-
aminoefhyl)-benzene-sulfonylfluorid hydrochlorid) was purchased from Merck. Activated 
Thiol-Sepharose, Fastflow Q-Sepharose and HiLoad Q-Sepharose (preparative grade), 
Sephacryl S400 (preparative grade), Superose-6 (analytical grade) and Superdex-200 
(analytical grade) were purchased from Pharmacia Fine Chemicals. The sequencing primers 
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were from Pharmacia Biotech. Chymotrypsin and trypsin were from Sigma. Endoproteinase 
Glu-C was from Boehringer. Molecular weight markers were from Pharmacia Fine Chemicals. 
All other chemicals used were of analytical grade. 
The E. coli strain TG2, a recA' version of TGI F' tra D36 lacfi A(lacZ) Ml5 proA+B+/supE 
A(hsdM-mcrB) 5 fa niK McrB^ thi A(lac-proAB), was used (Gibson, 1984). The plasmids 
pUC9 and pUC18 were used as cloning vectors (Vieira & Messing, 1982). 
DNA cloning 
Standard DNA operations were performed as described (Ausubel, 1987). For construction of 
an overexpression system of A. vinelandii Elp the plasmid pRA177 (Hanemaaijer et al., 1988) 
was partially digested with Sau3A. Fragments of 2-3 and 3-4 kb were isolated and ligated in 
the BamHl site of pUC9. A clone containing the gene encoding Elp was found by screening 
with A. vinelandii Elp antiserum. This clone (p205) was completely sequenced. Digestion of 
p205 with Ddel rendered a fragment of 2688 bp encoding for Elp with only 30 bp before the 
start codon and none after the stop codon. The ends of this fragment were filled up with 
Klenow polymerase, ligated in the BamHl site of pUC 18 (pAFHOO 1) and transformed into E. 
coli TG2. Colonies were screened for Elp expression using SDS-PAGE and Western blotting 
using Elp antibodies. 
DNA sequence determination and analysis 
The DNA-sequence of the double-stranded plasmid p205 was determined using 
oligonucleotide primers specifically annealing to the plasmid. The sequencing primers used 
are shown in figure 1. The DNA-sequence was determined using an Applied Biosystems 373 
DNA sequencer-stretch, wrt 48 cm. The sequencing kit used was the ABI PRISM dye 
terminator sequencing ready reaction kit with amplitaq DNA polymerase. 
Expression 
E. coli TG2 harboring the recombinant plasmid pAFHOOl were grown at 35 °C or 37 °C in 
TY medium, containing 75 ug/ml ampicillin and 20 ug/ml IPTG, for 12 to 20 h. For analysis 
5.0 ml samples were taken from the cultures. The cells were harvested by centrifugation and 
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resuspended in 400 jul 50 mM potassium phosphate buffer, pH 7.0, containing 0.4 mM 
thiamin diphosphate, 0.4 mM MgCl2, 25 uM EDTA, 50 uM Pefabloc and 0.02% NaN3 
(standard buffer). The cells were disrupted by sonification, after which samples of the 
supernatant and pellet were separately subjected to SDS-PAGE, or cells were directly boiled 
in SDS-PAGE-sample buffer and subjected to SDS-PAGE. 
Isolation 
A single colony from E. coli TG2 (pAFHOOl) was picked from a TY-plate containing 50 
(ig/ml ampicillin and resuspended in 3 ml TY. 0.2 ml of this suspension was used to inoculate 
each often 3-liter flasks containing 500 ml TY, ampicillin (75 ug/ml) and IPTG (20 ug/ml). 
This culture was grown for 14 hours at 35 °C. Using these conditions 80-90% of the 
expressed Elp was soluble. Cells were harvested and used for isolation of Elp. All steps 
described below were carried out at 4 °C unless mentioned otherwise. 
The harvested cells were resuspended in ice-cold standard buffer and disrupted using a French 
press. The presence of Elp was monitored using SDS-PAGE. The disrupted cells were 
centrifuged at 33000 x g for 30 minutes, the resulting supernatant was fractionated by 
protamine sulphate precipitation (2 mg/ml final concentration) and again centrifuged at 33000 
x g for 30 minutes. The resulting supernatant was subjected to a two step ammonium sulphate 
fractionation. The fraction between 20% and 50% saturation was collected by centrifugation, 
dissolved in standard buffer (20 mM potassium phosphate) and directly loaded onto a 
Fastflow Q-Sepharose column. The column was washed with standard buffer (20 mM 
potassium phosphate) and proteins were eluted with a linear gradient of 0-0.6 M KC1 in the 
washing buffer. Elp eluted from the column at 0.40-0.42 M KC1. Fractions containing Elp 
were pooled and concentrated by ultrafiltration (Filtron £2100) and loaded onto a Sephacryl 
S400 column. Proteins were eluted in standard buffer, containing 150 mM KC1. Fractions 
containing Elp were again pooled and loaded onto a HiLoad Q-Sepharose column. The 
column was washed and eluted as described for the Fastflow Q-Sepharose. Fractions 
containing Elp were pooled, concentrated to a 10 mg/ml solution and stored at 4 °C. All 
solutions including protein solutions were kept sterile by filtration using a sterile 0.22 um 
filter. 
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Activity assays 
For assaying the Elp component two methods were used. Firstly the oxidative 
decarboxylation of pyruvate was measured using 2,6-dichlorophenol-indophenol (Cl2Ind) as 
an artificial electron acceptor (Khailova et al., 1977). The activity was measured in 200 ul 50 
mM TrisHCl, pH 7.5, 0.1 mM MgCl2, 0.1 mM thiamin diphosphate, 20 uM Cl2Ind and 5.0 
mM pyruvate. To this mixture 5 -15 ul enzyme was added. The absorbance decrease at 600 
nm due to the oxidation of C^Ind was followed in time (e = 21.7 M" cm" ) on a Pharmacia 
Ultrospec HI spectrophotometer. One unit of activity is defined as the amount of enzyme 
required for the oxidation of 1.0 umole of Cl2Ind per minute. Secondly, the El activity was 
measured by reconstitution of the overall PDHC-activity. The PDHC-activity was assayed 
spectrophotometrically at 340 nm and 25°C (Schwartz & Reed, 1970). For this purpose PDHC 
was isolated as described in (Bosma et al., 1984) and the E2p and E3 components were 
separated and isolated after immobilization on Thiol-Sepharose (De Graaf-Hess & De Kok, 
1982). 
The irreversible inactivation of Elp by incubation at different pH values was measured after 
incubating 1 ml Elp for 15 min in 9 ml 50 mM potassium phosphate, 50 mM ethanolamine, 
0.1 mM thiamin diphosphate, 0.1 mM MgCl2, 50 mM Pefabloc, 25 mM EDTA, pH 7.4 to pH 
10 at room temperature. After 15 min either PDHC activity was reconstituted by combining 
the E2p and E3 component with the Elp component in a cuvette or Cl2Ind activity was 
measured as described above. 
Limited proteolysis 
The isolated A. vinelandii Elp component (1.0 mg/ml) was incubated with trypsin, 
chymotrypsin or endoproteinase Glu-C (10 |xg/ml) in standard buffer without Pefabloc at 0°C, 
either nothing, 5 mM pyruvate or equimolar amounts of E2p were added to this mixture. 
Samples were withdrawn at timed intervals and the proteolysis was stopped by adding either 
an equal volume of sample buffer (80°C) for SDS-PAGE, 100 uM Pefabloc (trypsin or 
chymotrypsin) or 330 mM L-l-chloro-3-(4-tosylamido)-7-amino-2-heptanone-HCl 
(endoproteinase Glu-C) for analytical gelfiltration or activity measurements. 
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N-terminal sequence determination 
The samples to be analysed were applied to SDS-PAGE according to Laemmli (Laemmli, 
1970). Separated protein bands were blotted onto polyvinylidene difluoride membranes. The 
protein sequencing was carried out by Edman-degradation on an automated sequenator 
(Model 477A, Applied Biosystems). 
Analytical size-exclusion chromatography 
The interaction of Elp with E2p was studied using two different methods. Firstly, the 
dissociation of the 24-meric E2p core into trimers upon binding of Elp was monitored on 
Superose-6 and Superdex 200 gelfiltration columns using an AKTA explorer system 
(Pharmacia Biotech). The proteins were eluted with standard buffer, containing 150 mM KC1 
(Schulze et al., 1991c). Secondly, the PDHC activity, reconstituted from wild type E2p, wild 
type E3 and overexpressed Elp was assayed as described above. 
Samples obtained from limited proteolysis experiments and from incubations at various pH 
were also analysed on Superose 6 and Superdex 200 columns. Both columns were calibrated 
using the following proteins: cytochrome c (12.4 kDa), myoglobin (17.8 kDa), 
chymotrypsinogen (25 kDa), bovine albumin (67 kDa), alcohol dehydrogenase (144 kDa), 
catalase (232 kDa), pyruvate kinase (237 kDa), vanilyl alcohol oxidase (500 kDa), citrate 
lyase (550 kDa) and dextran blue (2000 kDa). 
Others 
SDS-PAGE was performed as described by Schagger and von Jagow (Schagger & Von 
Jagow, 1987). For the purpose of Western blotting SDS-PAGE was performed as described by 
Laemmli (Laemmli, 1970). Protein concentrations were estimated by the microbiuret method 
(Goa, 1953), Bovine serum albumin was used as a standard. 
For the production of antiserum Elp was extracted from SDS gels as described in 
(Hanemaaijer et al., 1987) and mixed with Freund's incomplete adjuvant. Male New Zealand 
White rabbits were used for immunisation. After five weeks a booster injection was given and 
ten days later the antisera were collected. The monoclonal antibodies 18A9 against E. coli Elp 
were kindly provided by Prof. F. Jordan (McNally et al, 1995b; McNally et al., 1995a). 
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Results and discussion 
Cloning strategy 
From partially digested pRA177 fragments of 3-4 kbp were isolated and ligated into the 
BamUl site of pUC9. E. coli TG2 cells transformed with these plasmids were screened using 
antiserum raised against A vinelandii Elp. Of 400 colonies screened 10 positives were found, 
2 of which produced the intact Elp as judged by SDS-PAGE and western blotting. The 
plasmid containing an insert of 3301 bp (p205) was used for sequence analysis. Expression of 
Elp in E. coli TG2 harboring the recombinant plasmid p205 could be detected by Western 
blotting, but no clear protein band could be seen on SDS-PAGE or activity could be measured 
through reconstitution with E2p and E3. For the purpose of overexpression of Elp a new 
construct was made. To have Elp expressed under the pUC18 promoter region, the p205 
insert was truncated by digestion with Ddel and ligated into pUC18. This gave a fragment 
with only 30 bp before the start codon and 3 bp after the stop codon. The 30 bp before the 
start codon did include the -10 ribosome binding site region but not the -35 region (figure 1). 
The cell-free extract of a colony of this construct (pAFHOOl) showed a thick band on SDS-
PAGE at about 100 kDa, which cross-reacted with A. vinelandii Elp antiserum. Also an 
increase in PDHC activity could be measured when A. vinelandii E2p and E3 were added to 
the cell-free extract. This increase in PDHC activity can only be due to the presence of A. 
vinelandii Elp, since E. coli Elp is not able to reconstitute PDHC activity if combined with A. 
vinelandii E2 and E3 components. 
Sequence 
The 3301-bp insert in p205 was completely sequenced in both directions using oligo-
nucleotide primers designed to specifically anneal to the double stranded p205 (figure 1). A 
265 5-bp open reading frame was found just downstream of the gene encoding E2p and 
identified as the gene encoding the pyruvate dehydrogenase component of PDHC. The 
deduced amino acid sequence showed a high degree of identity with other known Elp 
sequences from gram-negative bacteria, e.g. 58 % identity with E. coli Elp. None or very low 
similarity could be found with heterotetrameric Elp and Elb or with homodimeric Elo. The 
ThDP binding motif (Hawkins et al., 1989), was also found in the A. vinelandii Elp, starting 
at residue 227. Even though this motif is shared by all ThDP-dependent enzymes its location 
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in the amino acid sequence is different for the various enzymes (Hawkins et al., 1989; Berg et 
al., 1996). 
2 3 4 5 
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Figure 2. Purification of pyruvate dehydrogenase bom A. vinelandii, expressed in £ coli 
TG2. Fractions were analysed using SDS-PAGE. Lane 1 and 8, marker proteins; lane 2, 
cell extract; lane 3, supernatant after protamine sulphate treatment; lane 4, resuspended 
fraction after ammonium sulphate fractionation; lane 5, fractions pooled from FastFlow Q-
Sepharose chromatography; lane 6, fractions pooled from Sephacryl S400 
chromatography; lane 7, fractions pooled from HiLoad Q-Sepharose chromatography. 
Expression 
Both complete cells, cell pellet and cell-free extract from cultures grown at 35 and 37 °C for 
14 to 20 hours were applied to SDS-PAGE to determine optimal growth conditions. The 
amount of expressed Elp is equal under all conditions, but the amount of soluble Elp is 
highest (80-90%) when the cells are grown at 35 °C for 14 hours. If grown at 37 °C or at 35 
°C for 20 hours the expression level of Elp is equally high, but 60-90% of the enzyme is 
found in the pellet and cannot be dissolved, indicating Elp to be present in inclusion bodies. 
Thus, the expression of soluble Elp is highly sensitive to small changes in the growth 
conditions. 
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Purification 
A. vinelandii Elp was expressed and purified as described in Materials and Methods. 30-g of 
E. coli TG2 cells harboring the plasmid pAFHOOl yielded 63 mg of purified Elp. It is very 
important that the disruption of the cells and the precipitation steps are carried out very fast 
and at 0 °C, because the expressed Elp is highly sensitive to protease degradation. Only the 
water soluble Pefabloc was used as a protease inhibitor. Protease inhibitor mixtures, e.g. 
Complete Protease inhibitor mix (Boehringer), inactivated Elp. 
Figure 2 shows the results of the purification of Elp as monitored using SDS-PAGE. Due to 
the high NADH oxidase activity and the E. coli PDHC activity in the crude preparations it is 
not possible to accurately measure PDHC-activity in the first steps of the purification. The 
measurement of the El activity in the crude preparations is not possible because of the low 
specific activity of Elp in this assay. For these reasons only the specific activities of the 
purified enzymes have been determined. The specific activity of purified Elp using C^Ind as 
artificial electron acceptor is 0.086 U/mg, which is comparable to wild-type Elp activity 
(0.082 U/mg). Reconstitution of the overall PDHC activity results in a specific activity of 28.9 
U/mg E2p, at an optimum molar ratio of 1.9 dimers Elp per trimer E2p and dimer E3. The 
wild type activity at comparable conditions is 30 U/mg E2p, with an optimum ratio of 2 
dimers Elp per trimer E2p and dimer E3. From these results it can be concluded that the 
cloned Elp is fully active. 
Identification 
The determined N-terminal sequence, using the Edman-degradation method, of the cloned and 
expressed Elp is DMQDLDP. The determined sequence of wild type Elp is MQDMQDLDPI. 
The size of the cloned Elp as determined by electronspray mass determination is 99863 ± 127 
Da, but the calculated molecular mass of Elp is 100051 Da. This also indicates that the cloned 
Elp lacks one or two N-terminal residues. It is not clear what effect causes this truncation at 
the N-terminus, but clearly it has no influence on the activity of Elp nor on other properties 
(see below). From the alignment of the N-terminal sequences of all know homodimeric Elp it 
can be seen that these residues are not conserved. The observed N-terminal sequence is not 
found in the E. coli Elp amino acid sequence proving the isolated Elp being A. vinelandii 
Elp. 
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The interaction of the A. vinelandii E2p with the cloned Elp was studied by two different 
methods. First complex activity could be reconstituted as described in the previous section. 
Secondly the dissociation of the 24-subunit E2p core into trimers upon binding of Elp was 
monitored by analytical gelfiltration (Schulze et al., 1991a). The A. vinelandii E2p core 
consists of 24 subunits that form a cubic structure, yet it behaves in a unique way: upon 
binding of Elp and/or E3 the core dissociates into trimers (Mattevi et al., 1992c; Bosma, et 
al., 1984). Figure 3, panel A shows that the cloned Elp is, like the wild type Elp, able to 
dissociate the 24 meric E2p into trimers. The binding properties of the cloned Elp are thus 
unchanged compared to wild type Elp. These results again confirm our previous conclusion 
that the cloned Elp is fully functional. 
Stability 
When dissociated from the complex Elp from A. vinelandii is very unstable and inactivates in 
a few days. We have noticed that the expressed Elp is much more stable and keeps its activity 
after storage for 6 months at 4 C in saturated ammonium sulphate, pH 7.0. Because buffers 
with a high pH, e.g. ethanolamine pH 9.4, are used in the dissociation procedure (De Graaf-
Hess & De Kok, 1982), the effect of incubation in buffers of different pH was studied as 
described in Experimental procedures. Only 60% of the PDHC activity remains after 
incubation of Elp for 15 min. at pH 9.5. Thus at this pH Elp partially loses its ability to 
reconstitute PDHC activity. On the other hand the C^Ind activity remains high. At pH 9.5 
Elp eluted as a single peak with a retention volume corresponding to a molecular weight of 
approximately 120 kDa, indicating monomerization. Monomerization has also been observed 
with the E. coli Elp at high pH (Reed & Oliver, 1968b) but no evidence of irreversible loss of 
activity was given. Presumably only the dimer interacts with E2p, comparable to the binding 
of E3 to E2p (Mande et al., 1996; Schulze et al., 1991a). We conclude that the monomer 
undergoes time and pH-dependent structural changes and upon lowering the pH, part of Elp 
does not dimerize correctly and is unable to interact with E2p. 
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Figure 3. Binding properties of 
the expressed Elp component of 
the pyruvate dehydrogenase 
complex (Panel A) and of the Elp 
proteolysed by chymotrypsin 
(Panel B). E2p was added in 
molar ratios to the Elp samples. 
50 ml samples were loaded on the 
Superose 6 column and eluted 
with 50 mM potassium phosphate 
buffer pH 7.0 containing 150 mM 
KC1 and 50 mM Pefabloc. 
In general, the enzyme is unstable in low ionic strength buffers and in the presence of organic 
solvents. Even the addition of 1-2 % ethanol results in rapid inactivation. 
Kinetics 
The kinetic behaviour of complex-bound Elp has been investigated previously (Bosma 1984; 
Bresters, De Kok & Veeger, 1975). For measuring the oxidative decarboxylation of pyruvate 
ferricyanide was used as an artificial electron acceptor. A Hill-coefficient of 1.4-1.6 (Bosma, 
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Figure 4. Hill-plots of the 
dependence of the rate of the 
Cl2lnd reaction on the pyruvate 
concentration in the presence and 
absence of effectors. The reaction 
mixture is as described in the 
experimental procedures, pyruvate 
is added as indicated. (•) no 
effector present; (•) 45 mM 
AcCoA; (x) 1 mM AMP. 
1984) or 1.1-1.5 (Bresters, De Kok, & Veeger, 1975) was found for the complex bound Elp. 
The Hill-coefficient did not change significantly in the presence of positive (AMP) or negative 
(acetyl CoA) effectors. Although these effects were found with the Elp reaction it could not 
be excluded that some of these effects were exerted through interaction with the other 
components of the complex. Therefore we have repeated these experiments with the expressed 
(non-complex-bound) Elp. In figure 4 a Hill-plot of the expressed Elp is shown. A Hill-
coefficient of 1.2 - 1.6 was calculated from this plot. This demonstrates that non-complex-
bound Elp shows the same cooperativity as found for complex bound Elp. The Hill-
coefficients again do not seem to change significantly in the presence of negative (acetyl 
coenzyme A) or positive (AMP) effectors, thus the effect exerted by pyruvate is apparently not 
influenced by these effectors. It must be mentioned that the C^Ind activity assay is, like the 
ferricyanide assay, quite insensitive and much more difficult to handle than the PDHC-
reaction, but since all results found sofar are consistent we conclude that the observed 
deviation from h=1.0 is significant. The allosteric inhibition of Elp by acetyl CoA is 
remarkable and sofar only shown for E. coli PDHC (Schrenk, & Bisswanger, 1984). Acetyl 
CoA shows strong product inhibition (Ki 8 uM) in the PDHC reaction (Bresters De Kok, & 
Veeger, 1975). The results shown here indicate that, apart from interaction with the active site 
on E2p, acetyl CoA interacts directly with the Elp component. Due to the insensitivity of the 
30 Chapter 2 
Cynd assay an accurate S0.5 value could not be determined however it is estimated at about 
10 uM. 
Limited proteolysis 
Limited proteolysis experiments were performed to obtain more information about the domain 
structure of the homodimeric Elp. Both proteolysis with trypsin and chymotrypsin yields two 
main fragments (Tl, T2 and CI, C2) (figure 5). The sizes of these fragments as determined by 
SDS-PAGE are 40 kDa and 54 kDa for the tryptic fragments and 59 kDa and 38 kDa for the 
chymotryptic fragments. Size determination by MALDI was not possible because the 
fragments were very unstable in buffer with a KC1 concentration below 150 mM. The N-
terminal amino acid sequence of the four fragments was determined using Edman-degradation 
(figure 1). 
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Figure 5. Limited proteolysis of cloned 
Elp. Lane 1, marker proteins; lane 2, incu-
bation with trypsin; lane 3, incubation with 
trypsin and 5 mM pyruvate; lane 4, incu-
bation with chymotrypsin; lane 5, 
incubation with chymotrypsin and 5 mM 
pyruvate. 
Analytical gelfiltration of the samples obtained after proteolysis shows a single peak with a 
retention volume corresponding to a molecular weight of 140 kDa or 146 kDa respectively for 
trypsin and chymotrypsin. SDS-PAGE shows that the Elp in this peak is completely 
proteolysed by either trypsin or chymotrypsin and only the two main fragments (Tl, T2 or CI, 
C2) are present. Intact Elp has a single peak with a retention volume corresponding to a 
molecular weight of 174 ± 9 kDa. From these results it can be concluded that proteolysed Elp 
is smaller than the intact Elp, but that it must still be present as a dimeric molecule. Thus, the 
proteolysed residues are not involved in the monomer-dimer interaction. 
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For both the trypsin and the chymotrypsin fragments it was not possible to reconstitute PDHC 
activity after only 30 s digestion time, while the C^Ind-activity was still 100%. At this time a 
very small increase in migration was observed, without the appearance of other degradation 
products. This indicates that the active site is still present after proteolysis, but that Elp has 
lost its ability to interact with E2p. This is confirmed by the loss of their ability to dissociate 
the 24-subunit E2p core into trimers (figure 3 B). 
Figure 1 shows that fragments Tl and CI should contain the ThDP-binding motif. Western 
blot analysis using a monoclonal antibody (mAb) raised against E. coli Elp (mAb 18A9) 
(McNally, Motter & Jordan, 1995b; McNally, Mattsson & Jordan, 1995a) showed the highest 
cross reactivity against these fragments. mAb 18A9 inhibits E. coli PDHC for more than 98% 
and is most likely directed against the active site of Elp. Thus these results confirm that active 
site residues are most likely present in fragment CI and Tl. Moreover, Elp is partially 
protected against proteolysis by binding to E2p (results not shown), which confirms the 
conclusion that Elp is digested in a region responsible for the binding to E2p. 
From the N-terminal sequences of the fragments and a comparison of fragment size as 
determined by SDS-PAGE and calculated from the sequence it is concluded that Tl is 
fragment 44-400 and fragment T2 is fragment 418-885. Likewise fragment CI is 38-552 and 
C2 is 553-885. The start of fragment CI is puzzling because digestion at R37 is not expected 
for chymotrypsin. Rather the sequence YLL just prior to R37 seems a more likely target. The 
C-termini of the fragments Tl and CI are not well defined as there are several potential 
cleavage sites in this region. 
Since Elp digested by both trypsin and chymotrypsin behaves in a similar way, e.g. a loss of 
PDHC-activity combined with a small decrease in molecular weight, it is most likely that the 
38-40 N-terminal amino acids are involved in the binding of Elp to the E2p-component and 
the internal "loops" available to the proteases are not. 
Experiments with endoproteinase Glu-C confirm this conclusion. This protease only cuts off a 
small fragment, comparable to the initial cleavage product by trypsin or chymotrypsin, leaving 
the remaining protein intact. The digestion causes a time dependent loss of complex activity 
without affecting the El activity, like the other proteases. The N-terminal sequence of the 
large fragment obtained by limited proteolysis with endoprotease Glu-C was found to be 
LATRTGT, starting at position 41 in the original sequence (figure 1). 
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Previously it was shown that a point mutation in the N-terminal region of the catalytic domain 
of A. vinelandii E2p resulted in a very weak Elp binding; thus, Elp binds not only to the 
binding domain but also to the E2p catalytic domain (Schulze et al., 1991c). Cryoelectron 
microscopy of frozen-hydrated pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase 
complexes from E. coli shows that the El and E3 subunits seem to be separated from the 
surface of the E2 core by 3 - 5 nm, and thin bridges of density are seen in the gap between the 
E2 core and the bound subunits (Wagenknecht, Grassucci & Schaak, 1990). It is therefore 
assumed that E1 itself provides a linker sequence to the core. The experiments here indicate 
that the N-terminal part of Elp is involved in this interaction. Furthermore, incubation of Elp 
in potassium phosphate buffer, pH 7.0, containing MgCl2 and thiamin diphosphate, with 5 
mM pyruvate partially protects against proteolysis (figure 5). This indicates that Elp changes 
its conformation upon binding of pyruvate as expected from the cooperative behaviour of this 
enzyme. 
Summarising, the limited proteolysis studies show that the N-terminal region of Elp is easily 
split off and thus it can be concluded that it has an extended conformation or forms a separate 
domain. Furthermore, this N-terminal region seems to be involved in the binding to E2p. The 
digested enzyme is still present as a dimer. 
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1 GATCGCGCAC CCGTCTCGAG GACGAACCCG CTGTTCGCGC AGACCCGTGC GAAGCCGCGC GCCGCCGGCG 
71 GCCAGATCGG CAAAGGGCGT CGCCGGACTT GTCGCCGAGC GTGCCGGCGG GCGTCCCCGA AGCGTTGCAG 
141 GGCCTGATTG CCCAGGGTCT CCAGCGCGGG GGGGAAGTTC GATCAGCGTA GGTAGGCTCA TGCTCGTGTC 
211 CTGATATCGG CCAGACTTTC CAAAGCGGGT TGAGCCCGAC CCGTGGGGTA ATTTTACAAA AGTCCTCGGA 
281 GGGGGGGCTG AAAACCCAAT TGTTTTGTAG TAAAACTACA ACGACAGTCG GATCACCCCG GCCCGAACCA 
351 ACTAACAACA ATCCCGCAGC CGCCCATAAG GCCGGCTGTG TATCCGGGCT CCCAACTCAG GGATGCCTTC 
M Q D M Q D L D P I E T Q E W L D S 
421 CGCTATGGAG CflAGACATGC AAGACATGCA AGACCTTGAC CCCATCGAGA CCCAGGAGTG GCTGGACTCG 
18 
L E S V L D H E G E E R A H Y L L T R M G E L 41 
4 91 CTCGAATCAG TCCTCGACCA CGAAGGCGAA GAGCGCGCCC ATTATCTGCT GACCCGGATG GGCGAACTGG 
A T R T G T Q L P Y A I T T P Y R N T I P V T H 6 5 
561 CCACTCGCAC GGGCACCCAA CTGCCCTATG CGATCACCAC CCCCTATCGC AACACCATTC CGGTGACCCA 
E A H M P G D L F M E R R I R S L V R W N A L 88 
631 CGAAGCGCAC ATGCCCGGCG ACCTGTTCAT GGAACGCCGC ATCCGCTCCC TGGTGCGCTG GAATGCGCTG 
A T V M R A N K K D P D L G G H I S T F A S S 111 
701 GCCACGGTCA TGCGGGCGAA CAAGAAGGAC CCGGACCTGG GTGGACACAT CTCCACCTTC GCCTCCAGCG 
A T L Y D I G F N Y F F Q A P T A E H G G D L I 135 
771 CCACGCTCTA CGATATCGGC TTCAACTATT TCTTCCAGGC GCCCACGGCA GAACACGGCG GCGACCTGAT 
Y F Q G Q A A P G V Y A R A F L E G R I S E A 158 
841 CTACTTCCAG GGCCAGGCCG CTCCCGGCGT CTACGCCCGC GCCTTCCTCG AAGGCCGCAT CAGCGAAGCG 
Q L Q Q F R Q E V D G D G L S S Y P H P H L M 181 
911 CAACTGCAGC AGTTCCGGCA GGAAGTCGAC GGCGACGGCC TGTCCTCCTA TCCGCACCCG CACCTGATGC 
P D F W Q F P T V S M G L G P I Q A I Y Q A R F 205 
981 CGGACTTCTG GCAGTTCCCC ACCGTTTCCA TGGGGCTGGG CCCGATCCAG GCGATCTACC AGGCGCGCTT 
M K Y L E H R G F I P A G K Q K V W C F M G D 228 
1051 CATGAAGTAC CTGGAGCACC GCGGCTTCAT TCCCGCCGGC AAGCAGAAGG TCTGGTGCTT CATGGGCGAC 
G E C D E P E S L G A I S L A G R E K L D N L 251 
1121 GGCGAATGCG ACGAGCCGGA ATCCCTCGGC GCCATCTCCC TGGCCGGCCG CGAGAAGCTG GACAACCTGA 
I F V I N C N L Q R L D G P V R G N G K I I Q E 275 
1191 TCTTCGTCAT CAACTGCAAC CTGCAGCGCC TCGACGGCCC GGTCCGCGGT AACGGCAAGA TCATCCAGGA 
L E G V F R G A Q W N V N K V V W G R F W D P 298 
12 61 ACTCGAAGGG GTGTTCCGCG GCGCCCAGTG GAACGTCAAC AAGGTGGTCT GGGGCCGCTT CTGGGACCCG 
L F A K D H A G L L Q Q R M D E V V D G D Y Q 321 
1331 CTGTTCGCCA AGGACCATGC CGGCCTGCTG CAGCAGCGCA TGGACGAGGT GGTCGACGGC GACTACCAGA 
N Y K A K D G A F V R K H F F G A R P E L L E L 345 
1401 ACTACAAGGC CAAGGACGGA GCCTTCGTAC GCAAGCATTT CTTCGGCGCG CGCCCCGAGC TGCTGGAGTT 
V K D M S D E D I W K L N R G G H D P Y K V Y 368 
1471 GGTCAAGGAC ATGTCCGACG AGGACATCTG GAAGCTCAAC CGTGGCGGCC ACGACCCCTA CAAGGTCTAC 
A A Y H Q A V N H Q G Q P S V I L A K T I K G 391 
1541 GCAGCCTATC ACCAGGCGGT CAACCACCAG GGCCAGCCGA GCGTGATCCT CGCCAAGACC ATCAAGGGCT 
Y G T G A G E A K N I A H N V K K V D V E S L K 415 
1611 ACGGCACCGG CGCCGGCGAG GCGAAGAACA TCGCCCACAA CGTGAAGAAG GTCGATGTCG AGAGCCTCAA 
L F R D K F D V P L K D E E L E D L P F Y R P 438 
1681 GCTGTTCCGC GACAAGTTCG ACGTCCCGCT GAAGGACGAG GAGCTGGAAG ACCTGCCGTT CTACCGGCCG 
D E N S P E M K Y L R S R R E A L G G F V P Q 461 
1751 GACGAGAACA GCCCGGAGAT GAAGTACCTG CGCAGCCGCC GCGAGGCCCT GGGCGGCTTC GTGCCGCAGC 
R R R K S I S I P T P P L D S L K A I L D G T G 485 
1821 GCCGCAGGAA GAGCATCAGC ATCCCGACCC CGCCGCTGGA CAGCCTCAAG GCGATCCTCG ACGGCACCGG 
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D R E 1 S T T M A F V R I L A Q L V K D K E L 508 
1891 CGACCGCGAA ATCTCCACCA CCATGGCCTT CGTGCGAATC CTCGCGCAAC TGGTCAAGGA CAAGGAGCTG 
G S R I V P I I P D E A R T F G M E G M F R Q 531 
1961 GGCTCGCGCA TCGTGCCGAT CATCCCCGAC GAGGCGCGCA CCTTCGGCAT GGAAGGCATG TTCCGCCAGC 
L G I Y S S V G Q L Y E P V D K D Q V M F Y R E 555 
2031 TCGGCATCTA CTCCTCGGTC GGCCAGCTCT ACGAGCCGGT GGACAAGGAC CAGGTGATGT TCTATCGCGA 
D K K G Q I L E E G I N E A G A M S S W I S A 578 
2101 GGACAAGAAG GGCCAGATCC TCGAGGAAGG CATCAACGAA GCCGGCGCCA TGTCCAGTTG GATCTCCGCG 
A T A Y S N H N Q P M L P F Y V F Y S M F G F 601 
2171 GCGACCGCGT ACAGCAACCA CAACCAGCCG ATGCTGCCGT TCTACGTGTT CTATTCGATG TTCGGCTTCC 
Q L I G D L A W T A G D S Q A R G F L I G G T A 625 
2241 AACTCATCGG CGACCTCGCC TGGACGGCCG GCGACAGCCA GGCGCGCGGC TTCCTGATCG GCGGTACCGC 
G R T T L N G E G L Q H E D G H S H I L A S T 648 
2311 CGGCCGCACC ACGCTCAACG GCGAAGGCCT GCAGCACGAG GACGGCCACA GCCACATCCT CGCCTCGACC 
I P N C R T Y D P T Y A Y E M A V I I R E G I 671 
2381 ATCCCGAACT GTCGCACCTA CGATCCGACC TATGCCTATG AGATGGCGGT GATCATCCGC GAAGGCATCC 
R Q M T E E Q Q N V F Y Y I T A M N E A Y T Q P 695 
2451 GCCAGATGAC CGAGGAGCAG CAGAACGTCT TCTACTACAT CACCGCGATG AACGAGGCCT ACACCCAGCC 
A M P E G A E A G I V K G M Y L L E E D K R D 718 
2521 GGCCATGCCG GAAGGGGCCG AGGCAGGCAT CGTCAAGGGC ATGTACCTGC TCGAGGAAGA CAAGCGCGAC 
A A H H V Q L L G S G T I L R E V R E A A K I 741 
2591 GCCGCGCACC ATGTCCAGTT GCTCGGCAGC GGCACCATCC TGCGCGAAGT GCGCGAAGCG GCGAAGATCC 
L R E D Y N V A A D V W S V T S F N E L R R N G 765 
2 661 TCCGCGAGGA CTACAACGTC GCCGCCGACG TGTGGAGCGT GACCAGCTTC AACGAACTGC GCCGCAACGG 
L A V E R R N R L H P E Q K P E Q S Y V E Q C 788 
2731 CCTGGCCGTG GAACGCCGCA ACCGCCTGCA CCCGGAACAG AAGCCGGAGC AGAGCTACGT CGAGCAGTGC 
L N G R K G P V V A S T D Y M K L F A D Q I R 811 
2801 CTGAACGGCC GCAAGGGCCC GGTGGTGGCC TCCACAGACT ACATGAAGCT GTTCGCCGAC CAGATCCGCC 
Q W V P S R E Y K V L G T D G F G R S D T R K K 835 
2871 AGTGGGTCCC GAGCCGCGAG TACAAGGTGC TCGGCACCGA TGGCTTCGGC CGCAGCGATA CCCGCAAGAA 
L R H F F E V D R Y W V V L A A L E A L A D R 858 
2 941 GCTGCGTCAT TTCTTCGAAG TGGACCGCTA CTGGGTTGTG CTGGCCGCGC TGGAAGCGCT GGCCGATCGT 
G D I E A K V V P K P F A K F G I D P D K R N 881 
3011 GGCGACATCG AAGCCAAGGT GGTGCCGAAG CCATTCGCCA AGTTCGGCAT CGATCCCGAC AAGCGCAACC 
P L D C * S E I I R V P D I G G D G E 
3081 CCCTGGACTG CTGAGGAGAG CCATCGTGAG CGAAATCATC CGCGTACCCG ATATCGGCGG CGATGGGGAA 
V I E L L V K T G D L I E V E Q G L V V L E S 
3151 GTCATCGAAT TGCTGGTCAA GACCGGCGAC CTCATCGAGG TCGAGCAGGG GCTGGTGGTG CTGGAGTCCG 
A K A S M E V P S P K A G V V K S V S V K L G D 
3221 CCAAGGCGAG CATGGAAGTT CCCAGTCCCA AGGCCGGAGT GGTCAAGAGC GTGAGCGTCA AGCTGGGCGA 
K L K E G D A I 
3291 CAAGCTCAAG GAAGGCGACG CGATC 
Figure 1. Nucleotide sequence of the A. vinelandii pyruvate dehydrogenase gene (Elp) and surrounding regions 
and the deduced amino acid sequence. The deduced N-terminal amino acid residues of the dihydrolipoyl 
transacetylase component (E2p) are also shown. The ribosome binding site is shown in bold italics. The specific 
oligo nucleotide primers used for sequencing the complete gene are underlined. The restriction sites for Ddel 
(CTGAG) are marked with bold letters. The N-terminal sequences of the limited proteolyses fragments Tl 
(TGTQLPY), T2 (DKFDVPL), CI (MGELATR), C2 (REDKKGQ) and Gl (LATRTGT) are marked with bold 
letters. 
3 Pyruvate dehydrogenase from Azotobacter vinelandii. Properties of the N-terminally truncated enzyme. 
This chapter is a modified version of Hengeveld, A.F.; Schoustra, S.E.; Westphal, A.H. & de Kok, A 
(1999): "Pyruvate dehydrogenase from Azotobacter vinelandii: Properties of the N-terminally truncated 
enzyme' Eur. J. Biochem. 265, 1098-1107. 
Abstract 
The pyruvate dehydrogenase multienzyme complex (PDHC) catalyses the oxidative decarboxylation of pyruvate 
and the subsequent acetylation of coenzyme A to acetyl-CoA. Previously, limited proteolysis experiments 
indicated that the N-terminal region of the homodimeric pyruvate dehydrogenase (Elp) from Azotobacter 
vinelandii could be involved in the binding of Elp to the core protein (E2p) (Hengeveld, A. F., Westphal, A. H. 
and De Kok, A. (1997) Eur J. Biochem. 250, 260-268.). To further investigate this hypothesis N-terminal 
deletion mutants of the Elp component of Azotobacter vinelandii pyruvate dehydrogenase complex were 
constructed and characterised. 
Up to 9 N-terminal amino acids could be removed from Elp without effecting the properties of the enzyme. 
Truncation of up to 48 amino acids did not effect the expression or folding abilities of the enzyme, but the 
truncated enzymes could no longer interact with E2p. The 48 amino acids deletion mutant (ElpA48) is 
catalytically fully functional: it has a Vmax identical to that of wild type Elp, it can reductively acetylate the 
lipoamide group attached to the lipoyl domain of the core enzyme (E2p) and it forms a dimeric molecule. On the 
other hand, the S0 5 for pyruvate is decreased. 
A heterodimer was constructed containing one subunit of wild type Elp and one subunit of ElpA48. From the 
observation that the heterodimer was not able to bind to E2p it is concluded that both N-terminal domains are 
needed for the binding of Elp to E2p. The interactions are thought to be mainly of electrostatic nature involving 
negatively charged residues on the N-terminal domains of Elp and previously identified positively charged 
residues on the binding and catalytic domain of E2p. 
Introduction 
The pyruvate dehydrogenase multienzyme complex (PDHC) from gram-negative bacteria 
consists of multiple copies of three different enzyme components: pyruvate dehydrogenase 
(Elp), dihydrolipoyl acyltransferase (E2p) and lipoamide dehydrogenase (E3). The complex 
catalyses the oxidative decarboxylation of pyruvate and the subsequent acetylation of 
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coenzyme A to acetyl-CoA (for recent reviews: Perham 1991; Mattevi et al., 1992a; Berg & 
De Kok, 1997; De Kok et al., 1998). The substrate specific thiamin diphosphate dependent 
Elp catalyses the decarboxylation of pyruvate and subsequently the reductive acetylation of 
the lipoamide groups attached to E2. The E2 component then transfers the acyl group to CoA. 
Finally, the reduced lipoyl group is reoxidised by the FAD dependent E3 component, which 
transfers the reduction equivalents to NAD+. 
The E2 component plays a central role in of the complex, both catalytically and structurally. 
This component consists of three to five domains interconnected by flexible linkers of 20 to 
40 amino acids. This architecture allows a high degree of flexibility of the individual domains, 
required for catalysis. One to three N-terminal lipoyl domains, each carrying a lipoyl-lysine 
group, are attached to the E1/E3 binding domain. The C-terminal catalytic domain forms the 
structural core of the complex. Three-dimensional structures of the different domains of E2 
have been solved either by X-ray crystallography (Mattevi et al., 1992c; Mattevi et al., 1993a) 
or by NMR (Berg et al., 1997; Berg et al., 1996b; Ricaud et al., 1996; Green et al., 1995; 
Dardel et al., 1993). Structures of E3 from several sources have been solved by X-ray 
crystallography (Mattevi et al., 1991; Mattevi et al., 1993b). The well-conserved E2p binding 
domain consists of two parallel helices connected by a short strand, a turn and a disordered 
loop (Kalia et al., 1993; Robien et al., 1992). The binding mode of Bacillus 
stearothermophilus E3 to the binding domain was recently solved by X-ray crystallography 
(Mande et al., 1996). The interactions between E3 and the binding domain are dominated by 
an electrostatic zipper formed by basic residues of the binding domain and acidic residues of 
one of the subunits of E3. Because E3 is homodimeric the binding domain can interact with 
both E3 subunits, but the binding site is located so close to the twofold symmetry axis that it 
is impossible for two molecules of the binding domain to bind simultaneously to one E3 
dimer. The E2p binding domain behaves like a Janus-face protein: While E3 interacts with the 
N-terminal helix, mutagenesis experiments indicate that Elp from Azotobacter vinelandii 
interacts with the C-terminal part (Schulze et al., 1991a). The point mutation R416D in the 
catalytic domain from A. vinelandii also resulted in highly impaired Elp binding. Deletions in 
the flexible linker region between the binding and the catalytic domain had no effect on the 
affinity of Elp for E2p. Thus it can be concluded that the binding site for Elp consists of two 
regions, one located on the binding domain and one on the catalytic domain. 
The El component exists both as a homodimer (a2) or a heterotetramer (a2|32) depending on 
the source and type of complex. Homodimeric El with a molecular mass of approximately 
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100 kDa is found in all 2-oxoglutarate dehydrogenases (Elo) and in pyruvate dehydrogenases 
from gram-negative bacteria. Heterotetrameric El is found in branched-chain-2-oxoacid 
dehydrogenases (Elb) and in pyruvate dehydrogenases from eukaryotes and gram-positive 
bacteria. Little sequence similarity is found between the different classes of El (Matuda et al., 
1991), with exception of the thiamin diphosphate binding motif, present in all thiamin 
diphosphate dependent enzymes (Hawkins et al., 1989). Until now no structural information is 
available for either homodimeric or heterotetrameric El and any information on the 
interaction between El and E2 is lacking. Previously, cryoelectron microscopy experiments 
showed that Elo, Elp and E3 are separated from the surface of the E2 core by 4 - 6 nm, and 
sometimes thin bridges of density are visible in the gap between the core and the bound 
subunits. The bridging density between El and E2 seems to represent more mass than 
between E2 and E3 (Wagenknecht et al., 1990; Wagenknecht et al., 1992). Studies by 
scanning transmission electron microscopy show that El is bound along the edges of the cubic 
core, while E3 is present on the faces of the core (Yang et al., 1985). When El is bound to the 
complex, the lipoyl domains are located mostly at the E2-E1 interfaces, while removal of El 
from the complex gives a much larger conformational freedom to the lipoyl domains (Yang et 
al., 1994). 
Elp from A. vinelandii has recently been cloned and expressed in Escherichia coli, which 
makes it possible to study the interaction between El and E2 in more detail. Limited 
proteolysis experiments of A. vinelandii Elp showed that its N-terminal region can easily be 
cleaved off (Hengeveld et al., 1997). The remaining fragment is still active, but unable to bind 
to E2p. This suggests that Elp has an N-terminal domain that is involved in the binding to 
E2p, but not in catalysis. To further investigate the role of this domain in the binding to E2p 
N-terminal deletion mutants were made using endonuclease Bal-31. The characterisation of 
these mutants is described in this paper. 
Experimental Procedures 
Materials 
Restriction endonucleases, Endonuclease Bal-3l, T4-DNA-ligase and Taq polymerase were 
obtained from Bethesda Research Laboratory (BRL). Klenow Polymerase was obtained from 
Biolabs. Alkaline phosphatase (calf intestinal), Goat-anti-rabbit IgG-alkaline phosphatase and 
Endoproteinase GluC were obtained from Boehringer Mannheim. The QIAprep Spin 
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Miniprep kit and the QIAquick Nucleotide Removal kit were obtained from Qiagen. The 
Genecleanll kit was obtained from Westburg. a-32P-ATP was obtained from Amersham. 
14 
Sodium (2- C)-pyruvate was obtained from New England Nuclear research products. 
Pefabloc SC (4-(2-aminoethyl)-benzene-sulfonylfluorid hydrochloride) was obtained from 
Merck. Activated Thiol-Sepharose, Fastflow Q-Sepharose and HiLoad Q-Sepharose 
(preparative grade), Sephacryl S400 (preparative grade), Superose-6 (analytical grade), 
Superdex-200 (analytical grade), MonoQ (prepacked, 1 ml) and molecular weight markers 
were obtained from Pharmacia Fine Chemicals. The sequencing primers were from Pharmacia 
Biotech. Chymotrypsin and trypsin were from Sigma. All other chemicals used were of 
analytical grade. 
The E. coli strain TG2, a recA- version of TGI [AflacproAB), thi, supE, Res' Mod (k), F' 
(traD36 proA+B+ Jacfi lacZ AM15] was used (Gibson 1984). The plasmids pUC9 and 
pUC18 were used as cloning vectors (Vieira & Messing, 1982). 
Construction ofN-terminal deletion mutants. 
Standard DNA operations were performed as described (Ausubel, 1987). 
pAFHOOl (Hengeveld, Westphal. & De Kok, 1997), containing the complete Elp gene, was 
used as the starting material for the construction of the endonuclease Bal-3\ deletion mutants. 
The general approach for preparing Bal-3\ deletion mutants was derived from (Sambrook, 
Fritsch, & Maniatis, 1989). The region encoding A. vinelandii Elp was excised from 
pAFHOOl using EcoRI and Hindlll and cloned into pUC18 digested with Hindi. The resulting 
construct pSESOl was used for the deletion experiments. A 1829 basepair A.-DNA fragment 
(EcoRl-Xmal) was inserted upstream from the Elp encoding region to prevent removal of 
bases from the region encoding the promoter and ribosome binding region of the vector 
(pSES02) (figure 1). pSES02 (5 mg) was linearised with Smal and incubated with Bal-3\ 
nuclease (0.015 U) at 37 °C yielding a digestion speed of 12 basepairs per min. Aliquots were 
taken at timed intervals up to 25 minutes and the reaction was stopped by addition of EGTA, 
pH 9.0 up to a final concentration of 70 mM. The samples were digested by EcoRl to remove 
the remaining A.-DNA fragment, made blunt-ended, ligated and transformed in E. coli TG2 
cells. The transformed E. coli TG2 cells were screened for Elp expression by Western 
blotting using antiserum raised against A. vinelandii Elp (Hanemaaijer, 1987). Positive 
colonies were subsequently analysed by SDS-PAGE. The plasmids were isolated and the 
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DNA-sequences of the N-terminal coding regions were determined using Taq polymerase 
according to (Sambrook, Fritsch, & Maniatis, 1989). 
Enzyme expression and purification 
E. coli TG2 harbouring either the recombinant plasmid pAFHOOl, expressing wild type Elp, 
or a deletion mutant were grown and purified as described in (Hengeveld et al., 1997). 
However, ElpA48 elutes at 0.2 M KC1 from the Q-Sepharose column while wild type Elp 
elutes at 0.4 M KC1. A. vinelandii wild type E2p and E3 were expressed and purified from E. 
coli TG2 as described in (Hanemaaijer et al., 1989; and Westphal & De Kok, 1988). 
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Figure 1 Scheme of the construction of the Bal-31 deletion mutants. The top bar represents linearised 
pSES02. pSES02 (5 mg) was incubated with Bal-31 nuclease (0.015 U) at 37 °C yielding a digestion speed 
of 12 basepairs per min.. Aliquots were taken at timed intervals up to 25 minutes. The samples were digested 
by EcoRl to remove the remaining 1-DNA fragment, made blunt-ended, ligated and transformed in E. coli 
TG2 cells. RBS is the Azotobacter vinelandii Elp ribosome binding site. LacZ' is the promoter and 
ribosome binding site region of the vector and the region encoding the N-terminal part of p-galactosidase. 
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Activity assays 
For the assay of the Elp component two methods were used. The oxidative decarboxylation of 
pyruvate was measured at 600 nm using 2,6-dichlorophenol-indophenol (C^Ind) (E = 
21.7xl03 M'cm"1) as an artificial electron acceptor (Khailova et al., 1977). One unit of 
activity is defined as the amount of enzyme required for the oxidation of 1.0 umole of C^Ind 
per minute. The ability of Elp to reconstitute overall PDHC-activity was measured 
spectrophotometrically at 340 nm as described in (Schwartz & Reed, 1970). 
The pH-inactivation of Elp and ElpA48 was measured by incubating the enzyme for 30 
minutes at a pH ranging from 5.5 to 9.5. Subsequently the El-activity was measured as 
described above. 
Reductive acetylation assay 
Reductive acetylation of the lipoyl domains by wild type Elp or a deletion mutant in the 
presence of 14C-labelled pyruvate was assayed as described in (Packman et al., 1984a; Berg et 
al., 1998) with the following modifications. Lipoyl domain (6 uM to 60 uM) was incubated 
with 2.5 mg Elp in 100 ml 50 mM potassium phosphate pH 7.0, containing 0.1 mM thiamin 
diphosphate and 1.0 mM MgC^. The reaction was started by addition of sodium (2-'4C) 
pyruvate to a final concentration of 0.25 mM. The reaction was stopped after 30 seconds. 
Interaction of Elp and ElpA48 with E2p. 
The interaction of Elp with E2p was studied by two methods. Firstly, the dissociation of the 
24-meric E2p core into trimers upon binding of Elp was monitored on Superose-6 and 
Superdex 200 gelfiltration columns using a AKTA explorer system (Pharmacia Biotech). The 
proteins were eluted with 50 mM potassium phosphate buffer, pH 7.0, containing 0.1 mM 
thiamin diphosphate (ThDP), 0.1 mM MgCl2, 25 uM EDTA, 50 ^M Pefabloc and 0.02% 
NaN3 (standard buffer), containing 150 mM KC1 (Schulze et al., 1991a; Hengeveld et al., 
1997). Both columns were calibrated using the following proteins: cytochrome c (12.4 kDa), 
myoglobin (17.8 kDa), chymotrypsinogen (25 kDa), bovine albumin (67 kDa), alcohol 
dehydrogenase (144 kDa), catalase (232 kDa), pyruvate kinase (237 kDa), vanilyl alcohol 
oxidase (500 kDa), citrate lyase (550 kDa) and dextran blue (2000 kDa). 
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Secondly, the PDHC activity reconstituted from wild type E2p, wild type E3 and wild type or 
mutant Elp was assayed as described above. 
Preparation ofheterodimers 
For the preparation of heterodimers containing one subunit of the wild type Elp and one 
subunit of a deletion mutant, wild type Elp and the deletion mutant were mixed in an 
equimolar ratio in standard buffer (0.4 mg/ml). The pH of this mixture was raised to 9.5 by 
addition of 7.5 ul ethanolamine ( 1 % w/v) to 100 ul mixture. The mixture was incubated on ice 
for 15 min. Subsequently the pH was lowered to 7 by addition of potassium phosphate (1 M, 
pH 6.9) to a final concentration of 75 mM and incubated on ice for 1 hour. After the addition 
of potassium phosphate in some cases fresh ThDP was added to a final concentration of 0.1 
mM. The resulting mixture of homodimers of wild type Elp, deletion mutant and 
heterodimers was separated on a MonoQ column (1 ml) in standard buffer with a gradient of 0 
- 0.6 M KC1 using an AKTA explorer system (Pharmacia Biotech) for monitoring. The 
heterodimers were used immediately for further analysis. 
Others 
SDS-PAGE was performed as described in (Schagger & Von Jagow, 1987). For the purpose 
of Western blotting SDS-PAGE was performed as described in (Laemmli, 1970). Protein 
concentrations were estimated using the microbiuret method (Goa, J., 1953), bovine serum 
albumin was used as a standard. Antiserum against A. vinelandii E lp was produced as 
described in (Hanemaaijer et al., 1987). 
Limited proteolysis experiments using trypsin, chymotrypsin and endoproteinase GluC were 
performed as described in (Hengeveld et al., 1997). 
Results and discussion 
Construction of N-terminal deletion mutants 
When studying the structure/function relationships of Elp it was found that the N-terminal 
region can easily be removed by limited proteolysis without effecting catalysis. This 
truncation caused the loss of its ability to bind to the core component of the complex (E2p). 
42 Chapter 3 
Therefore, we decided to study the role of the N-terminal region in greater detail by 
constructing N-terminal deletion mutants of A. vinelandii El p. 
Incubation of pSES02 with endonuclease Bal-31 starting 60 basepairs upstream of the start 
codon of Elp (figure 1) resulted in 412 mutants, divided into 4 groups, based on the 
incubation time (Table 1). Because the deletion mutants lack the A. vinelandii ribosome 
binding site and the start codon, they were expressed as a protein fused to the first 6 amino 
acids (MTMITN) of P-galactosidase. The number of deletion mutants that result in an 
expressed fusion-product (Table 1) corresponds well to the expected number. The sequencing 
results in Table 2 show that the largest deletion expressing Elp in group III is 196 basepairs 
even though the group contains deletions up to 300 basepairs. This indicates that deletions 
beyond 196 basepairs do not result in expression of a folded protein. As seen from Table 2 a 
preference is seen for some truncations, mostly situated in the region where the proteolytic 
sites for trypsin (R44), chymotrypsin (R37) and endoproteinase GluC (E40) are found. 
Proteolysis sites are usually in flexible regions on the surface of a protein. Truncated proteins 
starting in these regions are therefore more likely to fold correctly. This could explain why 
many of deletions are found in a region highly susceptible to proteolysis. Since truncations of 
26 and 29 amino acids are also prominent, this suggests a more flexible or loop region. 
Table 1 The results of the construction of N-terminal deletion mutants using Bal-3\, divided into groups based 
on the incubation time (12 basepairs sec"1). The mutants were constructed as described in the experimental 
procedures. 
Group 
I 
II 
III 
IV 
Number of 
Colonies 
154 
128 
64 
66 
Deleted basepairs 
0-24 
48-96 
144-192 
240-300 
Antibody 
screeninga) 
129 (84%) 
60 (47%) 
20(31%) 
5 (8%) 
Overexpression b) 
n.a. 
18 
13 
4 
Sequenced c) 
0 
13 
13 
4 
a)
 The number of colonies that showed Elp expression using antibodies raised against Elp, and the percentage of 
colonies showing Elp-expression to the total number in this group. 
' The number of colonies that showed over-expression of Elp in SDS-PAGE. Only colonies that were found 
positive by antibody screening were used. n.a. means not analysed 
c)
 Number of mutants that were sequenced. Only mutants that showed Elp over-expression on SDS-PAGE were 
used. 
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A number of mutants were tested for their ability to reconstitute complex activity (Table 2). 
Up to 13 amino acids could be fused to the N-terminus without impairing the ability to 
reconstitute complex activity (6 from P-galactosidase + 7 upstream from the start codon of 
Elp). Up to 9 amino acids could be deleted without effecting this ability. Truncation from 9 
up to 48 amino acids resulted in expression of folded enzyme, but in all cases the ability to 
reconstitute complex activity was completely lost. Truncations larger than 48 amino acids did 
not result in a folded enzyme. This demonstrates that almost the entire N-terminal region is 
necessary for the folding of a functional N-terminal domain. If only part of the N-terminal 
domain is removed and part is present as a misfolded or unfolded structure, this might 
interfere with the interactions between Elp and E2p. For this reason the mutant ElpA48 (-196 
basepairs) was selected for further characterisation. 
Expression and purification of deletion mutant ElpA48 
The expression of the mutant ElpA48 differed considerably from that of the wild type enzyme 
(Hengeveld et al., 1997). The mutant shows a much higher expression level, while it is not 
found in inclusion bodies. This can be explained by the fact that wild type Elp from A. 
vinelandii binds to E. coli E2p, but this does not result in a completely active complex (60 %) 
(De Kok & Westphal, 1985; Schulze et al, 1992). ElpA48 lacks its N-terminal domain and 
thus does not bind to and inhibit the E. coli PDHC. 
The purification procedure of ElpA48 was identical to that described for wild type Elp. 
ElpA48 shows an increased stability compared to wild type Elp, indicating that the instability 
of Elp is (partly) caused by its N-terminal domain. This could also explain the increased 
stability of Elp when bound to E2p. 
L im ited proteolysis 
Proper folding of ElpA48 was checked by limited proteolysis studies. The proteolysis patterns 
were compared to those found for Elp as described previously (Hengeveld ,et al., 1997). 
Endoproteinase GluC does not cleave ElpA48. In wild type Elp it cleaves at a single site 
(E40) in the N-terminal region and since no extra cleavage sites are found in ElpA48, ElpA48 
clearly folds in a similar way. Both trypsin and chymotrypsin cleave wild type Elp at two 
sites, one of them in the N-terminal region (R44 + R418 and R37 + Y553 respectively). 
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Because ElpA48 is truncated very close to the N-terminal proteolysis sites the large fragments 
obtained after proteolysis are expected to be almost identical (only 4 and 11 amino acids 
difference respectively) to those obtained for Elp. The digestion patterns obtained for ElpA48 
with trypsin and chymotrypsin are indeed very similar to those of Elp, again showing that 
ElpA48 is correctly folded. 
Interactions ofElpA48 with E2p 
The binding of Elp and ElpA48 to E2p was studied by two different methods. Firstly the 
E2p-E3 subcomplex was titrated with either wild type Elp or the deletion mutant. For the 
wild type enzyme reconstitution of the overall PDHC activity resulted in a specific activity of 
28.9 U/mg E2p at an optimum molar ratio of 1.9 Elp dimers per E2p trimer and E3 dimer 
(Hengeveld et al., 1997). Using up to 40 ElpA48 dimers per E2p trimer and E3 dimer we 
were not able to reconstitute any PDHC-activity. 
i • • ' ' i 
10 15 
Edition Volume (ml) 
Figure 2. Binding properties of the N-
terminal deletion mutant ElpA48. A. 
vinelandii E2p was added in equimolar 
ratios to the ElpA48 sample. 50 ml 
samples were loaded on a Superose 6 
column and eluted with 50 mM 
potassium phosphate, pH 7.0, 
containing 150 mM KC1, 0.1 mM 
MgCl2, 0.1 mM ThDP and 50 mM 
Pefabloc. is ElpA48, 
is E2p and is ElpA48 + E2p. 
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Table 2 Ability of a number of Bal-31 deletion mutants to reconstitute PDHC-activity. PDHC-activity was 
measured by recombining cell extract of the deletion mutant with E2p and E3 from Azotobacter vinelandii, as 
described in the experimental procedures. Mutants were N-terminally fused to the amino acids "MTMITN". 
a)
 The 6 amino acids from P-galactosidase fused to the N-terminus are not included in this number. 
Number of Number of deleted/added Number of 
Group deleted basepairs amino acidsa) PDHC-activity mutants 
li 
II 
II 
II 
II 
II 
II 
IV 
III 
HI 
III 
III 
III 
IV 
IV 
IV 
Secondly, the binding of ElpA48 to E2p was monitored by analytical gelfiltration 
experiments. The A. vinelandii E2p core consists, like that of other gram-negative bacteria, of 
24 subunits, forming a cubic structure. However, upon binding of Elp and/or E3 the 24-
subunit core dissociates into trimers (Mattevi et al., 1992c). This property can easily be 
monitored by analytical gelfiltration (Schulze et al., 1991b). Figure 2 shows that ElpA48 has 
no influence on the 24-subunit core and elutes as a separate fraction. The size of ElpA48 was 
estimated from these experiments and it was evident that ElpA48 is present as a dimer and is 
only slightly smaller in size than the wild type enzyme. 
The above-mentioned measurements all confirm our hypothesis that the N-terminal region of 
Elp is required for the binding of Elp to E2p. The fact that ElpA48 lacks this region, but is 
still correctly folded and present as a dimer, points to the presence of a separate folding 
domain. It is clear that the N-terminal domain is necessary for the binding of Elp to E2p, but 
24-48 
25 
31 
40 
52 
79 
97 
130 
139 
151 
160 
163 
166 
172 
181 
196 
wild type 
+9 
+7 
+4 
0 
-9 
-15 
-26 
-29 
-33 
-36 
-37 
-38 
-40 
-43 
-48 
+ 
n.a. 
+ 
+ 
+ 
+ 
-
-
-
-
-
-
-
-
-
-
7 
1 
1 
1 
1 
1 
1 
2 
3 
1 
1 
3 
1 
1 
4 
1 
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it is unclear if one or both N-terminal domains in a dimer are involved in the binding. For this 
reason a heterodimeric molecule was prepared containing one subunit Elp and one subunit 
ElpA48. 
Heterodimer Preparation and Isolation 
Elp can be monomerised by raising the pH (Reed. & Oliver, 1968a). If the pH is lowered, Elp 
dimerises, although after this procedure the stability of the enzyme is somewhat decreased as 
shown before (Hengeveld et al., 1997). A mixture of Elp and ElpA48 was monomerised by 
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Figure 3. Preparation and isolation of 
heterodimeric Elp-ElpA48. 
Heterodimeric Elp-ElpA48 was prepared as 
described in detail in the experimental 
procedures. The dimers were separated on a 
MonoQ column (1 ml) in standard buffer using a 
gradient of 0 - 0.6 M KC1. Panel A, 50 ml 
sample. Panel B, 1 ml in which, after the 
addition of potassium phosphate ThDP was 
added to a final concentration of 0.1 mM. Part 
of the protein was not bound to the column and 
washed out at 0 M KC1. Peak I contains 
ElpA48, peak II contains the heterodimer Elp-
ElpA48 and peak III contains Elp. Panel C, 
SDS-PAGE of fractions of peak I, II and HI 
from panel B. The gel was stained using silver 
stain. HMW is high molecular weight marker, 
LMW is low molecular weight marker. I are two 
fractions of peak I, II are two fractions of peak 
II and III are two fractions of peak III. 
incubation at pH 9.5 for 15 minutes and subsequently dimerised by lowering the pH to 7. 
Theoretically the mixture should contain three dimers in a ratio 1:2:1 (Elp-Elp : Elp-ElpA48 
: ElpA48-ElpA48). 
As was already seen during the purification of ElpA48 the deletion mutant binds weaker to an 
anion exchange column than wild type enzyme. The observed difference in binding can be due 
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to the differences in pi as calculated from the primary sequences (5.8 (Elp) and 6.3 (ElpA48) 
respectively). The pi value of the heterodimer is expected to be in between these two values 
Figure 3 A and 3B show elution patterns of dimer mixtures to which, after lowering the pH to 
7, 0.1 mM ThDP was (fig 3B) or was not added (fig 3A). Fractions corresponding to the three 
peaks shown in both figures 3A and 3B were subjected to SDS-PAGE (fig 3C). Peak I shows 
a single protein band corresponding to ElpA48, peak III shows a single band corresponding to 
Elp. Peak II shows two bands corresponding to both Elp and ElpA48, present in equal 
amounts. Analytical gelfiltration using a Superose 6 column showed that the molecules in all 
three peaks were present as dimers. Fractions of all three peaks were tested for their ability to 
reconstitute PDHC-activity. Complex activity could only be detected using peak III. Using up 
to a 40 times excess of enzyme from peaks I and II did not result in the reconstitution of any 
complex activity. From these experiments it is clear that peak II contains heterodimeric 
molecules consisting of one subunit of Elp and one subunit of ElpA48. 
Comparing figure 3 A and 3B shows that in the absence of ThDP (fig 3 A) during dimerisation 
there is a strong preference for the formation of homodimeric molecules. This preference 
disappears if 0.1 mM ThDP is added during dimerisation (fig 3B) and the ratio of the formed 
dimers is much closer to the theoretically expected 1:2:1 ratio. ThDP is rapidly hydrolysed at 
high pH (Sober & Harte, 1970) and therefore it might be degraded during monomerisation. 
Therefore, in the absence of ThDP most likely apo-enzyme is formed, while in the presence of 
ThDP holo-enzyme is formed. The high sequence identity (44 %) between the ThDP binding 
site of Elp and yeast transketolase suggest a similar binding mode of ThDP in both enzymes. 
In transketolase the binding of ThDP occurs on the dimer interface and involves residues of 
both subunits of the dimer (Lindqvist et al., 1992). In Elp ThDP influences the dimerisation, 
confirming the binding of ThDP at the dimer interface. The heterodimer is a very unstable 
molecule; concentrating it by several different methods resulted in inactivation. Due to these 
difficulties only small amounts of heterodimer could be obtained and used in activity 
measurements (see below) or binding studies. The concentration of the heterodimer is in the 
range where the 24-meric E2p partly dissociates into trimers. Therefore, the patterns obtained 
in analytical gelfiltration were not clear-cut. Using specific antibodies raised against both Elp 
and E2p it was shown however, that no binding occurs between the heterodimer and E2p. This 
demonstrates that for the binding of Elp to E2p both N-terminal domains are required. 
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Kinetic characterisation 
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Figure 4. Substrate titration 
curve of ElpA48 and Elp in 
50 mM potassium phosphate, 
pH 7. The reaction mixture is 
as described in the 
experimental procedures. 
Panel A shows the titration of 
ElpA48. The inset shows a 
detail of the titration of 0 - 1 
mM pyruvate. Panel B shows 
the titration of Elp. 
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To analyse whether the N-terminal domain solely functions as a binding domain (analogous to 
the binding domain of E2p), or if it has more functions, we investigated the kinetic properties 
of ElpA48. The reaction mechanism of Elp consists of several steps, as described in the 
introduction. Using an artificial electron acceptor (C^Ind), the oxidative decarboxylation of 
pyruvate can be measured. In figure 4 v/s curves of Elp and ElpA48 are shown. The resulting 
So.5 values, Vmax values and Hill coefficients for ElpA48 at different conditions were 
calculated (Table 3). The kinetic behaviour of wild type Elp, both bound in the complex and 
free has been investigated previously (Hengeveld et al., 1997; Bosma, 1984; Bresters et al., 
1975). These data are now compared to those of the deletion mutant ElpA48 (Table 3). From 
figure 4 one can see that both Elp and ElpA48 are inhibited by its substrate at high 
concentrations. The Kj values were calculated to be 31 mM (Elp) and 37 mM (ElpA48) 
respectively. 
Wild type Elp and ElpA48 both have a similar Vmax. The Hill-coefficients of ElpA48, 
indicative of the allosteric nature of the enzyme, remain the same within the experimental 
error. Besides this, the pH-inactivation curves of Elp and ElpA48 are very similar (results not 
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shown) with an optimum activity if incubated at pH 7. These experiments indicate that the 
deletion mutant is not only correctly folded but that is also has the same catalytic properties as 
wild type Elp. 
Surprisingly however, the S0.5 values of ElpA48 all decreased an order of magnitude 
compared to those of wild type Elp. Both AMP and potassium phosphate have a strong 
decreasing effect on the S0.5 values of both Elp and ElpA48. The inhibitor acetyl Co A 
decreases the S0.5 values for Elp while for ElpA48 the S0.5 value increases. The S0.5 value of 
ElpA48 in the absence of effectors (0.24 mM) is very similar to that of Elp in the presence of 
an activator (0.2 mM - 0.4 mM). It seems therefore, that the removal of the N-terminal domain 
results in activation of Elp. ElpA48 in this "activated conformation" has retained most of the 
kinetic properties of wild type enzyme; effectors show similar effects on the enzyme and its 
allosteric properties do not seem to have changed significantly. Moreover, the inhibition of 
Elp by its substrate does not change significantly due to truncations of the N-terminal region. 
Slight alterations in the Hill-coefficients could possibly be due to the insensitivity and 
inaccuracy of the C^Ind-assay. On the other hand, the proximity of the highly negatively 
charged N-terminal domain (P, 4.0) to the active site in wild type Elp might decrease the 
effective concentration of pyruvate resulting in an apparent higher S0.5 
Table 3 Summary of the kinetic parameters for the El-reaction by Azotobacter vinelandii Elp and ElpA48. S0.5 
and V ^ values are calculated from the v/s curves in the presents of several different effectors. The Hill 
coefficients are calculated from the log(s) / log(Vmax-v/v) curve. The reactions were performed as described 
under the experimental procedures. 
Tris, pH 7.4 
KPi, pH 6.9 
KPi, pH 7.4 
Tris&KPi, pH 7.4 
Tris&acetylCoA, pH 7.4 
Tris&AMP, pH 7.4 
S0.5(mM) 
E l p " 
2.0 
0.2 
n.a. 
n.a. 
1.5 
0.4 
ElpA48 
0.2 
0.03 
0.05 
0.01 
0.5 
0.02 
Hill coefficient 
E lp 1 ' 
1.3 + 0.2 
1.2 ±0.2 
n.a. 
n.a. 
1.3 ±0.2 
0.8 ±0.1 
ElpA48 
1.0 ±0.2 
1.4 ±0.2 
1.4 ±0.2 
1.5 ±0.2 
1.2 ±0.2 
0.6 ±0.1 
V™, (U/mg) 
E l p " 
0.07 ±0.01 
0.08 ±0.01 
n.a. 
n.a. 
0.09 ±0.01 
0.1 ±0.02 
ElpA48 
0.06 ±0.01 
0.07 ±0.01 
0.07 ±0.01 
0.06 ± 0.01 
0.07 ±0.01 
0.04 ±0.01 
1) Kinetic constants for Elp were partially obtained from (24). n.a. is not analysed 
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The kinetic characterisation of the heterodimer shows that it is catalytically functional, 
although quite unstable. The Vmax (0.06 U/mg) is very similar to that of both Elp and ElpA48. 
The low concentration and the instability of the heterodimer, combined with the insensitivity 
of the C^Ind-assay resulted in rather inaccurate data in the v/s curve, so that no conclusions 
on the So.5 could be drawn. 
Figure 5. Reductive acetylation of the 
lipoyl domain of A. vinelandii, 
catalysed by Elp or ElpA48. The 
reaction mixture was as described in 
the experimental procedures, (x) Elp 
and(o)ElpA48. 
20 30 40 
[Lipoyl domain] (^M) 
The second part of the El-reaction, the transfer of the acyl group from hydroxy-ethyl-ThDP to 
the free lipoylated lipoyl domain was measured using radioactive labelled pyruvate at different 
lipoyl domain concentrations (figure 5). Km and kcat values for free lipoyl domain found for 
ElpA48 (24 uM and 1.1 s"1) are very similar to those found for Elp (27 uM and 0.9 s"1). The 
removal of the N-terminal domain clearly has no influence on the interactions of Elp with the 
lipoyl domain and on catalysis in the acyl-transfer. The fact that the Km and kcat values for 
complex-bound Elp (Km 43 uM and a kcat 0.8 s"' (Berg et al., 1998)) and non-complex-bound 
are highly comparable also confirm this: the binding of Elp to E2p has no influence on the 
interactions of Elp with free lipoyl domain. 
Summarising, the deletion mutant ElpA48 is catalytically fully functional. It can both 
decarboxylate pyruvate and transfer the acyl moiety to the lipoyl group. On the other hand, 
removal of the N-terminal domain decreases the S0.5 values for pyruvate, indicating the 
proximity of the N-terminal domain to the active site. 
Model of the interactions between Elp and E2p The N-terminal domain is highly conserved 
among all Elp's from gram-negative bacteria (figure 6). Previously, it was stated that no 
significant homology could be found between different ThDP-dependent enzymes, except in 
the ThDP-binding motif (Matuda et al., 1991; Hawkins et al., 1989). An overall identity of 
24% was found however between A. vinelandii Elp and yeast transketolase, even though Elp 
is 884 amino acids long and transketolase only 680 amino acids. Amino acids 1-70 from Elp 
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are completely absent in transketolase, indicating that these residues have a function that is 
absent in transketolase. The proposed binding function of the N-terminal region of Elp is in 
good agreement with this. Surprisingly the N-terminal sequence from Elp is completely 
absent in heterotetrameric El, indicative of a different binding mode in these enzymes. 
The secondary structure prediction program PHDsec (Rost & Sander, 1993) predicts a 
structure as shown in figure 6. Amino acids 1-9, which could be removed from Elp without 
effecting its binding properties, are predicted to form a loop-like structure. Amino acids 13-25 
and 28-44 are predicted to form two helices. It is likely that this region forms the core of the 
N-terminal domain; two helices connected by a small loop. From table 2 it can be seen that 
from amino acid 15- 26 no truncated enzymes were found, while truncated enzymes starting at 
residues 26 and 29 are very prominent, indicating an exposed region around residues 26 and 
29. Finally, a second loop region is predicted, separating the N-terminal domain from the 
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Figure 6. Aligned N-termini of Elp from several Gram-negative bacteria. A. vin. Azotobacter vinelandii Elp 
(Hengeveld et al., 1997); P. aer. Pseudomonas aeruginosa Elp (Rae et al., 1997); A. eut. Alcaligenus eutrophus 
Elp (Hein, & Steinbiichel, 1994); N. men. Neisseria meningitidis Elp (Ala' Aldeen et al., 1996); E Col. 
Escherichia coli Elp (Stephens et al., 1983); H. inf. Haemophilus influenzae Elp (Roe, Clifton, Dyer, 
Genococcal Genome Sequencing Project). Acidic residues are shown in boxes. The proteolytic sites for trypsin 
(R44), chymotrypsin (R37) and endoproteinase GluC (E40) are shown in bold. The bottom line shows the 
secondary structure as given by the secondary structure prediction program PHDsec (Rost & Sander, 1993). "1" is 
loop, "h" is helix, " • " means no prediction is made for this residue. On the right the amount and percentage 
(between brackets) of positively and negatively charged residues in the N-terminal region is shown. 
remaining part of the enzyme. Analysis of the structure of a synthetic peptide representing the 
N-terminal sequence of Elp is in progress. 
From previous experiments (see introduction) it was concluded that the binding site for Elp 
on E2p consists of two regions, one on the binding domain and one on the catalytic domain. In 
both regions, as shown by mutagenesis (Schulze et al., 1991a), positively charged residues are 
involved in the interactions (figure 6). The N-terminal region of Elp is highly negatively 
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charged. A. vinelandii Elp contains 24 % acidic residues in the first 50 amino acids compared 
to an average of 14 % in the complete enzyme. The amount of basic residues is relatively low 
(10% in the first 50 amino acids, compared to 14 % in the complete enzyme). 
Residues El4, D17, E20, D24 and E28 would, according to the secondary structure prediction, 
all be present in a helix and moreover all on the same side of this helix. This indicates that 
these residues might be involved in the interactions between Elp and E2p. Site directed 
mutagenesis studies are in progress to confirm this hypothesis. 
Binding studies using the heterodimeric Elp-ElpA48 showed that both N-terminal domains 
are essential for the binding of Elp to E2p. Because binding occurs to both the binding 
domain and the catalytic domain of E2p (Schulze et al., 1991a), we propose that one N-
terminal domain binds to the binding domain, while the other one interacts with the catalytic 
domain. Most likely the acidic residues on the N-terminal domain and basic residues (Schulze 
et al., 1991a) on E2p are involved these interactions. The observed stochiometry in A. 
vinelandii PDHC (three Elp dimers per E2 trimer) (Bosma , 1984) seems to exclude a 
symmetric binding mode in which one dimer of Elp interacts with two E2p binding domains. 
Apparently an asymmetric binding mode is preferred, as is the case with E3 (Mande et al., 
1996). 
Summarising we can conclude that Elp has an N-terminal domain functioning as the binding 
domain for its binding to E2p. The Elp dimer binds to E2p through interactions of this 
domain with both the binding domain of E2p and the catalytic domain of E2p. Besides its 
binding function the N-terminal domain also influences the kinetic behaviour of Elp, 
indicating that the N-terminal domain is in proximity of the active site. 
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4 Functional and structural characterisation of the N-
terminal domain of prokaryotic pyruvate dehydrogenase. 
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Annechien F. Hengeveld , Carlo P. M. van Mierlo, Henno W. van den Hooven , Antonie J. W. G. 
Visser, Aart de Kok. Functional and structural characterisation of the N-terminal domain of prokaryotic 
pyruvate dehydrogenase. 
Abstract 
We used a synthetic peptide (Nterm-Elp) to characterise the structure and function of the N-terminal region 
(amino acid residues 4-45) of the pyruvate dehydrogenase component (Elp) from the pyruvate dehydrogenase 
multienzyme complex (PDHC) from Azotobacter vinelandii. Activity and binding studies established that Nterm-
Elp specifically competes with Elp for binding to the dihydrolipoyl acyltransferase component (E2p) of PDHC. 
Moreover, the experiments show that the N-terminal region of Elp forms an independent folding domain that 
functions as a binding domain. CD measurements, 2D- H NMR analysis and secondary structure prediction all 
indicate that Nterm-Elp has a high a-helical content. Here we propose a structural model of the N-terminal 
domain. 
We demonstrate that the peptide is present in two conformations, the population of which depends on the sample 
conditions. The conformations are designated "unfolded" at a pH above 6 and "folded" at a pH below 5. The 2D-
H TOCSY spectrum of a mixture of folded and unfolded Nterm-Elp shows exchange cross peaks that "link" the 
folded and unfolded state of Nterm-Elp. We suggest that the exchange rate between the two species is in the 
range of 0.5 to 5 seconds . Sharp resonances in the NMR-spectra of wild type Elp demonstrate that this 200 
kDa enzyme contains highly flexible regions. The observed dynamic character of Elp and of Nterm-Elp is likely 
required for the binding of the Elp dimer to the two different binding sites on E2p. Moreover, the flexibility 
might be essential to sustain the allosteric properties of the enzyme bound in the complex. 
Introduction 
The pyruvate dehydrogenase multienzyme complex (PDHC) from gram-negative bacteria 
consists of multiple copies of three different enzyme components: pyruvate dehydrogenase 
(Elp), dihydrolipoyl acyltransferase (E2p) and lipoamide dehydrogenase (E3). The complex 
catalyses the oxidative decarboxylation of pyruvate and the subsequent acetylation of 
coenzyme A to acetyl-CoA (for reviews see Perham, 1991; Mattevi et al., 1992a; Berg and De 
Kok, 1997; De Kok et al., 1998; Perham, 2000). The substrate specific, thiamin diphosphate 
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dependent Elp catalyses the decarboxylation of pyruvate and subsequently the reductive 
acetylation of the lipoamide groups attached to E2p. The E2p component then transfers the 
acyl group to CoA. Finally, the reduced lipoyl group is re-oxidised by the FAD dependent E3 
component, which transfers the reduction equivalents to NAD+. 
E2p plays a central role in the complex, both catalytically and structurally. It consists of four 
to five domains interconnected by flexible alanine/proline rich linkers of 20 to 40 amino acids. 
This architecture allows a high degree of flexibility of the individual domains, required for 
catalysis. From N- to C-terminus, E2p consists of two or three lipoyl domains, each carrying a 
lipoyl-lysine group, an E1/E3 binding domain and a catalytic domain that also forms the 
structural core of the complex. Three-dimensional structures of the different domains of E2p 
have been solved either by X-ray crystallography (Mattevi et al., 1992c; Mattevi et al., 1993a; 
Knapp et al., 1998; Knapp et al., 2000; Izard et al., 1999) or by NMR spectroscopy (Dardel et 
al, 1993; Green et al. 1995; Ricaud et al, 1996; Berg et al, 1997). 
The E1/E3 binding domain of E2p behaves like a Janus-face protein: E3 interacts solely with 
the N-terminal helix of the E1/E3 binding domain, while Elp interacts with the C-terminal 
part of the E1/E3 binding domain. The binding mode of B. stearothermophilus E3 to the 
binding domain was solved by X-ray crystallography (Mande et al, 1996). An electrostatic 
zipper dominates the interactions between the E3 dimer and the well-conserved E1/E3 binding 
domain, with acidic residues on E3 and basic residues on the binding domain of E2. Since 
point mutations in the E1/E3 binding domain and in the catalytic domain from A. vinelandii 
E2p both result in highly impaired Elp binding (Schulze et al, 1991a), it can be concluded 
that the binding site for Elp, unlike the binding site for E3, consists of two regions, one 
located on the E1/E3 binding domain of E2p and one on the catalytic domain of E2p. This 
was confirmed by the construction of A. vinelandii - Escherichia coli chimeric E2p (Schulze 
et al, 1992): Elp only interacts strongly with a chimeric E2p when both the E1/E3 binding 
domain and the catalytic domain are of the same origin as Elp. 
The Elp component exists both as a homodimer (a2) or a heterotetramer (a2p2) depending on 
the source and type of complex. Recently the 3-dimensional structures of the heterotetrameric 
branched-chain 2-oxoacid dehydrogenase (Elb) from Pseudomonas putida and from human 
were solved (/Evarsson et al, 1999; ^Evarsson et al, 2000). No structural information is 
available though for the homodimeric El. However, recent studies (Hengeveld et al, 1997) 
have given insight into the binding mode of homodimeric Elp to E2p. Limited proteolysis 
experiments of Azotobacter vinelandii Elp showed that its N-terminal region (amino acids 1-
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50) could easily be cleaved off. The remaining fragment is still active, but unable to bind to 
E2p. This suggests that the N-terminal region is involved in the binding to E2p, but not in 
catalysis. The role of the N-terminal sequence of A. vinelandii Elp in the binding to E2p was 
confirmed by the construction of a series of N-terminal deletion mutants (Hengeveld et al., 
1999). Construction of a heterodimeric Elp, containing only one N-terminal region, 
demonstrated that not one but both N-termini of the homodimer are necessary for good 
binding. 
From the previous studies it is not evident whether the N-terminal region of Elp forms an 
independent folding domain, and if so, how this domain functions. To attempt to answer these 
questions, we used a synthetic peptide called Nterm-Elp that comprises amino acids 4-45 of 
the N-terminal region of Elp from A. vinelandii in both functional and detailed spectroscopic 
studies. By answering these questions we expect to gain more insight in the binding process of 
Elp to its two different binding sites on E2p. 
Experimental Procedures 
Peptide synthesis 
A peptide consisting of 42 amino acid residues (designated Nterm-Elp) 
(MQDLDPIETQEWLDSLESVLDHEGEERAHYLLTRMGELATRT) that mimics the N-
terminal region of Elp was synthesised by Genosys Biotechnologies. The peptide was 
supplied lyophilised and purified (84%) by reversed phase high performance liquid 
chromatography (HPLC) using an acetonitrile/water solvent gradient containing 0.1% 
trifluoroacetic acid (TFA). The peptide was further purified to 98% by HPLC using the same 
solvents. 
Enzyme isolation 
The E. coli strain TG2, a recA- version of TGI [AflacproAB), thi, supE, Res' Mod ' (k), F' 
(traD36 proA+B+, lacl q lacZ AM 15)] (Gibson, 1984) harbouring the recombinant plasmid 
pAFHOOl, expressing wild type Elp was grown and purified as described in (Hengeveld et al., 
1997). A. vinelandii wild type E2p and E3 were expressed and purified from E. coli TG2 as 
described in (Hanemaaijer et al., 1989) and (Westphal and De Kok, 1988). A. vinelandii E3-
Y16F was expressed and purified as described in (Benen et al., 1992). 
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Activity assays 
The oxidative decarboxylation of pyruvate by Elp was measured at 600 nm using 2,6-
dichlorophenol-indophenol (C^Ind) (e = 21.7*103 M"'cm"') as an artificial electron acceptor 
(Khailova et al., 1977). The E2p component was assayed as described in (Bresters et al., 
1977). The E3 and E3-Y16F component were assayed as described in (Van den Broek, 1971). 
The overall PDHC-activity was reconstituted by incubating E2p with Elp and E3 or E3-Y16F 
and was measured spectrophotometrically at 340 nm as described in (Schwartz and Reed, 
1970). 
Binding studies 
The binding of Nterm-Elp to E2p was analysed by analytical size-exclusion chromatography 
using a Superose 6 column (Pharmacia Biotech) as described in (Hengeveld et al., 1997). The 
collected fractions were analysed by SDS-PAGE (Schagger and Von Jagow, 1987). The E2p 
concentration was 8.3 uM; the Nterm-Elp concentration was 40.6 uM. 
Protein concentrations were estimated using the microbiuret method (Goa, 1953), Bovine 
serum albumin was used as a standard. 
Limited proteolysis and MALDI-TOF MS 
Truncated A. vinelandii Elp for NMR spectroscopy was obtained by limited proteolysis of 
Elp by endoproteinase GluC as described in (Hengeveld et al., 1999). A 1 mg/ml 
concentration of Elp was used and the reaction was stopped by addition of TLCK (260 uM 
final concentration). After proteolysis, the small fragments and the protease were removed 
from the sample by ultrafiltration, using a 100 kDa cut-off filter. This step was repeated three 
times. The sample was concentrated to the original starting volume of the undigested Elp 
NMR sample, resulting in a concentration of approximately 0.5 mM of digested Elp. 
For MALDI-TOF MS truncated A. vinelandii Elp was obtained by limited proteolysis of the 
enzyme by endoproteinase GluC as described in (Hengeveld et al., 1999). The small fragments 
were separated from the large (core) fragment on a Superdex peptide column. The collected 
fractions were freeze-dried and subsequently dissolved in 20-100 ul water. Remaining salt 
was removed by use of cation exchange chromatography (Biorad AG50W-X8 column). 
Finally the samples, which were changed by hydrophobic interaction chromatography (Millex-
FH, Millipore Corporation) into 50% AcNi + 0.1% TFA / H20, were analysed by MALDI-
TOF MS on an applied Biosystems voyager DE RP using x-cyano 4 hydroxy cynamic acid as 
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a matrix solution. TFA was used to decrease the pH of the samples. Microperoxidase (MP-8) 
(Kraehenbuhl et al., 1974) was used for calibration. 
Spectroscopic measurements 
Circular dichroism spectroscopy 
CD spectra were recorded at 20 °C on a Jasco spectropolarimeter, model J-715. Spectra were 
recorded in cuvettes with a 0.1 cm path length. The peptide concentration was 10.1 uM (50 
ug/ml) in 10 mM potassium phosphate (pH 4.8). The pH was adjusted by addition of aliquots 
of 250 mM NaOH or of 250 mM HC1 to values ranging from pH 3-7. The ionic strength was 
increased by the addition of aliquots of 3M KC1. 
Fluorescence spectroscopy 
The fluorescence emission spectra were measured on a Fluorolog 3 (SPEX) fluorimeter at 
several temperatures using excitation wavelengths of 280 or 295 nm, with 1 nm slits. The 
sample conditions were identical to those described for the CD measurements. Spectra were 
recorded in 1 ml fluorescence cuvettes with a 1 cm path length. 
Time-resolved fluorescence spectroscopy 
Time-resolved fluorescence measurements were carried out using mode-locked continuous 
wave lasers and time-correlated counting as detection technique. A mode-locked CW Yttrium 
Lithium Fluoride (YFL) laser was used for the synchronously pumping of a cavity-dumped 
Rhodamine 6G dye laser. The samples were 1 ml with a light path of 1 cm. Fluorescence was 
detected at an angle of 90° with respect to the excitation light beam. An interference filter 
(Schott 348.8 nm) was used for detection. Measurements consisted of repeated sequences of 
measuring during 10 s parallel and 10 s perpendicular polarised emission. Background 
emission of the buffer solution was measured and used for background subtraction. The fast 
and single exponential fluorescence decay of para-terphenyl in 50/50% cyclohexane/CCLi was 
measured for obtaining a dynamic instrumental response. Data analysis was performed using a 
home-built computer program (Novikov et al., 1999). The peptide concentration was 10.1 or 
20.2 uM in 10 mM potassium phosphate (pH 4.8). The pH was adjusted by the addition of 
aliquots of 250 mM NaOH or of 250 mM HC1. The E2p concentration was 3.5 or 7.0 uM. 
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NMR spectroscopy 
Samples of the peptide Nterm-Elp contained 4.05 mM protein in 90% H20 / 10% 2H20 (ID 
NMR measurements) or 8.1 mM protein in 90% H20 / 10% 2H20 (2D NMR measurements). 
The Elp samples contained 0.5 mM protein in 90% H20 / 10% H20. The pH was adjusted 
by the addition of a small amount of a solution of 250 mM NaOH or of 250 mM HC1. ThDP 
was added to the Elp and to the truncated Elp sample to a concentration where the NMR 
signals originating from free ThDP were just visible in the recorded NMR spectra. Truncated 
Elp was obtained by limited proteolysis of Elp by endoproteinase GluC as described above. 
The Elp NMR-sample was diluted to a 1 mg/ml solution. NOESY (xm=50 ms) (Kumar et al., 
1980; Macura & Ernst, 1980) and TOCSY (xm =50 ms) (Braunschweiler and Ernst, 1983) 
spectra were acquired on a Bruker AMX500 spectrometer. The used carrier frequency 
coincided with the water resonance. The sample temperature was maintained at 284 or 298 K 
as calibrated with tetramethylammonium nitrate (TMA). The NOESY spectra were acquired 
with pre-saturation during the relaxation delay and mixing time. The TOCSY spectra were 
acquired using homonuclear Hartman-Hahn transfer using the clean-MLEV17 sequence for 
mixing, using two power levels for excitation and spinlock (Bax et al., 1988). Time 
proportional phase incrementation (TPPI) (Marion & Wuthrich, 1983) was used in all 
experiments. The TOCSY experiments were recorded with 120 t\ experiments and 2048 data 
points. The TOCSY experiment of Elp was recorded with 64 t\ experiments and 2048 data 
points. The NOESY experiments were recorded with 176 t\ experiments and 2048 data points. 
The spectral width was 8406 Hz. The chemical shift is reported relative to an external 
standard (2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS)). The obtained data were 
processed using XWINNMR software (Bruker). The data were digitally filtered using a sine-
bell shifted by 45° in the t2 dimension and a squared cosine-bell in the t\ dimension. After 
double Fourier transformation and interactive phase correction a baseline correction with a 
polynomial of maximum order 5 was performed to all spectra. The 2D spectra are presented as 
contour plots with 14 levels increasing by a factor of 1.3. 
A ID version of the 3-pulse NOESY sequence and phase cycle was used to collect the ID 
NMR data. No window functions were applied to the ID NMR data and no zero filling was 
applied. 
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Results and discussion 
Functionality of the peptide representing the N-terminal region ofElp 
To establish the function of the N-terminal region of Elp from A. vinelandii, we used a 
synthetic peptide representing amino acid residues 4-45 of Elp. Initially we tried to obtain the 
N-terminal region by limited proteolysis of Elp using endoproteinase GluC. The small 
fragments obtained after partial proteolyses were analysed by MALDI-TOF MS. A wide range 
of fragment sizes was found ranging from 392 to 1507 Da. Based on the sequence, fragments 
ranging from 285-4759 Da (3-40 amino acids) were predicted. The expected molecular mass 
of the entire N-terminal domain is about 4700 Da, indicating that the N-terminal region itself 
is sensitive to the protease and that it is digested into small (3-13 amino acids) fragments. 
Since we were not able to isolate the N-terminal region itself by the above-described method, 
we used the synthetic peptide "Nterm-Elp" in our studies. For reasons described in the 
discussion section we have chosen a region of the N-terminus of Elp that starts at amino acid 
4 and that ends at amino acid 45. To determine whether this peptide forms a functional 
binding domain, we performed several functional studies. 
First, complex activity was measured: E2p was incubated with different concentrations of 
Nterm-Elp, subsequently Elp and E3 were added and finally complex-activity was measured 
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Figure 1 Reconstitution of A. vinelandii 
PDHC in the presence of a varying 
concentration of Nterm-Elp. E2p (1.6 uM) 
was incubated with varying concentrations of 
Nterm-Elp. Subsequently it was recombined 
with Elp (1.6 uM) and mutant E3 (Y16F) 
(1.0 uM) (Benen et al., 1992), and finally, 
after 15 minutes incubation, complex-activity 
(0) and E3 activity (x) were measured. 
(figure 1). To establish whether Nterm-Elp competes for binding to E2p with Elp, E3 or 
both, we used the mutant E3-Y16F (Benen et al., 1992) instead of wild type E3. This dimer-
interface mutant is impaired in its dimerisation (E3-E3) and virtually inactive. Upon binding 
to E2p however, it forms a stable and active dimer. This enables us to distinguish between the 
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bound and unbound form of E3. Figure 1 shows the results of a titration of E2p with Nterm-
Elp and the subsequent recombination with Elp and E3-Y16F. The results show that Nterm-
Elp inhibits complex activity, whereas it has no influence on the activity of E3-Y16F. 
Maximum inhibition is about 45% at a 20 : 1 Nterm-Elp to E2p ratio. This partial inhibition 
can be caused by several factors. First of all, it is possible that the apparent maximum 
inhibition is not a real plateau but a very shallow increasing slope that will reach 100 % 
inhibition at infinite peptide concentration. On the other hand, it could also be that the peptide 
can only interact with one of the two Elp binding sites on E2p and therefore can only partially 
inhibit the Elp binding to E2p. The activities of the different components of the complex in 
the presence of a 15-fold excess of Nterm-Elp were measured and no significant effect was 
found. Consequently, the inhibitory effect on complex activity must be due to competition of 
Nterm-Elp with either Elp or E3 or both for binding to E2p. As no effect of Nterm-Elp on 
the Y16F-E3 activity was measured (figure 1) Nterm-Elp must be competing with Elp for 
specific interactions with one or both of the Elp binding site(s) on E2p. It is very difficult to 
accurately calculate a binding constant for Nterm-Elp. The measured reaction is very 
complex: it involves three enzyme components and an inhibitor. Moreover, Elp and E3 
influence each other's binding to E2p (Bosma et al., 1984). 
Secondly, the binding of Nterm-Elp to E2p was monitored by analytical gelfiltration (data not 
shown): free E2p mainly elutes in a "24-mer" peak, but upon addition (and binding) of Elp or 
E3 it dissociates into trimers. An analytical gelfiltration column can separate these fractions 
very well (Hengeveld et al., 1997; Hengeveld et al., 1999; Mande et al., 1996; Schulze et al., 
1991a). When E2p is pre-incubated with an excess amount of Nterm-Elp (1:5 ratio) one extra 
elution peak appears at an elution volume expected for Nterm-Elp. Whereas the integral of 
the E2p elution peak increases its elution volume does not change compared to the elution 
volume of the free E2p sample. This demonstrates that although Nterm-Elp binds to E2p it 
does not (unlike wild type Elp) influence the trimer-trimer interactions of E2p. 
Nterm-Elp has a pH dependent conformation 
CD measurements 
The conformational behaviour of Nterm-Elp was investigated using CD-, fluorescence- and 
NMR-spectroscopy. The CD-results are shown in figure 2. At pH 4.8, a spectrum with two 
minima at 208 nm and at 222 nm and a crossover point at 200 nm is observed, which is 
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characteristic of a highly a-helical conformation. At pH 6.8, the CD-spectrum exhibits only a 
minimum at 203 nm and the crossover point is shifted to 193 nm, which is more typical for an 
unfolded protein. To evaluate the secondary structure of Nterm-Elp we used the program 
CONTIN (Provencher and Glockner, 1981) (table 1). Indeed, at pH 4.8 the peptide is mostly 
a-helical (68%), while at pH 6.8 it is mostly unordered (54%). For brevity we will, from here 
on, refer to the conformation of the peptide at pH 4.8 as "folded" and to the conformation of 
the peptide at pH 6.8 as "unfolded". We are aware that this does not fully 
describe the conformation of the peptide under these conditions and have conducted more 
detailed studies using NMR- and fluorescence-spectroscopy to determine the conformation of 
Nterm-Elp at various conditions in more detail (see below). 
190 200 210 220 230 240 250 
Wavelength 
Figure 2 Far-UV CD spectrum of Nterm-Elp at varying pH values and in the presence of different 
concentration of GuHCl. The samples were prepared as described in the methods section. Nterm-Elp at 
pH 4.8 (A), Nterm-Elp at pH 6.8 (0), Nterm-Elp at pH 6.8 with 0.6 M GuHCl (O), Nterm-Elp at pH 
6.8 with 1.2 M GuHCl (^). 
Fluorescence measurements 
Nterm-Elp contains a single tryptophan and therefore fluorescence spectroscopy is a very 
suitable technique for studying the microenvironment of this residue. All experiments were 
recorded with excitation at 295 nm, where only tryptophan absorbs light. At pH 4.8 the 
tryptophan has a fluorescence maximum at 335 nm (figure 3A), while between pH 5.5 and pH 
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6.8 the maximum is at 350 nm. The emission maximum at 350 nm is typical for a tryptophan 
in a polar environment (with few protein contacts). The blue-shifted maximum at 335 nm at 
pH 4.8 results from a less polar environment: a tryptophan buried in a protein (i.e. in a folded 
structure). Thus, this local structure is in agreement with the CD observations that the peptide 
can exist in two conformations: folded and unfolded. The fluorescence of the peptide at pH 
6.8 is quenched by 40 % compared to the fluorescence at pH 4.8. This is caused by the 
exposure of the tryptophan to the solvent, as a tryptophan's emission pattern is highly 
sensitive to the polarity of the solution. Since the peptide, besides the tryptophan, also 
contains one tyrosine, emission spectra with excitation at 280 nm, where both tryptophan and 
tyrosine absorb light, were recorded as well. Difference spectra were obtained by normalising 
the spectra and subsequently subtracting the spectrum with excitation at 295 nm from the 
Table 1. The secondary structure content of Nterm-Elp at different pH values as calculated from CD 
measurements by the program CONTIN (Provencher and Glockner, 1981). The predicted secondary structure 
content of the peptide as determined using the neural network algorithms from the European Molecular Biology 
Laboratory (EMBL) (Rost and Sander, 1993; Rost and Sander, 1994) is also shown. The samples were prepared 
as described in the methods section. 
cc-helix (%) p-sheet (%) P-turn (%) Unfolded (%) Unknown (%) 
pH4.8 
pH6.8 
Prediction 
67 
12 
73 
0 
24 
0 
14 
10 
17 
19 
54 
_ 10 
spectrum with excitation at 280 nm. Both difference spectra (figure 3D) (pH 4.8 and pH 6.8) 
resemble the spectrum expected for a tyrosine, but the relative contribution of the tyrosine has 
increased at pH 6.8. This increase in tyrosine fluorescence probably occurs because of a larger 
distance between the tryptophan and the tyrosine due to unfolding of the peptide, which would 
lead to a decreased energy transfer between the two aromatic residues. 
Besides steady state fluorescence, we also measured time dependent fluorescence decay and 
fluorescence anisotropy of the peptide at 348.8 nm using time resolved fluorescence 
measurements (table 2). The fluorescence decay was in both cases (pH 4.8 and pH 7.0) best 
fitted using a 4 component exponential decay. In the time resolved fluorescence measurements 
the average fluorescence lifetime of the peptide at pH 7.0 is slightly shorter than at pH 4.8 
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(table 2), which is in agreement with the decreased fluorescence intensity in the steady state 
measurements (figure 3 A). A fluorescence lifetime of the tryptophan close to 2 ns was found 
for the peptide at both pH 4.8 and pH 7.0, indicating quenching of the tryptophan fluorescence 
at both conditions (the average lifetime of a tryptophan is about 3 ns). 
Table 2. The fluorescence decay and fluorescence anisotropy parameters of Nterm-Elp at pH 4.8 and pH 7.0 
(duplicates). Samples were prepared as described in the methods section. 
pH4.8 
pH4.8 
pH7.0 
pH7.0 
"Qualit 
' Avera 
31
 Rotati 
Fluorescence 
decay 
2 ]) 2) 
1.05 2.05 
1.08 2.08 
1.02 1.97 
0.99 2.00 
y of fit criterion 
;e fluorescence lifetir 
onal correlation times 
Fluorescence anisotropy 
x2 
1.05 
1.05 
1.07 
1.03 
Tie 
<H 3) (ns) [CI]4) 
0.28 [0.14-0.52] 
0.31 [0.17-0.49] 
0.19 [0.032-ND] 
0.18[0.051-ND] 
P l 5 ) 
0.11 [0.073-0.14] 
0.12 [0.09-0.15] 
0.066 [0.025-ND] 
0.071 [0.033-0.12] 
4)
 67 % confidence 
5)
 Relative contribu 
ND is not defined 
i>2 (ns) [CI] 
2.05 [1.62-2.85] 
2.32 [1.85-3.20] 
1.32 [1.10-1.92] 
1.31 [1.11-1.75] 
interval 
tion of f to the total 
P2 
0.13 [0.094-0.17] 
0.12 [0.088-0.15] 
0.17 [0.087-0.20] 
0.17 [0.11-0.20] 
anisotropy 
This quenching can be caused by a nearby tyrosine, glutamine, glutamic acid, aspartic acid or 
histidine (Lakowicz et al., 1998). 
The anisotropy decays of the peptide at pH 4.8 and at pH 7.0 contain two components (table 
2): a short sub-nanosecond component and a component of 1-2 ns. The short component 
probably originates from internal flexibility of the tryptophan. The smaller contribution of this 
component to the total fluorescence anisotropy at pH 7.0 compared to the contribution of the 
sub-nanosecond component at pH 4.8 probably results from a smaller amplitude of the 
movement of the tryptophan in the pH 7.0 sample. 
The second anisotropy component of the peptide at pH 4.8 correlates excellently with the 
expected rotational correlation time of a globular protein of 4.9 kDa (1.9 ns) (Visser and Lee, 
1980). The shorter rotational correlation time (1.3 ns) of the peptide at pH 7.0 supports a 
changed, less compact, conformation under these conditions, i.e. the peptide being 
"unfolded". 
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NMR measurements 
1 ID- H-NMR spectra of Nterm-Elp were recorded at pH values ranging from pH 5.0 to pH 6.5 
(figure 4). Due to overlap of most of the NMR resonances, assignment of the resonances to 
their corresponding protons is not possible based on these 1D-NMR spectra. 
3A 
6.0E+04 
5.0E+04 
360 380 
Wavelength 
Figure 3 Fluorescence spectra obtained with excitation at 295 nm of Nterm-Elp at varying pH 
values (A), at varying ionic strengths (B) and in the presence of various concentrations of the 
denaturant GuHCl (C). Normalised fluorescence spectra obtained with excitation at 280 nm of 
Nterm-Elp at pH 4.8 and pH 6.8 are shown in (D). Difference spectra were obtained by 
normalising the fluorescence spectra and subtracting the spectrum obtained with excitation at 295 
nm from the spectrum obtained with excitation at 280 nm. (A) Nterm-Elp at pH 4.8 (n), at pH 5.5 
(•), at pH 6.2 (A) and at pH 6.8 (0);(B) Nterm-Elp at pH 4.8 (A), Nterm-Elp at pH 5 with 50 mM 
KC1 (•), Nterm-Elp at pH 5 with 100 mM KC1 (0), Nterm-Elp at pH 5 with 150 mM KC1 (x), 
Nterm-Elp at pH 5.2 with 250 mM KC1 (O) and Nterm-Elp at pH 5.2 with 400 mM KC1 (line); 
(C) Nterm-Elp at pH 4.8 (thin dotted line), Nterm-Elp at pH 6.8 (thick dotted line), Nterm-Elp at 
pH 6.8 with 0.6 M GuHCl (thin line) and Nterm-Elp at pH 6.8 with 1.2 M GuHCl (thick line); (D) 
Nterm-Elp at pH 4.8 with excitation at 280 nm (o), Nterm-Elp at pH 4.8 with excitation at 295 nm 
(—), Nterm-Elp at pH 6.8 with excitation at 280 nm (O), Nterm-Elp at pH 6.8 with excitation at 
295 nm (thick dotted line), the difference spectrum of Nterm-Elp at pH 4.8 (0), the difference 
spectrum of Nterm-Elp at pH 6.8 (A). 
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Figure 3, continued 
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Figure 3, continued 
An exception to the latter forms the resonance with a chemical shift of 10.12 ppm (in the 
spectrum recorded at pH 6.5). This resonance is assigned to the aromatic side chain NH of the 
single tryptophan in Nterm-Elp (Bundi, and Wuthrich, 1979). At low pH two resonances 
instead of one are found in the low-field region of the NMR spectrum. The new resonance 
emerges at a chemical shift of 10.43 ppm, and also originates from the aromatic side chain NH 
of the tryptophan residue (see following sections). The resonance at 10.43 ppm gives rise to 
many NOE cross peaks in the 2D NOESY NMR spectrum (figure 5), whereas the resonance at 
10.12 ppm does not. Consequently, the resonance at 10.43 ppm corresponds to the aromatic 
NH of a tryptophan in a folded environment. The tryptophan aromatic NH resonance at 10.12 
ppm has virtually no NOE contacts with the remainder of the peptide and its chemical shift is 
typical for that of an exposed tryptophan, i.e. a tryptophan in an unfolded protein. 
The equilibrium between the folded and the unfolded conformation of Nterm-Elp 
The experiments described above show that the conformation of Nterm-Elp is pH dependent. 
At pH 6.5 it seems to be unfolded, while at pH 5.0 a mixture of folded and unfolded peptides 
exists. To test the influence of a change in sample condition on this equilibrium, 1D- H-NMR 
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spectra were recorded at different ionic strengths (figure 4). Additionally, fluorescence spectra 
were recorded at different ionic strengths (figure 3B), at different temperatures and in the 
presence of different concentrations of GuHCl (figure 3C). Finally, CD-spectra were recorded 
in the presence of different concentrations of GuHCl (figure 2). 
Table 3 shows the ratios of the integrals of the tryptophan resonances at 10.43 and 10.12 ppm 
at different pH values and at different ionic strengths. From figure 4 and table 3 it is clear that 
at pH 6.5 the folding equilibrium is completely shifted towards the unfolded state of the 
peptide. Under these conditions, only one resonance is observed for a tryptophan aromatic NH 
proton and the H-NMR spectrum has limited chemical shift dispersion, typical for that of a 
largely unfolded protein. 
The other sample conditions tested always resulted in a mixture of folded and unfolded 
Nterm-Elp. The folding equilibrium is shifted towards the folded state upon lowering the pH, 
but this effect is limited by the solubility of the peptide: at pH 3.5-4.3 the peptide precipitates 
due to protonation of the carboxyl groups of the peptide (pKa ~ 4). For this reason the lowest 
pH value used in our experiments is pH 4.8. Raising the ionic strength of the solution by the 
addition of KC1 results in a further shift in the folding equilibrium towards the folded state: a 
ratio of folded : unfolded of about 2:1 was the maximum reached under the conditions used by 
us. However, under the latter circumstances, significant line broadening of the NMR 
resonances is observed. Consequently, we did not use these sample conditions for the 2D 
NMR measurements. 
Raising the ionic strength of the solution at pH 5 by the addition of KC1 had no noteworthy 
effect on the fluorescence maximum of the tryptophan (figure 3B). Also, addition of a 
denaturant (GuHCl) to an Nterm-Elp sample at pH 6.8 (unfolded state) had no effect on the 
tryptophan fluorescence maximum (figure 3C). It did however slightly affect the CD spectrum 
(figure 2): addition of GuHCl results in a small reduction of the far-UV CD signal suggesting 
some slight further unfolding of Nterm-Elp. In conclusion, both fluorescence and NMR 
measurements suggest that the peptide is largely unfolded under these conditions. 
2D-NMR: analysis of the secondary structure of Nterm-Elp 
To obtain more detailed information about the conformation of Nterm-Elp in the folded (pH 
5.0) and unfolded (pH 6.5) state, 2D 'H-TOCSY and 2D 'H-NOESY NMR spectra were 
recorded (figure 6 and figure 5). We did not attempt to obtain a complete sequential resonance 
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assignment of the proton resonances of Nterm-Elp at pH 5 as the 2D-NMR spectra are very 
complex: two species are populated to a significant extent at pH 5, considerable resonance 
overlap is observed, and several signals are broadened due to exchange phenomena. In 
addition, as the synthetic peptide is isotropically unenriched, heteronuclear multidimensional 
NMR spectroscopy could not be employed to our benefit. For these reasons, only the main 
features of the 2D H NMR spectra are discussed below. 
Figure 6 shows the fingerprint and the NH cross-peak region of a TOCSY spectrum at pH 5 
(figure 6A, 6C) and at pH 6.5 (figure 6B, 6D). The 2D NMR spectrum of Nterm-Elp at pH 5, 
where a mixture of folded and unfolded peptide exists, shows much more NH resonances and 
cross peaks than the 2D NMR spectrum of Nterm-Elp at pH 6.5. The extra resonances 
observed fall outside the chemical shift ranges expected for an unfolded peptide. A about 10-
15 dNN NOE's are observed for the folded species. This is consistent with the CD results 
(table 1) that indicate a significant a-helicity of the folded state. The 2D H-TOCSY spectrum 
recorded at pH 6.5 is typical for that of a random coil protein. Cross peaks corresponding to 
amide groups of the same amino acid residue types in the unfolded protein have minimal 
chemical shift differences. 
The backbone amide proton resonances resonate between 7.8 ppm and 8.6 ppm. The 
resonances with chemical shifts between 6.6 ppm and 7.6 ppm can be assigned to the aromatic 
side chain protons. Consistently, the 2D- H-NMR NOESY spectrum recorded at pH 6.5 is 
typical for that of a flexible peptide. 
Most of the NH-resonances and cross peaks in the TOCSY spectrum of unfolded Nterm-Elp 
are also present in the TOCSY spectrum acquired at pH 5. However, some of these resonances 
could not be observed in the TOCSY spectrum of the mixture of folded and unfolded Nterm-
Elp. This can be due to several causes: firstly, the intensities of the cross peaks of the peptide 
in the unfolded state are reduced in the TOCSY spectrum of the mixture of both folding states 
as only about half of the molecules are unfolded. Secondly, some signals in the 2D H NMR 
spectra are severely broadened (compare figure 6A and 6B) as a result of exchange at an 
intermediate exchange rate on the chemical shift timescale, presumably between partially 
folded and fully unfolded molecules. Thirdly, the pH change can cause the shift of several 
cross peaks. 
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Figure 4 500 MHz 1D-1H NMR spectra of Nterm-Elp in 90% H2O/10% H20 recorded at various pH values 
and various ionic strengths, at a temperature of 298 K. The samples were prepared as described in the methods 
section. (A) Nterm-Elp at pH 6.5, (B) Nterm-Elp at pH 5.8, (C) Nterm-Elp at pH 5.0, (D) Nterm-Elp at pH 5.0 
with 138 mM KC1, (E) Nterm-Elp at pH 5.3 with 415 mM KC1, (F) Nterm-Elp at pH 5.5 with 1 M K.C1. 
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Figure 5:500 MHz 2D-'H NOESY spectra of Nterm-Elp in 90% H2O/10% 2H20 recorded at pH 5.0 and 
at pH 6.5 at a temperature of 298 K. The mixing time was 50 ms. (A) Fingerprint region of the NOESY 
spectrum of Nterm-Elp at pH 5.0, (B) Fingerprint region of the NOESY spectrum of Nterm-Elp at pH 
6.5. 
pH 
6.5 
5.8 
5.0 
5.0 
5.3 
5.5 
KCI (mM) 
0 
0 
0 
138 
415 
1000 
Ratio 10.43 ppm 
0 : 1 
0.82 : 1 
1.49 : 1 
1.67: 1 
1.85: 1 
1.20: 1 
10.12 ppm Table 3. The ratios of the integrals of the 
tryptophan resonances at 10.43 and 10.12 
ppm as a function of pH and ionic strengths. 
The tryptophan resonance at 10.43 ppm 
represents the "folded" state of Nterm-Elp, 
whereas the tryptophan resonance at 10.12 
ppm represents the "unfolded" state of the 
peptide. The samples were prepared as 
described in the methods section. 
The rate of exchange between folded and unfolded Nterm-Elp 
Thus far we described the peptide's function and conformation and studied the conditions that 
influence the equilibrium between the two conformations of the peptide. Here we focus on an 
interesting phenomenon displayed by the 2D H-TOCSY spectrum recorded at pH 5.0 and 
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298 K. This spectrum not only shows the two aromatic side chain NH resonances of the 
tryptophan in its folded and unfolded state, but it also shows a cross peak that "links" these 
two resonances. Several similar cross peaks are observed in the low-field region of the 
TOCSY spectrum (figure 6C). These cross peaks must be due to chemical exchange that is 
fast on the NMR Tj timescale, but not on the chemical shift timescale (A8>kexch>Tf ). 
For the majority of these exchange cross peaks, one of the frequencies could be assigned to 
the folded state of Nterm-Elp and the other frequency component resulted from the 
corresponding amide of unfolded Nterm-Elp. The exchange cross peaks disappear once the 
folded state of Nterm-Elp is fully populated. Similar exchange cross peaks "linking" folded 
and unfolded species that are in equilibrium have been observed for folding intermediates of 
bovine pancreatic trypsin inhibitor (BPTI) (van Mierlo et al., 1991; van Mierlo, et al., 1993). 
Based on estimates of the likely T; values for Nterm-Elp, we suggest that the exchange rate 
between the folded and the unfolded Nterm-Elp molecules at 298 K is in the range 0.5 to 5 
seconds" . 
The TOCSY experiment was repeated at 284 K, which yielded the same folded : unfolded 
ratio for the Nterm-Elp species as was found at 298 K. However, now no exchange cross 
peaks between the folded and unfolded tryptophan NH resonance are observed. Additionally, 
no exchange cross peaks in the low-field region of the TOCSY spectrum are observed under 
these conditions. Thus, temperature does seriously affect the exchange rate, but it does not 
affect the folding equilibrium of the Nterm-Elp species. 
NMR characterisation of the 200 kDa Elp homodimer 
The observed dynamic exchange between the folded and unfolded state of Nterm-Elp 
suggests that the N-terminal domain of Elp is highly mobile. In the past, flexibility of regions 
of Elp was suggested on basis of the sensitivity of Elp to proteases (Hengeveld et al., 1997) 
and on its resistance to crystallisation (personal communication, W. Hoi). Highly mobile parts 
of a protein should be visible in an NMR experiment, even if the entire protein is very large 
(the Elp dimer has a molecular weight of 2 x 100 kDa). For this reason we recorded ID- H 
(figure 7A) and 2D-'H-TOCSY (figure 8A) NMR spectra of the intact Elp at pH 5.5. The ID 
and 2D NMR spectra show a number of sharp resonances normally not expected for a 
structured enzyme with the size of Elp. ThDP (Elp's cofactor) was present in the sample in 
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Figure 6:500 MHz 2D-'H TOCSY spectra of Nterm-Elp in 90% H2O/10% 2 H 2 0 recorded at pH 5.0 and 
at pH 6.5 at a temperature of 298 K. The mixing time was 50 ms. (A) Fingerprint region of the TOCSY 
spectrum of Nterm-Elp at pH 5.0, (B) Fingerprint region of the TOCSY spectrum of Nterm-Elp at pH 
6.5, (C) NH cross-peak region of the TOCSY spectrum of Nterm-Elp at pH 5.0, (D) NH cross-peak 
region of the TOCSY spectrum of Nterm-Elp at pH 6.5. 
very small excess. To identify the resonances originating from free ThDP we recorded the 
spectrum of ThDP (figure 7C). 
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Clearly, besides these resonances, the spectra contain additional sharp resonances (figure 7A 
and 8A), indeed confirming the presence of highly mobile regions in Elp. Most of these 
resonances are found in the 7.8-8.6 ppm region, suggesting unstructured parts of the protein. 
Upon comparison of the Elp NMR spectra with the NMR spectra recorded of Nterm-Elp, we 
were unable to identify distinct cross peak patterns at comparable chemical shifts in both 
' i • • ' ' i ' 
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Figure 7: 500 MHz lD-'H NMR spectra of Elp and truncated Elp in 90% H2O/10% 2H20 recorded at pH 5.5 
at a temperature of 298 K. (A) Elp, (B) Elp truncated by endoproteinase GluC, (C) ThDP. Samples were 
prepared as described in the methods section. 
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spectra. Nevertheless, the TOCSY spectrum of Elp shows some similarity to the spectrum of 
the unfolded peptide. Thus, although we demonstrate that the entire Elp contains highly 
mobile/flexible regions, we are, based on these experiments, unable to unambiguously proof 
that these peaks originate from residues in its N-terminal domain. 
To determine whether the observed sharp resonances originate from the N-terminal region of 
Elp, or from other flexible regions in the enzyme, we partially digested the sample with 
endoproteinase GluC. This protease cuts Elp at amino acid residue E40 and thus digestion 
results in removal of amino acid residues 1-40. The subsequently recorded ID- H and 2D- H-
TOCSY NMR spectra are shown in figure 7B and 8B. Comparison of the spectra of digested 
and undigested Elp shows that quite a number of sharp resonances in the spectrum of the 
complete Elp have disappeared in the spectrum of the truncated Elp. Thus, it seems that at 
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Figure 8: 500 MHz 2D-H TOCSY spectra of Elp and truncated Elp in 90% H2O/10% 2U20 
recorded at pH 6.5 at a temperature of 298 K recorded at 500 MHz. The mixing time was 50 ms. (A) 
Fingerprint region of the TOCSY spectrum of Elp, (B) Fingerprint region of the TOCSY spectrum of 
Elp truncated using endoproteinase GluC. 
least part of the sharp resonances originate from the N-terminal residues 1-40 of Elp. Some 
sharp resonances however are not affected by truncating Elp, suggesting that these resonances 
either originate from another mobile region of Elp, or from impurities in the sample that are 
not sensitive to the protease. Previously we demonstrated that the core of Elp starts at amino 
acid 49, therefore truncation at amino acid 40 likely results in a small N-terminal "tail". This 
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could explain that the 2D- H TOCSY spectrum of the truncated Elp still contains sharp 
resonances. Moreover, Elp is cleaved by chymotrypsin and trypsin at respectively residue 
R418 and residue R554 (Hengeveld et al., 1997). 
It seems likely that exposed loops or turns are present at these sites. Possibly these loops are 
flexible causing sharp NMR resonances. Nevertheless, these results strongly indicate that the 
N-terminal region of Elp is flexible, analogous to Nterm-Elp. 
Discussion 
In the present study we describe the structural and functional characterisation of a synthetic 
peptide (Nterm-Elp) that represents the N-terminal region of Elp. 
Previous experiments showed that the N-terminal region of Elp is necessary for the binding of 
Elp to E2p (Hengeveld et al., 1999). The design of the peptide representing the N-terminal 
St 
region is based on the following considerations. 1 , deletion experiments show that the 
structural core of Elp starts from amino acid 49 (Hengeveld et al., 1999). 2" , amino acids 
R37, E40 and R44 are all highly sensitive to proteases indicating a more flexible/extended 
region (Hengeveld et al., 1997). 3rd, deletion experiments show that amino acid residues 1-8 
are not necessary for the binding of Elp to E2p (Hengeveld et al., 1999). 4th, due to the 
decrease of the accuracy of the peptide synthesis upon the increase of the peptide size, the size 
of the peptide had to be minimised. Consequently, we decided to construct a peptide starting 
at Met4 and ending at Thr45. 
Using activity and binding essays we demonstrate that the peptide Nterm-Elp binds to E2p 
and that in doing so it specifically competes with Elp. Furthermore, we show that the peptide 
has no influence on the binding of E3 to E2p. Thus, here we unambiguously proof that the N-
terminal region of Elp forms a separate domain involved in the binding to E2p. Moreover, 
these experiments justify the use of the synthetic peptide for the characterisation of the 
structure and function of the N-terminal domain of Elp. 
Both the CD experiment (table 1) and the 2D NMR analysis of Nterm-Elp at pH 4.8 indicate 
that the peptide has a high a-helical content. The calculated secondary structure content of 
Nterm-Elp at pH 4.8 based on the CD data is remarkably similar to the predicted secondary 
structure content of the peptide based on an analysis by the neural network algorithms from 
the European Molecular Biology Laboratory (EMBL) (Rost and Sander, 1993; Rost and 
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Sander 1994). From the secondary structure prediction and our own data we infer the 
following model of the N-terminal domain of Elp. The domain likely consists of two a-
helices connected by a loop or turn. Because residues 1-8 could be removed without affecting 
Elp, these residues probably do not belong to the first helix. Since the Elp "core" starts at 
amino acid 49 and residues R37, E40 and R44 are highly sensitive to proteases, it seems very 
likely that this region forms an extended "linker", connecting the N-terminal domain to the 
Elp core. Analysis of the sequences of the putative a-helices in the N-terminal domain shows 
that mainly the first helix (approximately amino acids 13 - 25) has a high content of acidic 
residues. A helical wheel of this sequence shows that D17, E20 and D24 are all on the same 
side of the amphipatic helix, separated by a single turn. The opposite side of the helix has the 
same pattern, but now with hydrophobic residues. The second helix (for which it is less 
eminent where is starts and ends) also has one side that has a high content of hydrophobic 
residues. We suggest therefore that the N-terminal domain is formed by these two helices, the 
hydrophobic patches of which interact, forming a hydrophobic "core". The acidic residues of 
helix 1 form the binding region to E2p. Mutagenesis experiments are in progress to prove this 
hypothesis. 
Using CD, fluorescence and NMR spectroscopy, we demonstrate that the peptide is present in 
two conformations, the population of which depends on the sample conditions. The 
conformations are designated "unfolded" at high pH (above pH 6) and "folded" at low pH 
(below pH 5). The secondary structure estimation based on the CD data suggests that the 
unfolded state is not entirely unfolded. Addition of GuHCl however, results in only a slight 
further unfolding of the peptide (figure 2). Addition of GuHCl has no influence on the 
fluorescence maximum of the tryptophan; the immediate environment of this residue is thus 
largely unfolded at pH 6.8. Additionally, the TOCSY and NOESY NMR spectra of Nterm-
Elp at pH 6.5 suggest a largely unfolded protein. We therefore believe that the peptide is 
largely unfolded at high pH. 
The equilibrium between the folded and unfolded state of the peptide is not affected only by 
the pH but also by the ionic strength as NMR spectra show. The 2D H TOCSY spectrum of 
the mixture of folded and unfolded Nterm-Elp at pH 5 and 298 K shows a cross peak linking 
the two aromatic side chain NH resonances of the single tryptophan, corresponding to the 
folded and unfolded state of Nterm-Elp. The absence of the exchange peaks at 284 K 
compared to 298 K in the 2D TOCSY NMR spectrum demonstrates that the exchange rate is 
dependent on the temperature. The exchange rate between the folded and unfolded Nterm-Elp 
The N-terminal domain of El p. 77 
molecules is in the range 0.5 to 5 seconds" . Similar exchange rates were found for the 
exchange between the folded and unfolded state of BPTI folding intermediate (Van Mierlo et 
al., 1991; Van Mierlo, et al., 1993). Just as in case of the BPTI folding intermediates, the 
folded conformation of Nterm-Elp is not very stable. 
As mutagenesis experiments identified basic residues in the E1/E3 binding domain and 
catalytic domain as the binding residues for Elp (Schulze et al., 1991a) it is likely that the 
acidic residues in the N-terminal domain are involved in ionic interactions between Elp and 
E2p. Shielding of these charges might mimic the bound state of the N-terminal domain, 
resulting in a shift in the equilibrium towards the folded state. 
It is surprising that at high pH the peptide is unfolded as at this pH Elp binds very well to 
E2p. However, it is possible that interaction with E2p induces a folded conformation 
(analogous to the charge shielding effect). Alternatively, removal of folded N-terminal domain 
by binding to E2p will force the equilibrium in the folded direction, since the folded and 
unfolded conformations are in slow exchange. Thirdly, we cannot exclude that interactions of 
the N-terminal domain of Elp with the Elp core stabilise the folded conformation of the N-
terminal domain. 
Sharp resonances in the NMR-spectra of the complete Elp (figures 7 and 8) unambiguously 
demonstrate that the 200 kDa enzyme contains highly flexible regions. Because several of 
these resonances are absent in the spectrum of the truncated Elp it is very likely that the N-
terminal region of Elp (amino acid 1-48) is flexible in the native enzyme. Efficient binding of 
Elp to E2p requires residues on both the binding and the catalytic domain of E2p (Schulze et 
al., 1991a). Only an Elp dimer (containing two N-terminal domains), and not a monomer or 
heterodimer (containing one N-terminal domain) binds strongly to E2p (Hengeveld et al., 
1999). The requirement for two N-terminal domains is most likely due to the distance between 
the binding residue R416 on the catalytic domain of E2p and the C-terminal helix of the 
binding domain of E2p, which is too large to be spanned by one N-terminal domain of Elp. 
Since Elp interacts with two different binding sites on E2p, it is likely that the flexible regions 
are necessary for the enzyme to be able to adapt to the two required "binding conformations". 
The observed dynamic character of Nterm-Elp is possibly required for it's binding to E2p. 
After binding of the first N-terminal domain of the Elp dimer to E2p a high degree of 
flexibility of Elp will be required to interact with the second binding site on E2p. Recent 3D 
electron microscopy of Saccharomyces cerevisiae E2p (Zhou et al., 2001) revealed striking 
dynamics of the E2p core; a 40 A difference in diameter was observed. Moreover, the intact 
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complex exhibits similar flexibility to that of the E2p core and the Elp on the outside of the 
core mimics the expansion/contraction of the underlying E2p core. It is therefore quite likely 
that the flexible regions that we observed in Elp and Nterm-Elp are involved in this dynamic 
process, assuming that this core flexibility is also present in the cubic E2p cores. 
Finally, the flexibility of Elp, and possibly the flexibility of the N-terminal domain of Elp can 
also be of importance for the catalytic properties of the enzyme. Elp is an allosteric enzyme, 
therefore requiring conformational freedom of the active site of the enzyme in the 
multienzyme complex. 
In summary, we demonstrated that Elp has an independent N-terminal folding domain that is 
necessary for binding of Elp to E2p. The domain (in the isolated peptide) samples both a 
folded and an unfolded conformation, the population of which is determined by pH and ionic 
strength. The observed exchange between the two conformations of the N-terminal domain 
and the flexible regions that we identified in the entire Elp are very likely necessary for the 
binding of Elp to E2p. 
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5 Identification of the E2-binding residues in the N-terminal domain of prokaryotic pyruvate dehydrogenase. 
A modified version of this chapter has been submitted to FEBS Letter: 
Annechien F. Hengeveld and Aart de Kok. Identification of the binding residues in the N-terminal 
domain of pyruvate dehydrogenase. 
Abstract 
Pyruvate dehydrogenase (Elp) is one of the components of the pyruvate dehydrogenase multienzyme complex 
(PDHC). Previously, it was shown that the N-terminal domain of Elp is involved in its binding to the core 
component (E2p) of PDHC. 
We constructed point mutations in this domain (D17Q, D17R, E20Q, E20R, D24Q and D24R) to identify the 
specific residues involved in these interactions. Kinetic and binding studies show that D17 is essential for the 
binding of Elp to E2p. D24 is involved in the binding, but not essential, whereas E20 is not involved. None of 
the mutations affects the folding or dimerisation of Elp 
Based on these observations we have refined the model of the binding mode of Elp and E2p In the proposed 
"helix-turn-helix" motif residues D17, E20 and D24 are on one side of the helix, whereas on the opposite side 
W15, L19 and V22 form a hydrophobic "patch". Helix II also has a hydrophobic side, which can form a 
hydrophobic "pocket" with the residues of helix 1. None of the mutations result in complete abolishment of the 
binding capacity of E1 p to E2p; neither do point mutations in E2p. Apparently the binding interface is composed 
of more than one region both on E2p (binding domain and catalytic domain) and on Elp. 
The binding of Elp to E2p is highly species specific: E. coli Elp binds very poorly to A. vinelandii E2p. The fact 
that the mutations D17Q and D24R both have such a strong effect on the binding abilities of Elp correlates well 
with this observation. 
Introduction 
The pyruvate dehydrogenase multienzyme complex (PDHC) from gram-negative bacteria 
consists of multiple copies of three different enzyme components: pyruvate dehydrogenase 
(Elp), dihydrolipoyl acyltransferase (E2p) and lipoamide dehydrogenase (E3). It catalyses the 
oxidative decarboxylation of pyruvate, resulting in the acetylation of coenzyme A and the 
transfer of reducing equivalents to NAD+ (for reviews see Perham, 1991: Mattevi et al., 
1992a; Berg and De Kok 1997; De Kok et al, 1998; Perham, 2000). 
From N- to C-terminus, E2p consists of two or three lipoyl domains, each carrying a lipoyl-
lysine group, an E1/E3 binding domain and a catalytic domain, which also forms the structural 
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core of the complex. Flexible alanine/proline rich linkers of 20 to 40 amino acids interconnect 
these domains. 
The El component exists both as a homodimer (012) or a heterotetramer (012P2) depending on 
the source and type of complex. Recently the 3-dimensional structure of the heterotetrameric 
branched-chain oxoacid dehydrogenase (Elb) from Pseudomonas putida and human were 
solved (iEvarsson et al., 1999; Aivarsson et al., 2000). For the homodimeric El however, no 
detailed structural information is available. Recent studies have given insight into the binding 
mode of homodimeric Elp from Azotobacter vinelandii; limited proteolysis experiments 
(Hengeveld et al., 1997) and mutagenesis studies (Hengeveld et al., 1999) showed that the N-
terminal region of Elp (amino acid 1-48) is essential for its binding to E2p. Additionally, 
mutagenesis experiments of E2p identified binding sites for Elp on both the E1/E3 binding 
domain of E2p and on the catalytic domain of E2p (Schulze et al., 1991a). The construction of 
chimeric E2ps confirmed the importance of both these domains in the interactions between 
Elp and E2p (Schulze et al., 1992). For tight binding the homodimeric Elp requires two N-
terminal binding regions (Hengeveld et al., 1999), therefore it seems likely that one N-
terminus of Elp interacts with the E1/E3 binding domain of E2p, whereas the other N-
terminal region of Elp binds to the catalytic domain of E2p. Structure and function of the N-
terminal region of Elp were studied in more detail using a synthetic peptide representing this 
region and it was shown that this region of Elp forms an independent folding domain that 
specifically competes with Elp for the binding to E2p. CD and NMR measurements indicated 
that the N-terminal domain is mostly a-helical. (unpublished observations) These data 
combined with a predicted secondary structure suggest that the domain consists of a "helix-
turn-helix" motif, attached to the core of El by an extended linker or loop. Using an amino 
acid sequence alignment of the N-terminal region of Elp from several gram-negative bacteria, 
combined with the above, we have identified the residues D17, E20 and D24 in the N-terminal 
domain to be likely candidates for the binding of Elp to E2p. Additionally, these residues 
might be involved in the species-specific binding of Elp to E2p. Here we describe a 
mutational analysis of these putative binding residues of Elp. 
The E2-binding residues in Elp. 
Experimental procedures 
Construction of Elp mutants 
The Elp mutants D17Q, D17R, E20Q, E20R, D24Q and D24R were constructed using 
standard PCR mutagenesis techniques. pAFHOOl (Hengeveld et al., 1997) was used as the 
wild type template plasmid DNA. 
Enzyme expression and purification 
The E. coli strain TG2, a recA- version of TGI [A(lac~proAB), thi, supE, Res' Mod (k), F' 
(traD36 proA+B+, lacF lacZ AM 15)] (Gibson, 1984) harbouring the recombinant plasmid 
pAFHOOl, expressing wild type Elp was grown and purified as described in (Hengeveld et al., 
1997). Elp mutants were expressed and purified from E. coli as wild type Elp to 
approximately 80% purity, omitting the gelfiltration and the second ion-exchange 
chromatography step. The purity of the mutant Elps was estimated from their relative 
intensity on SDS-PAGE (Schagger and Von Jagow 1987) coloured with Coomassie stain. A. 
vinelandii wild type E2p and E3 were expressed and purified from E. coli TG2 as described in 
(Hanemaaijer et al., 1989; Westphal & De Kok 1988). 
Enzyme activity assays 
The oxidative decarboxylation of pyruvate by Elp was measured at 600 nm using 2,6-
dichlorophenol-indophenol (C^Ind) (e = 21.7x103 M~lcm~l) as an artificial electron acceptor 
(Khailova et al., 1977). The overall PDHC-activity was reconstituted by incubating E2p with 
Elp or mutant Elp and E3 and was measured spectrophotometrically at 340 nm as described 
in (Schwartz & Reed 1970). Protein concentrations were estimated using the microbiuret 
method (Goa 1953), Bovine serum albumin was used as a standard. 
Interaction of Elp and Elp mutants with Elp 
The binding of Elp or mutant Elp to E2p was analysed by analytical size-exclusion 
chromatography using a Superose 6 column (Pharmacia Biotech) as described in (Hengeveld 
etal., 1997). 
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Results and Discussion 
Based on a secondary structure prediction (figure 1) and on experimental data showing that 
the N-terminal domain has a high a-helical content, we previously proposed a "helix-turn-
helix" motif for this domain (Hengeveld et al., 2001). Mainly the N-terminal a-helix has a 
very high content of acidic amino acid residues. The interactions between Elp and E2p are 
highly species specific, and it is therefore not likely that conserved residues are solely 
involved in these interactions. Residues D17, E20 and D24 of A. vinelandii Elp are not 
conserved and moreover, the construction of a helical wheel of amino acid residues 9-25 
shows that they are all on the same side of the helix. It therefore seems very likely that (some 
of) these residues are involved in the interactions between Elp and E2p. To test this 
hypothesis, we constructed the following mutants of Elp: Elp-D17Q, Elp-D17R, Elp-E20Q, 
Elp-E20R, Elp-D24Q and Elp-D24R. 
A. vin MQDMQ@L§PI gTQgwLDSLE SVLDH[E]GEER AHYLLTRMGE LATRTGTQLP 
P. aer MQ(D]L[D]PV §TQ[I]WLDALE SVLDR|||GEDR AHYLMTRMGE LASRSGTQLP 
A. eut MSAVPEQILGASSAN|D|A[D]PQ [E]TH[E]WLDALQ GVLAA[E]GPAR AAFLIDKQIE YARNNGVTQP 
N. men MSTQLH@V(D|PI gTQgWLDALS SVLEY[E]GGER AQYLLENLVK YCRDKGVRMP 
E. col MSERFPN@V@PI |E]TR[D]WLQAIE SVIREgGVER AQYLIDQLLA EARKGGVNVA 
H. inf MSEILKN@V[§PI §TQ§WLQSLD SLIRE§GVER AQYIVEQVIG QARTSGVSLP 
Figure 1 Sequence alignment of the N-terminal sequence of Elp from several Gram negative bacteria. A. 
vin, A. vinelandii Elp; P. aer, Pseudomonas aeruginosa Elp; A. eut, Alcaligenes eutrophus Elp; N. 
men, Neisseria meningitidis Elp; E. coli, E. coli Elp; H. infl, Haemophilus influenzae Elp. 
Table 1 shows the kinetic parameters of these mutants and of wild-type Elp. Clearly, the 
mutations D17R, E20Q, E20R and D24Q have no significant effects on the kinetic properties 
of the enzyme. The mutations D17Q and D24R on the other hand, do change the kinetics of 
the enzyme. Especially Elp-D24R is strongly impaired in its El-activity, whereas the effect 
on E1-D17Q is intermediate. Removal of amino acids 1-48 affects the affinity of Elp for 
pyruvate (Hengeveld et al., 1999) and it is therefore not entirely surprising that mutations in 
this region affect the kinetic parameters of Elp. From the structural and functional 
information available at this time it is not possible to give an explanation of this effect. 
Results shown below prove however that global misfolding of these mutants does not cause 
the effect on the activity of Elp-D24R and Elp-D17Q and therefore it is likely that the effects 
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on the catalytic activity of these mutants is not directly correlated with their ability to interact 
with E2p. 
R 
'"' *H 
Figure 2 A Reconstitution of A. vinelandii PDHC using wild type E2p (3.9 (jM) and E3 (2.8 \M) 
and either wild type or mutant Elp. E2p is preincubated with E3 at a molar ratio of 1:0.7 (E2p:E3). 
Subsequently varying amounts of Elp are added to restore complex activity. Elp-D17Q (0), Elp-
D17R (L), Elp-E20Q (A), Elp-E20R (x), Elp-D24Q (*), Elp-D24R (O) and wild type Elp (•). 
B, Idem at low E1/E2 chain ratio's. 
Binding properties of wild-type and mutant Elp 
Two different methods were used to study the binding of wild type and mutant Elp to E2p. 
Firstly, PDHC was reconstituted by the addition of wild type or mutant Elp to the E2p/E3 
sub-complex and PDHC-activity was measured (figure 2). Secondly, the binding properties of 
wild type and mutant Elp were studied by analytical gelfiltration. 
Binding studies by PDHC reconstitution. 
The first method shows that at an Elp:E2p ratio of 5:1 wild type Elp virtually saturates E2p 
(based on the PDHC-activity ). Elp-E20Q and Elp-E20R also saturate E2p at this ratio and 
consequently the residue E20 does not seem to be involved in the interactions between Elp 
and E2p. Addition of Elp-D17R, Elp-D17Q or Elp-D24R on the other hand, results in only 
1%, 28% or 10% of maximum PDHC-activity at a 5:1 Elp:E2p ratio. The mutation D24Q has 
an intermediate effect (65%) on the PDHC-activity at this ratio. At a 60-fold excess of Elp the 
PDHC-activity of the severely affected Elp mutants (Elp-D17R and Elp-D24R) reaches 
about 50% of maximum PDHC-activity. Elp-D17Q almost saturates E2p at this ratio, 
whereas the mutant Elp-D24Q attains saturation of E2p at 16-fold excess. Since at a 60-fold 
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excess of Elp the PDHC-activity curves of the severely affected Elp mutants do not reach 
saturation, but are still increasing, it seems likely that at infinite mutant Elp concentrations 
saturation may occur. 
Comparing the effects of the mutations D17Q and D17R, one sees that even though Elp-
D17Q is quite impaired in its El-activity the mutation D17R (which has no effect on the El-
activity) has a stronger effect on the complex activity. Consequently, the impaired El-activity 
of Elp-D17Q cannot (fully) cause the decrease in complex activity. Similar considerations are 
valid for Elp-D24R and Elp-D24Q; here it is also likely that the effect of Elp-D24Q on the 
complex-activity is (at least partly) caused by effects on the binding properties of this mutant. 
Table 1 Summary of the kinetic parameters for the El-reaction by Azotobacter vinelandii Elp and A. vinelandii 
Elp mutants and the binding properties of wild-type and mutant Elp as determined by analytical gelfiltration. S0.5 
and Vmax values are calculated from V vs. [S] curves. The Hill coefficients are calculated from log([S]) vs. 
log((Vlmx-v)/v) curves. The reactions were performed as described in the experimental procedures. ND, not 
determined. 
S0.5 (mM) VmaxO-Jmg"1) Hill coefficient Dissociation of E2p 
Elp (wt) 0.03 ± 0.007 0.06 ± 0.003 
D17Q 0.02 ± 0.008 0.02 ± 0.002 
D17R 0.02 + 0.004 0.04 ±0.001 
E20Q 0.008 ± 0.0009 0.06 ±0 .001 
E20R 0.02 ± 0.003 0.09 ± 0.003 
D24Q 0.02 ± 0.005 0.06 ± 0.003 
D24R 0.01 ± 0.003 0.01 ± 0.0004 ND 
1.1 ±0.1 
0.5 ± 0.2 
1.0 ± 0.1 
1.2 + 0.1 
0.9 ±0.1 
1.0 ±0.1 
yes 
no 
no 
yes 
yes 
yes 
Binding studies by analytical gelfiltration. 
Free A. vinelandii E2p forms a 24-meric cubic core structure of about 1.5 MDa. Upon binding 
of wild type Elp or E3 the core dissociates into trimers with Elp or E3 bound (-400-800 
kDa). These two forms of E2p can be separated by gelfiltration chromatography (table 2). The 
results obtained by this method correlate very well with the results that we described above. 
The E2-binding residues in Elp, 85 
The absence of dissociation of E2p by Elp-D17Q, Elp-D17R or Elp-D24R is analogous to 
that observed in figure 2 at "low" (2:1) Elp:E2p ratio; no, or very low PDHC activity is 
measured at this ratio using these mutants. These experiments confirm that the low PDHC-
activities of E2p/E3 sub-complex recombined with either Elp-D17Q or Elp-D24R are not 
caused by their decreased El-activity, but (at least partially) by a decreased binding affinity 
for E2p. Even though binding of Elp-D24Q to E2p results in dissociation of E2p, a 
considerable fraction of Elp-D24Q remains unbound (data not shown), which correlates well 
with the intermediate effect that this mutant has on the complex-activity as was measured 
above. 
The elution volumes of all six mutant Elps are identical to the elution volumes of wild type 
Elp. This demonstrates that none of the mutations affects the folding or dimerisation of Elp 
(as the molecular sizes of the mutants are not affected). This important observation shows that 
the observed effects on the activity and on the binding properties of these mutants are not 
caused by misfolding of Elp. Dimerisation of Elp is crucial for the binding of Elp to E2p and 
these results rule out that effects on the binding are caused by an indirect effect via an 
impaired dimerisation. Summarising, the above-described measurements clearly establish that 
D17 is essential for the binding of Elp to E2p. D24 on the other hand seems to be involved in 
the interactions, but does not seem to be essential. Mutation of the middle amino acid residue 
(E20) of the acidic "patch" has no influence on the interactions of Elp to E2p. This last 
observation indicates that the effects on D17 and D24 are specific and not due to local 
misfolding. 
Model of the binding mode of Elp to E2p 
Using the above-described results we have refined the model of the binding mode of Elp and 
E2p that was postulated before. A helical wheel of helix I of the proposed "helix-turn-helix" 
motif (amino acids 9-25) shows that the residues D17, E20 and D24 are on one side of the 
helix, whereas on the opposite side W15, L19 and V22 form a hydrophobic "patch". Helix II, 
of which it is less evident where it starts and finishes, also has a hydrophobic side, which can 
form a hydrophobic "pocket" with the residues of helix I. As shown above, we have 
established that E20 is not involved in interactions between Elp and E2p. D24 likely is 
(indirectly) involved in the interactions between Elp and E2p, whereas D17 is an essential 
binding residue. None of the mutations result in complete abolishment of the binding capacity 
of Elp to E2p; neither do point mutations in E2p (Schulze et al., 1991a). Apparently the 
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binding interface is composed of more than one region both on E2p (binding domain and 
catalytic domain) and on El p. 
Species specificity 
Not only from their proposed location in the first helix of the N-terminal domain, but also 
based on species differences, it seems likely that D17, E20 or D24 are involved in the binding 
of Elp to E2p. Previously, it was shown that the binding of Elp to E2p is highly species 
specific (Schulze et al., 1992). Based on this, it seems likely that the binding residues in the 
N-terminal binding domain of Elp are not entirely conserved i.e. difference between species 
should be observed. Whereas the surrounding acidic residues (Ell, E14 and E26) are highly 
conserved, D17, E20 and D24 of A. vinelandii Elp exhibit differences with some of the other 
species (figure 1). In E. coli Elp these residues are Q17, E20 and R24. Previously, it was 
shown, using chimeras of E. coli and A. vinelandii E2p that E. coli Elp solely binds to E. coli 
E2p and not at all to A. vinelandii E2p. Binding, on the other hand, of, visa versa, A. 
vinelandii Elp to E. coli E2p still results in 60% residual PDHC activity. Testing the reverse 
effect (whether the mutations D17Q and D24R result in an increased binding to E. coli E2p) is 
extremely difficult, as it would require E. coli E2p that contains absolutely no E. coli Elp. The 
fact that the mutations D17Q and D24R both have such a strong effect on the binding abilities 
of Elp nevertheless correlates well with the fact that E. coli Elp binds very poorly to A. 
vinelandii E2p. 
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6 A structural alignment of the homodimeric and heterotetrameric 2-oxoacid dehydrogenases and 
transketolase. 
Abstract 
Several structures of thiamin diphosphate-dependent enzymes are known at this time. In striking contradiction 
with their structural similarity is their apparent lack of sequence similarity. Combining primary and secondary 
structural information enabled us to obtain a sequence alignment of homodimeric and heterotetrameric 2-oxoacid 
dehydrogenases and transketolase. This alignment consists of two parts, corresponding to the a- and P-strand of 
heterotetrameric 2-oxoacid dehydrogenase. Aligning the sequences of homodimeric pyruvate dehydrogenase 
(Elp) (Azotobacter vinelandii and Escherichia coli), transketolase (TK) (Saccharomyces cerevisiae), branched-
chain oxoacid dehydrogenase (Elb) (Pseudomonas putida and human) and heterotetrameric Elp (Bacillus 
stearothermophilus and human), 36 residues are identical while 32 residues are highly conserved. These residues 
are evenly spread throughout the sequence, although multiple gaps and/or insertions had to be introduced. The 
most likely candidates for ThDP binding and active site residues were identified. Furthermore, a common 
function was suggested for regions shared by TK and the 2-oxoacid dehydrogenases. A few conserved regions 
remain that no definite function could be assigned to. 
This new alignment opens possibilities to construct model structures for El. Especially for the homodimeric Elp, 
that up to now has resisted crystallisation attempts, this will be of great value. 
Introduction 
With the recent report on the high-resolution 3-D structure of branched chain 2-oxoacid 
dehydrogenase (Elb) from Pseudomonas putida (TEvarsson et al., 1999) and Homo sapiens 
(TEvarsson et al., 2000) it has become possible to compare the structures of five different 
thiamin diphosphate (ThDP)-dependent enzymes; transketolase (TK) (Lindqvist et al., 1992, 
Nikkola et al., 1994), pyruvate oxidase (POX) (Muller & Schulz, 1993), pyruvate 
decarboxylase (PDC) (Dyda et al., 1993), pyruvate ferredoxin oxidoreductase PFOR 
(Chabriere et al., 1999) and Elb. These structures all contain the consensus sequence of the 
previously identified ThDP-binding site motif "GDG X26/27 NN" (Hawkins et al., 1989) that 
2+ 
is involved in the binding of the pyrophosphate end of the ThDP molecule using a Mg or 
2+ 
Ca ion. Moreover, a common fold for ThDP-dependent enzymes was identified by 
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comparison of TK, POX and PDC (Lindqvist & Schneider, 1993, Muller et al., 1993). The 
recently solved Elb shows a similar fold (iEvarsson et al., 1999, iEvarsson et al., 2000). 
In striking contradiction to this structural similarity is the apparent lack of sequence homology 
between different members of the ThDP-dependent enzyme family (Hawkins et al., 1989, 
Wexler et al., 1991, Burns et al., 1988, Matuda et al., 1991, Green, 1989). Especially the 
reported lack of sequence similarity between the homodimeric and the heterotetrameric form 
of pyruvate dehydrogenase (Elp) from the pyruvate dehydrogenase complexes (PDHC) is 
puzzling. 
To solve this puzzle we have combined primary and secondary structural information to 
obtain a sequence alignment between the different ThDP-dependent enzymes. 
Materials and methods 
We used the amino acid sequence of Saccharomyces cerevisiae TK as reported in the 3-D 
structure (Lindqvist et al., 1992) because it differed considerably from the amino acid 
sequence as deduced from the nucleic acid sequence. We compared this sequence with the 
amino acid sequence from Pseudomonas putida Elb (Elba and ElbP) (Burns et al., 1988), 
Human Elb (Elba and Elbp) (Zhang et al., 1988, Chuang et al., 1990), Human Elp (Elpa 
and ElpP) (Koike et al., 1988), B. stearothermophilus Elp (Hawkins et al., 1990), 
Azotobacter vinelandii Elp (Hengeveld et al., 1997) and E. coli Elp (Stephens et al., 1983). 
Attempts to obtain computerised alignments by several different algorithms all failed to yield 
results that were compliant with know structural and functional information. These initial 
homology searches all resulted in mis-alignments in the know functional motifs. For this 
reason first the ThDP-binding motifs of TK and A. vinelandii Elp were manually aligned. 
This partial alignment was used as starting point for an alignment using a standard alignment 
program (CLUSTAL W) (Thompson et al., 1994). The resulting alignment was of bad quality, 
but it showed that the 680 amino acids sequence of TK could be aligned with the entire 885 
amino acid sequence of A. vinelandii Elp. This alignment was optimised by visual inspection. 
Secondly the primary sequence of TK and P. putida Elb were aligned on basis of their 
secondary structure. This alignment was also optimised by visual inspection. Heterotetrameric 
Elps, heterotetrameric Elbs and homodimeric Elps were aligned by using the standard 
alignment program. Heterotetrameric Elp vs. Elb was also aligned in this manner. The above-
mentioned alignments (TK vs. homodimeric Elp, TK vs. heterotetrameric Elb and 
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heterotetrameric Elb vs. heterotetrameric Elp) were combined, on basis of both primary and 
secondary structural information, to the alignment shown in figure 1. 
Results and Discussion 
Multiple research groups (Hawkins et al., 1989, Wexler et al., 1991, Burns et al., 1988, 
Matuda et al., 1991, Green, 1989) previously concluded that homodimeric and 
heterotetrameric Els show very low homology, restricted to the ThDP-binding motif. 
Robinson and Chun (Robinson & Chun, 1993) previously aligned different ThDP-dependent 
enzymes. Although they did state that all enzymes could be aligned, most of the functional 
groups were mis-aligned due to the lack of structural data. 
Using secondary structure information now available for P. putida Elb (lEvarsson et al., 
1999), human Elb (^Evarsson et al., 2000) and TK (Lindqvist et al., 1992, Nikkola et al., 
1994) we were able to align amino acid sequences of homodimeric and heterotetrameric Els 
and TK (figure 1). PDC and POX are organised in a different manner. An alignment between 
the two groups can only be obtained by dividing the PDC or POX sequence into two parts and 
reversing its order (Robinson & Chun, 1993). We have not attempted to make a detailed 
alignment is this way. The homodimeric oxoglutarate dehydrogenase (Elo) cannot be aligned 
to any other known ThDP-dependent enzyme (apart from the ThDP-binding motif) and is 
therefore not included in our alignment. The sequence alignment in figure 1 can be divided 
into two parts, corresponding to the a- and P-strand of heterotetrameric El. 36 residues are 
identical in all four types of enzymes while 32 residues are highly conserved. These residues 
were evenly spread throughout the sequence. In 63 cases 3 out of 4 types of enzymes in the 
alignment had identical residues and in 63 cases 3 out of 4 were highly conserved. More 
important, we could identify most known functional groups in all four types of enzymes. We 
will discuss this in more detail below. 
The a-strand shows three regions of high homology between the four types of enzymes, 
corresponding to amino acids 108-132, 153-191 and 208-252 of TK respectively. Two of 
these regions are involved in the binding of ThDP. 
The first region contains the residues involved in binding the N4' and N3' of the amino 
pyrimidine-moiety of ThDP. The specific residues were identified as Gn6 and Ln8 for TK 
(Lindqvist et al., 1992, Nikkola et al., 1994, Schneider & Lindqvist, 1998), G182 and Li84 for 
P. putida Elb (iEvarsson et al. 1999) and S207 and L209 from human Elb (iEvarsson et al. 
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2000). Homologous residues in homodimeric Elp are G195 and I197 for A. vinelandii Elp and 
G197 and I200 for E. coli Elp. In heterotetrameric Elp the residues were identified as and G165 
and V167 (human) and I142 and I144 (B. stearothermophilus). The second region is the well-
recognised ThDP-binding motif (Hawkins et al., 1989). It contains amino acids that bind the 
2+ 2+ 
phosphate moiety of ThDP via a divalent metal ion (Ca or Mg ). The residues were, among 
others, identified as D157 and Nig7 for TK (Wang et al., 1997), D228 and N258 for A. vinelandii 
Elp, D213 and N242 for P. putida Elb and D196 and N225 for human Elp. Moreover, it 
contains a conserved glutamate involved in increasing the protonation potential of the 
glutamate necessary for cofactor activation (E218 in P. putida Elb, E243 in human Elb and 
E]62 in TK). The counterpart in homodimeric Elp is E233 (A. vinelandii) or E235 (E. coli). In 
heterotetrameric Elp however, no likely candidate could be identified. The third conserved 
region in the a-strand does not contain active site residues or any other residue that has a 
previously identified function. This region was absent in PDC and POX, indicating a function 
only present in TK and the 2-oxoacid dehydrogenases. In both TK and Elb this third 
conserved region is found on the exterior of the protein, close to the N-terminal residues. 
Wexler et al. (Wexler et al., 1991) previously identified this region as being highly conserved 
among heterotetrameric Elps and Elbs but not in homodimeric Elps. They suggested it to be 
involved in the ab-subunit interaction. We can now conclude from both our alignment (that 
includes homodimeric Elp) and the 3-D structures of TK and Elb that this is not the case. 
Since this region is found in both the 2-oxoacid dehydrogenases and in TK a function in the 
binding of El to another component of the multienzyme complex seems unlikely. 
Besides these three conserved regions we identified conserved amino acids involved in the co-
ordination of the pyrophosphate moiety of ThDP or catalysis. H69 (TK) (Wikner et al., 1997) 
interacts with the phosphate moiety of ThDP. Analogous residues in P. putida Elb (Y133) and 
human Elb ( Y ^ ) also form a hydrogen bond with a phosphate oxygen of ThDP (iEvarsson et 
al., 1999, iEvarsson et al., 2000). In heterotetrameric Elp this residue is conserved as a 
tyrosine while in homodimeric Elp a conserved histidine was found. A. vinelandii Elp is an 
exception to this: the histidine is replaced by a glutamine. H263 (TK) (Wikner et al., 1997) 
(H312 in P. putida Elb and H336 in human Elb) is oriented towards the reactive C2 of ThDP 
and is likely involved in catalysis. This histidine is conserved throughout all 2-oxoacid 
dehydrogenases and TK. 
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The phosphorylation sites in human El were previously identified as S293 and S300 for Elp 
(Korotchkina & Patel, 1995) and S337 and S347 in Elb (Zhao et al., 1994). As expected these 
amino acids are not found in the other enzymes since regulation by 
phosphorylation/dephosphorylation is unique to eukaryotic 2-oxoacid dehydrogenases. One S 
(S313) is present in P. putida Elb, but does not function as a phosphorylation site. 
Interestingly, the first phosphorylation site is very near the catalytic active site histidine (H336 
in human Elb). 
The P-strand shows high homology in the region corresponding to amino acids 417-448 of 
TK. This region contains the main ThDP binding residues that are present in the P-strand. E4]8 
(TK) (Wikner et al., 1994, Hawes et al., 1995), E89 for human Elp (Fang et al., 1998), E127 
(human Elb) and Eg2 (P- putida Elb) co-ordinate the Ni' of the amino pyrimidine moiety of 
ThDP. This glutamate is important in cofactor activation. It is completely conserved in all 2-
oxoacid dehydrogenases and TK. Secondly, hydrophobic residues in this region form a 
hydrophobic binding pocket for the pyrimidine moiety. In TK these residues are F442, F445 and 
Y448 forming an FxxFxxY motif (Lindqvist et al., 1992, Nikkola et al., 1994). The analogous 
motif in Elb is FxxYxxP in which only the F and Y are found in the binding pocket. The 
residues FxxFxxX form this motif in heterotetrameric Elp. For homodimeric Elp the motif is 
slightly unclear and can either be FxxFxxM or YxxY/FxxF. 
Besides the residues in the above-described region we identified another conserved histidine. 
H481 (TK) (Wikner et al., 1997) is near the N4' of ThDP, oriented towards the reactive C2 and 
likely involved in catalysis. This histidine is conserved in all 2-oxoacid dehydrogenases and 
TK. 
The remaining part of the P-strand is very well conserved, although multiple gaps and/or 
insertions had to be introduced into the sequences. The C-terminal P-domain is not conserved 
throughout the entire ThDP-family, but it is found in all Els, pyruvate:ferredoxin 
oxidoreductase (PFOR) (Chabriere et al., 1999) and TK. Its function in TK is unknown but for 
Elb a protein-protein (E1-E2) interaction function has been proposed (iEvarsson et al., 1999., 
iEvarsson et al., 2000). In particular it has been suggested that the C-terminal domain of the P-
subunit binds to the small E1/E3-binding domain of the E2 core protein. In homodimeric Elp, 
on the other hand, limited proteolysis (Hengeveld et al., 1997) and mutagenesis experiments 
(Hengeveld et al., 1999) show that an extended N-terminal domain is responsible for the 
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Figure 1 Sequence alignment of ThDP-dependent enzymes. The alignment was constructed as described in the methods and contains 
the following sequences: Elp (A.vin), A. vinelandii pyruvate dehydrogenase, accession no. Y15124; Elp (E.coli), E. coli pyruvate 
dehydrogenase, accession no. P06958 and P78049; TK (Yeast), S. cerevisiae transketolase, accession no. P23254; Elb (P.put), P. 
putida branched chain a-keto acid dehydrogenase (a and (3 chain), accession no. P09060 and P09061; Elb (Hum) branched chain a-
keto acid dehydrogenase (a and p chain), accession no. P12694 and P21953; Elp (B.ste) B. stearothermophilus pyruvate 
dehydrogenase (a and (3 chain), accession no. P21873 and P21874; Elp (Hum) Human pyruvate dehydrogenase (a and (3 chain), 
accession no. P08559 and PI 1177. Residues of a known secondary structure are blue and green for a-helices and p-sheets respectively. 
Conserved residues are highlighted in red. Active site residues are highlighted in yellow. Proteolysis sites in A. vinelandii Elp are 
highlighted in green. The mitochondrion import sequences of human Elp and Elb are shown in italics. 
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binding to E2. Even more puzzling is the fact that the C-terminal domain of the P-subunit of 
heterotetrameric El is also found in homodimeric Elp, TK and PFOR (Chabriere et al., 1999) 
indicating a common function in all these enzymes. Clearly more experiments are necessary to 
elucidate the binding mode of both kinds of El to E2 and to reveal the function of the C-
terminal domain. 
Up to this point we tried to identify the function of identical or homologous residues and 
regions in this alignment. Besides the similarities between the four types of enzymes there are 
also some regions of large differences. First of all, in the N-terminal region the 2-oxoacid 
dehydrogenases have about 70 additional amino acids compared to TK. In A. vinelandii Elp 
this region forms an N-terminal domain necessary for binding to the E2 component of the 
complex (Hengeveld et al., 1999). This domain is extending from Elp by a flexible loop or 
linker that contains three proteolysis sites (Hengeveld et al., 1997) (figure 1). Some homology 
to this domain is found in P. putida Elb and B. stearothermophilus Elp, but, contrasting, the 
X-ray structure of P. putida Elb does not show an extended N-terminal domain. Parts of the 
N-terminal sequence of human Elp and Elb form a leader peptide necessary for import into 
the mitochondrion (Takakubo et al., 1995). The remaining part lacks any homology to the 
other two 2-oxoacid dehydrogenases. 
All other large insertions in the alignment are found in the homodimeric Elp sequence. For 
three out of four regions we can suggest a putative function. The first region (264-311 in A. 
vinelandii) overlaps with a region that was identified as a flexible loop in apo-TK, involved in 
ThDP binding (Sundstrom et al., 1992) and could have a similar function in Elp. The second 
region (321-348 in A. vinelandii) was identified as a putative DNA-binding region (R339-
L357) in A. vinelandii Elp (Regnstrom et al., 1999). The third region (405-424 in A. 
vinelandii) contains a limited proteolysis site (R418 in A. vinelandii) and therefore is likely to 
form an extended loop (Hengeveld et al., 1997). At this moment we cannot suggest any 
function to the fourth insertion (437-460 in A. vinelandii). 
The above analysis shows that ThDP-dependent enzymes can be divided into two groups: the 
first group containing POX and PDC, the second group containing 2-oxoacid dehydrogenases 
and TK. We have analysed the second group in detail and shown that the members of this 
group have conserved regions throughout the entire sequence. We identified the most likely 
candidates for ThDP binding and active site residues. Furthermore, this group of ThDP-
dependent enzymes contains conserved regions that we cannot assign definite functions to. 
The fact that both transketolase and 2-oxoacid dehydrogenases share these regions suggests a 
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common function. More research will have to be done to elucidate the function of these 
regions. 
The availability of 3-D structures for P. putida Elb, human Elb and TK and this new 
alignment open possibilities to construct model structures for both homodimeric and 
heterotetrameric El p. In combination with site-directed mutagenesis this will yield new 
insight into the structure-function relationships of El p. Especially for the homodimeric Elp, 
that up to now, has resisted all crystallisation attempts this will be of great value. 
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7 Structural basis of the dysfunctioning of human 2-oxoacid dehydrogenase complexes. 
A modified version of this chapter has been accepted for publication in Current Medicinal Chemistry 
A.F. Hengeveld and A. de Kok. Structural basis of the dysfunctioning of human 2-oxo acid 
dehydrogenase complexes. 
Abstract 
2-oxoacid dehydrogenase complexes are a ubiquitous family of multienzyme systems that catalyse the oxidative 
decarboxylation of various 2-oxoacid substrates. They play a key role in the primary energy metabolism: in 
glycolysis (pyruvate dehydrogenase complex), the citric acid cycle (2-oxoglutarate dehydrogenase complex) and 
in amino acid catabolism (branched-chain 2-oxoacid dehydrogenase complex). Malfunctioning of any of these 
complexes leads to a broad variety of clinical manifestations. Deficiency of the pyruvate dehydrogenase complex 
predominantly leads to lactic acidosis combined with impairment of neurological function and/or delayed growth 
and development. Maple urine disease is an inborn metabolic error caused by dysfunction of the branched-chain 
2-oxoacid dehydrogenase complex. An association between both Alzheimer disease and Parkinson's disease and 
the 2-oxoglutarate dehydrogenase gene has been reported. 
Currently a wealth of both genetic and structural information is available. Three-dimensional structures of three 
components of the complex are presently available: of the pyruvate dehydrogenase component (El), of the 
dihydrolipoyl acyltransferase component (E2) and of the lipoamide dehydrogenase component (E3). Moreover, 
detailed information on the reaction mechanism, regulation and the interactions between the different components 
of the complex is now at hand. Although only one of the structures is of human origin (Elb), model building by 
homology modelling allows us to investigate the causes of dysfunction. 
In this review we have combined this knowledge to gain more insight into the structural basis of the 
dysfunctioning of the 2-oxoacid dehydrogenase complexes. 
Introduction 
2-oxoacid dehydrogenase multienzyme complexes constitute a family of enzymes that 
catalyse the irreversible oxidative decarboxylation of various 2-oxoacids, generating the 
corresponding acyl-CoA derivative, NADH and CO2 (Perham, 1991; Mattevi et al., 1992a; De 
Kok et al., 1998; Patel & Roche, 1990). In man the members of this family comprise the 
pyruvate dehydrogenase complex (PDHC), the oxoglutarate dehydrogenase complex (OGDC) 
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and the branched-chain 2-oxoacid dehydrogenase complex (BCDC). All three of these 
complexes are located in the mitochondrial matrix compartment, associated with the inner 
membrane. Unique mitochondrial protein kinases and protein phosphatases are dedicated to 
the regulation of the complexes and closely interact with the multienzyme complexes (Roche, 
et al., 1996; Reed et al., 1996; Harris & Popov, 1996; Randle & Priestman, 1996; Abe, et al., 
1996). Each of the three members functions at a strategic point in primary energy metabolism: 
in glycolysis (PDHC), the citric acid cycle (OGDC) or amino acid catabolism (BCDC). PDHC 
uses pyruvate to produce acetyl CoA, which is used in the citric acid cycle. OGDC has part in 
transforming 2-oxoglutarate into succinyl CoA, while BCDC catalyses the oxidative 
decarboxylation of branched-chain a-keto acids (BCKA) produced by the transamination of 
the branched-chain amino acids (BCAA) valine, leucine and isoleucine. As glucose is of 
critical importance to some cells in the central nervous system conservation of it is of vital 
importance during carbohydrate depletion. Since the PDHC-reaction controls the oxidative 
utilisation of glucose, at times of depletion this reaction is reduced and fatty acids or ketone 
bodies are used as a source for acetyl-CoA in the central nervous system (Randle, 1986). In 
the brain, on the other hand, acetyl-CoA is nearly exclusively synthesised from pyruvate. 
Acetylcholine, the excitatory neurotransmitter is synthesised from acetyl-CoA. PDHC-activity 
is also reduced under diabetic conditions or starvation (Roche et al., 1996). The regulation of 
these mechanisms is primarily controlled by the phosphorylation / dephosphorylation of El 
(Roche etal., 1996). 
PDHC, OGDC and BCDC convert their respective substrates (figure 1) to the corresponding 
acyl-CoA derivative by the combined action of three enzymes: an a-keto acid dehydrogenase 
component (Elp, Elo or Elb), an acyltransferase component (E2p, E2o or E2b) and a 
dihydrolipoamide dehydrogenase component (E3). The last component (E3) is shared by all 
three enzymes. In PDHC an additional component is involved in the catalytic mechanism: the 
E3-binding component (E3BP, previously known as protein X). 
Malfunctioning of any of the complexes leads to a broad variety of clinical manifestations. 
Because of their important functions complete inactivation of any of the complexes is not 
expected and not found. Deficiency of PDHC leads to lactic acidosis, primary leading to 
impairment of neurological function, growth and development. Maple syrup urine disease 
(MSUD) is an inborn error caused by dysfunctioning of BCDC. Both deficiencies have been 
reviewed several times in the past years (Wynn et al., 1996; Indo & Matsuda, 1996; Kerr, et 
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al., 1996; Danner & McKean, 1996; Chuang & Shih, 1995; Robinson, 1995; Kerr & Zinn, 
RCCOOH - x 
El 
OH 
PDHC: R = CHj 
OGDC: R = HOOC-CHJ-CHJ 
BCDC: R=CH3-CH-CHj 
CH, 
E2 
Figure 1 Reaction mechanism of 2-
oxoacid dehydrogenase complexes. A 2-
oxoacid dehydrogenase (Elp, Elb or 
Elo) uses thiamin diphosphate (ThDP) 
to carry out the oxidative 
decarboxylation of the substrate, forming 
an acylated lipoic acid, covalently 
attached to the acyltransferase 
component (E2p, E2b or E2o) and CO2. 
The E2-component catalyses the transfer 
of the acyl group to coenzyme A (CoA). 
The resulting dihydrolipoyl group is then 
reoxidised by the dihydrolipoamide 
dehydrogenase component (E3) using 
NAD+, forming NADH. 
1995; Dahl, 1995; Patel & Harris, 1995; Brown, et al., 1989a). 
An association of both Alzheimer disease and Parkinson's disease with OGDC has been 
reported (Kish, 1997; Mizuno et al., 1994). 
These multienzyme systems form large and complicated complexes with molecular weights 
ranging up to 10 million Dalton. They share a common building design in which many 
peripheral components bind to a central core with either octahedral (24-subunits) or 
icosahedral (60-subunits) symmetry. 
Currently three-dimensional structures of all three components of the complex are available: 
Elb from Pseudomonasputida (TEvarsson et al., 1999) and man (TEvarsson et al., 2000), E2p 
(Mattevi et al., 1992c; Knapp et al., 1998; Izard et al., 1999 and Dardel et al., 1993; Green et 
al., 1995; Berg et al., 1996b; Berg et al., 1997; Ricaud et al., 1996 and Kalia et al., 1993; 
Robien et al., 1992; Mande et al., 1996) and E3 (Toyoda et al., 1998; De la Sierra et al., 1997; 
Mattevi et al., 1991; Mattevi et al., 1992b; Mattevi et al., 1993b) from several organisms. 
Although most of these structures are not of human origin, model building by homology 
modelling allows us to investigate the causes of dysfunctioning of human complexes. In this 
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review we will combine the current wealth of both genetic and structural information to gain 
more insight into the structural basis of the dysfunctioning of the 2-oxoacid dehydrogenase 
complexes. We will concentrate on those effects of dysfunctioning that have a molecular 
explanation. In order to understand the effect of different mutations in the complexes, first we 
will address the structure and functioning of the individual components of the complex and 
then their organisation within the complexes. Following, we will extrapolate this information 
to the human complexes. 
Dysfunctioning of 2-oxoacid dehydrogenase complexes 
As all 2-oxoacid dehydrogenase complexes hold crucial roles in energy metabolism deficiency 
of any of the complexes seems to be entirely incompatible with survival. We will try to shed 
some light onto this paradox by attempting to explain these deficiencies on a molecular and 
structural level. Previously, mutations in the chromosomal DNA of patients were identified, 
inventoried and structure-function relationships were postulated. Several review articles on 
both PDHC and BCDC-deficiencies have been published recently (Wynn et al., 1996; Indo & 
Matsuda, 1996; Kerr et al., 1996; Danner & McKean, 1996; Chuang & Shih, 1995; Robinson, 
1995; Kerr & Zinn, 1995; Dahl, 1995; Patel & Harris, R.A., 1995; Brown et al., 1989a). In 
case of El this has always been with the lack of an actual structure. Very recently the X-ray 
structure of Elb from P. putida and human origin were solved (£ivarsson et al., 1999; 
^varsson et al., 2000). This makes it possible to access the structure-function relationships of 
identified mutations in the availability of a structure. Mutations in Elb that cause MSUD were 
evaluated in this manner by ^Evarsson et al. (TEvarsson et al., 2000). For this reason our focus 
in this review will be mainly on Elp. In the next section we will re-evaluate the structure-
function relationship of identified mutations of El. Brief sections will be devoted to E2, E3 
and E3BP. Finally we will discuss the assembly of the complex and mutations that influence 
the complex activity on this level of organisation. 
PDHC-deficiency is extremely heterogeneous in its clinical manifestations (Robinson, 1995; 
Dahl, 1995; Brown & Brown, 1994). All forms include lactic acidosis, ranging from very 
severe, mostly resulting in death at birth, to more moderate clinical manifestations. Other 
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manifestations of PDHC-deficiency are neural disorders resulting in mental retardation or only 
mild developmental delay (Robinson, 1995). A poor correlation has been found between the 
severity of the symptoms and the residual activity of PDHC measured in different tissues. 
Factors that could attribute to this bad correlation are differences in phosphorylation and the 
amount of enzyme found in different tissues. The Elpa gene is located on the X-chromosome 
(Brown et al., 1989), which explains the relatively high prevalence and large heterogeneity of 
its mutations (Dahl, 1995; Brown et al., 1989). Random inactivation of the major part of one 
X-chromosome occurs in somatic cells of females during early embryogenesis; therefore, 
women heterozygous for a polymorphic X-linked gene have a mixture of cells expressing one 
or the other allele in their tissues (Lyon, 1962). Thus, a variable pattern of X-chromosome 
inactivation in females can also explain the poor correlation between PDHC activity and the 
severity of the symptoms. Up to now no null mutations of Elpa were identified in males, 
confirming that the total absence of PDHC would be lethal. In PHDC at least 65 mutations in 
Elpa were reported, while no mutations were reported to effect the ElpP subunit or the E2p 
or the regulatory enzymes El-kinase and phosphatase. Only a few mutations were reported in 
E3 (Randle & Priestman, 1996) and E3BP (Patel & Roche, 1990). 
Leigh syndrome (LS) is a progressive neurodegenerative disorder with onset usually in 
infancy or early childhood (Leigh, 1951; Rahman et al., 1996). LS has been associated with 
deficiencies of PDHC and of respiratory chain complexes. Moreover, mitochondrial DNA 
point mutations were found in LS patients. The portion of LS patients that were identified to 
have PDHC-deficiencies all had mutations in the Elpa gene. We discuss these mutations 
together with the other PDHC-deficiency causing mutations. 
MSUD is an autosomal recessive inborn error caused be mutations in any of the components 
of BCDC. All forms of MSUD result in keto-acidosis due to the accumulation of BCAA in 
plasma resulting in increased urinary excretion of the corresponding BCKA. The BCAA exert 
a direct neurotoxic effect, although its mechanism is yet unclear (Schadewaldt & Wendel, 
1997). This results in clinical effects ranging from mild symptoms to mental retardation and 
even death. The distinctive odour of the urine of the patient is caused by sotolone, a flavour 
component also found in maple syrup (Podebrad et al., 1999). The wide range of residual 
activity of BCDC has resulted in a classification of patients with different clinical features into 
five phenotypes: classic, intermediate, intermittent, thiamin-responsive and E3-deficient 
(Chuang & Shih, 1995). Patients with an E3-deficiency are deficient in all three 2-oxoacid 
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complexes and therefore usually show very severe clinical symptom, usually resulting in early 
(infant) death. There seems to be a correlation between the severity of the symptoms of the 
disease and the measured activity of BCDC. Most patients are now identified through new 
born screening programs. The incidence of MSUD varies from 1/150.000-1/200.000 in a 
general population (Danner & McKean, 1996) to 1/176 within an isolated Mennonite 
population (Peinemann & Danner, 1994). When an identified patient maintains a diet 
restricted in BCAA, sometimes supplemented with thiamin, it usually shows normal 
development (Hilliges et al., 1993; Treacy et al., 1992). 
Even though no molecular evidence was found up to now to link the OGDC with inborn 
errors several reports have been published that show a correlation between the activity of this 
complex and for example Alzheimer's disease (AD) (Kish, 1997; Cruts et al., 1995), 
Parkinson's disease (Mizuno et al., 1994), Wernicke-Korsakoff (Butterworth et al., 1993) or 
Freidrich's ataxia (Mastrogiacomo et al., 1996). As our scope in this review is to find relations 
between the molecular basis of the disease and the structure-function relationship of the 
corresponding enzyme we will not discuss this complex in any detail. 
Lissens et al. have recently publicised a mutation update on all the mutations that are found 
for the Elp gene (Lissens et al., 2000). They have evaluated the occurrence of these X-linked 
mutations in males and females and the diagnostic relevance of this evaluation. The total 
number of female and male patients is almost the same, although a difference in the 
distribution of the type of mutations is seen between the sexes, ^varsson et al. list and discuss 
all mutations that cause MSUD found in Elb (^Evarsson et al., 2000). We have summarised 
this information again, only listing mutations that result in point mutations, small deletions or 
insertions into the amino acid sequences of the different components of the complexes in 
Table 1. Table 1 also includes mutations found in E3. 
Alignment analysis: extrapolation to human structures 
Most structural information available on the catalytic components of the multienzyme 
complexes is from sources other than human or even mammalian. The availability of a large 
number of amino acid sequences of the different components of the complex makes it possible 
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to extrapolate known structural information to the human complexes. For both E2 and E3 
multiple structure based sequence alignments have been published before (Mattevi et al., 
1992c; Jentoft et al., 1992; Russell & Guest, 1991a) that show a high degree of similarity 
between enzymes from the different sources. No specific consensus sequences were found that 
distinguish E2-cores based on 24 subunits as found in OGDC and BCDC from those based on 
60 subunits as found in eukaryotic PDHC (Izard et al., 1999). All E2 sequences contain from 
N- to C-terminus 1 to 3 lipoyl domains, an E1/E3 binding domain and a catalytic domain, 
separated by alanine/proline rich linker sequences. The main difference in E2 sequences is the 
number of lipoyl domains present. Mammalian OGDC forms an exception to this rule as it 
lacks the binding domain. The binding of the El and E3 component to E2 will be discussed 
further along this review. 
For El the alignments were up to now limited to El's from the same kind of complex and 
even from the same class: either homodimeric or heterotetrameric (Wexler et al., 1991; Burns 
et al., 1988; Matuda et al., 1991). All OGDC and PDHC from gram-negative bacteria have 
homodimeric El, BCDC and PDHC from eukaryotes contain heterotetrameric El. 
Determination of the X-ray structure of Elb from P. putida (TEvarsson et al., 1999) and 
human (TEvarsson et al., 2000) has shown that the heterotetrameric Elb has a large structural 
homology to transketolase (TK). As TK in its turn shows significant (24%) sequence 
similarity to homodimeric Elp we are now able to combine the information available for both 
homodimeric and heterotetrameric El. Figure 2 shows the alignment of human Elp and Elb 
with Elb from P. putida and TK from Yeast (TK was recently reviewed by (Schneider & 
Lindqvist, 1998)). This alignment was obtained based on both primary and secondary 
structural information using standard alignment programs and optimised by visual inspection. 
The structure of the homodimeric Elo remains a puzzle as, besides the well recognised ThDP-
binding motif (Hawkins et al., 1989), no significant homology to any known ThDP-dependent 
enzyme could be found. Based on the large structural similarity found between different 
ThDP-dependent enzymes it is very likely though that Elo has a similar structure as other 
ThDP-dependent enzymes and El in particular. 
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TK 0 
PB MNEYAPLRLHVPEPTGRPGCQTDFSYLRLNDAGQARKPPVDVEHi 4 6 
HB mVAIAAARWRLNRGLSQAALLLLRQPGARGLARSHPPRQQQQFSSLDDKPQFtGASAEFlDKLEFIQP 70 
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Beta strand 
TK 357 
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HB MAWAAAAGWlLRLRAAGAEGHWRRLPGAGLARGFLHPAATVEDAAQRRGVhHFIFQPDPEPREtd^B 70 
H p MAAVSGLVRRPLREVSGLLKRRFHWTAPAAVQ 32 
TK 
PB 
HB 
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Figure 2: Sequence alignment of El amino acid sequences from several sources and transketolase based on 
structural homology. TK transketolase from Yeast, PB Pseudomonas putida Elb, HB human Elb, HP human 
El p. Known secondary structure is highlighted in green and yellow: a-helices are highlighted in yellow, p-sheets 
are highlighted in green. Mutations in human sequences that cause dysfunctioning of the compexes are shown in 
red (see also Table 1). Site directed mutant with known function (Table 2) are shown in bold and blue (in HB and 
HP). The putative lipoyl domain binding residues are shown in blue (in PB). The leader peptide sequences are 
shown in italics. 
A structural analysis of the dysfunctioning of El 
Replacement of active site residues 
The El component catalyses the reductive acylation of the E2 bound lipoyl groups (figure 1). 
It uses thiamin diphosphate (ThDP) to carry out the oxidative decarboxylation of the substrate 
(figure 3). Excellent reviews on ThDP-chemistry and ThDP-enzymes have been published 
recently in a special issue of Biochimica et Biophysica Acta (Schellenberger 1998). The 
cofactor-binding site is highly conserved between the different members of the ThDP-
dependent enzymes (Muller et al., 1993; Lindqvist & Schneider, 1993). Both by site directed 
mutagenesis and chemical modification several catalytically important amino acid residues 
have been identified in eukaryotic El (Table 2). 
The recent determination of the 3-D structures of human and P. putida Elb (#ivarsson et al., 
1999; ^varsson et al., 2000) has added a great deal of knowledge with respect to active site 
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residues of El. Figure 4 shows the residues involved in ThDP-binding in both human and P. 
putida Elb and in TK from yeast (Lindqvist et al., 1992; Nikkola et al., 1994). Essentially, 
most residues involved in ThDP-binding in Elb are conserved in all El's and TK (figure 2 
2+ 2+ 
and 4). All ThDP-enzymes require bivalent metal ions (Mg or Ca ) for coenzyme binding 
(Wangetal., 1997). 
Table 2. Catalytically important amino acid residues in eukaryotic El as identified by site directed mutagenesis 
or chemical modification. 
Subunit 
Elpa 
Elpa 
Elpa 
Elpa 
Elpa 
Elpa 
Elpa 
Elpa 
Elp 
Elpp 
ElPp 
Elpp 
Elba 
Elba 
Residue " 
C91 
S232 
S293 
S300 
R302 
E306 
E309 
R311 
R?? 
E89 
W165 
R269 
S337 
S347 
Function 
Catalysis 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Activation by 
proteolysis 
Activation by 
proteolysis 
Activation by 
proteolysis 
Activation by 
proteolysis 
Catalysis 
Catalysis 
ThDP-binding 
Pyruvate binding 
Phosphorylation 
Phosphorylation 
Source 
Bovine, 
human 
Human 
Human 
Human 
Porcine 
Porcine 
Porcine 
Porcine 
Pigeon 
Human 
Human 
Bovine 
Human 
Human 
Reference 
Ali et al., 1993 Korotchkina et at, 
1999 
Korotchkina et al., 1995 
Korotchkina et al., 1995 
Korotchkina et at, 1995 
Koike et at, 1992 
Koike etal., 1992 
Koike et at, 1992 
Koike etal., 1992 
Nemerya et at, 1996 
Fang etal., 1998 
Korotchkina et at, 1999; Ali et 
at, 1995 
Eswaran et at, 1995 
Zhao etal., 1994 
Zhao etal., 1994 
'' The amino acid is numbered according to the human homolog. 
The diphosphate-metal-anchor is the main linker group to the protein, the metal ion functions 
in complexing the pyrophosphate group to a conserved group of amino acid side chains in the 
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apo-enzyme. These amino acids are found in the ThDP-binding motif, a conserved sequence 
found in all ThDP-dependent enzymes (GDG-(X)25.30-N) (Hawkins et al., 1989). 
,
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CH, xCHj 
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Figure 3: The catalytic mechanism of ThDP enzymes 
is described as a cyanide-analogous charge catalysis 
(Schellenberger, 1998). The deprotonation of the 
catalytic centre of the coenzyme (the C2-atom of the 
thiazolium moiety) is the key step in the reaction (1). 
The C2-H dissociation rate is enhanced about 4 orders 
of a magnitude through the action of a conserved 
glutamine via the Ni'and the 4'-NH2 group of the 
amino-pyrimidine moiety of ThDP (Kern, 1997). The 
so-called V-conformation of ThDP (Shin, 1977) that is 
found for all enzyme-bound ThDP's brings the 4'-NH2 
group and the C2-H in direct contact. The C2-
carbanion forms a nucleophilic adduct with the 
substrate (2) which is rapidly decarboxylated (3) 
producing a ThDP-bound enamine. The enamine then 
reacts as a carbanion with lipoamide to form a 
tetrahedral intermediate (4). Rearrangement results in 
the formation of the acylated dihydrolipoamide and 
ThDP (5). The reaction mechanism of the second 
substrate (lipoamide) is far from understood. 
A tyrosine is stacked against the amino pyrimidine ring; hydrophobic sandwich the amino 
pyrimidine and thiazolium ring resulting in the characteristic V-conformation of enzyme 
bound ThDP. An important residue in cofactor activation is a glutamate from the P-subunit 
(E62p in P. putida), conserved in all El's and TK. The protonation potential of this glutamate 
is increased by a second conserved glutamate (E218a in P. putida) (Dyda et al., 1993; Arjunan 
et al., 1996; Meshalkina et al., 1997). A conserved glycine (G182a in P. putida) forms a 
second H-bond with the 4'-N atom of ThDP. Side chains of two conserved histidines 
(His312a and His 13 ip in P. putida) are oriented toward the reactive C2. Both histidines are 
conserved in all El's and TK and are most likely involved in catalysis. In Elb H131P is 
covalently bound to the substrate analogue inhibitor a-chloroisocaproate (^Evarsson et al., 
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1999). HI31(3 is equivalent to H481 in TK that is proposed to be involved in substrate 
recognition and binding. H312a is analogous to H263 in TK and both are proposed to be 
involved in polarisation of the substrate and catalysis (Wikner et al., 1995; Wikner et al., 
1997). 
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Figure 4: Thiamin diphosphate (ThDP)-protein interactions in the active site of, from top to 
bottom: transketolase (TK), human Elp and human Elb. Only conserved interactions are shown. 
The second substrate in the reaction mechanism, lipoamide, is covalently attached via an 
aliphatic lipoyl-lysine arm, specifically attached to a lipoyl domain. A channel lined with 
hydrophobic residues was identified in Elb positioning the disulphide of the lipoamide 
exactly in between the two previously mentioned active site histidines. Both are, from this 
model, very likely involved in catalysis, possibly as proton donor in the reduction of the 
disulphide bond. 
Free lipoamide is a very poor substrate for El and the binding of the lipoyl domain to El is 
very specific for the parent complex. Surface regions that are possibly involved in the 
recognition and binding of the lipoyl domain were proposed for Elb (figure 5). These 
proposed regions form the rims of the lipoamide channel opening. 
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Active site mutants ofElpa 
Of all mutations found in El pa the mutations that have a very clear structure-function 
relationship are those found in its active site, involved in the binding of ThDP. The residues 
involved in the binding of ThDP are, as mentioned above, highly conserved throughout all 
ThDP dependent-enzymes and thus extrapolation does not give any problems for these 
residues. 
Figure 5: Overall structure of human Elb (^Evarsson et al., 2000). 
The active site mutation that is probably the easiest to explain is V167M. V167a is conserved 
as a large hydrophobic amino acid chain (V, L or I) in all ThDP-dependent enzymes (LI84a in 
P. putida Elb). It interacts with the N3' of the amino-pyrimidine moiety of ThDP, supporting 
the V-conformation of ThDP. Site directed mutagenesis was performed on this residue in 
pyruvate decarboxylase (PDC) from Saccharomyces cerevisiae (1415) showing that decreasing 
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the size of this residue leads to diminished specific activity (Guo et al., 1998; Jordan et al., 
1996). 
The importance of this side chain is also shown by the effect of mutations on nearby residues 
as T231a. Changing T231a to an alanine will affect the position of VI67, having a similar 
effect as reducing the size of VI67. 
The residues G162a and N164a are not directly involved in interactions with ThDP, but both 
are very near the glycine residue that interacts with the N4' of the amino pyrimidine moiety. 
Alteration of these two residues (G162R and N164S) will therefore have an effect on the 
positioning of the residues that interact with the amino pyrimidine moiety. 
Only one mutation was found in the region where the phosphate moiety of ThDP interacts: 
A199T. At first glance it is surprising that this mutation has such a drastic effect because 
human A 199a is equivalent to a threonine in P. putida. Looking at the surrounding amino 
acids in both human Elp (DGAAN) and P. putida Elb (DGATA) or human Elb (EGAAS) 
suggest that the mutation A199T might result in a small change in the positioning of the helix 
that positions the phosphate moiety binding residues. 
Two other mutations in the active site are G291R and H292L. H292 is the highly conserved 
histidine (H312a in P. putida Elb) that is proposed to be involved in polarisation of the 
substrate and catalysis. As expected the effect of this mutation is very severe, resulting in only 
2% PDHC activity in fibroblasts. The mutation was found in a female patient and the (short) 
survival of this patient is probably due to the variable X-chromosome inactivation pattern. In 
TK this histidine (H263 in TK) was mutated resulting in severely impaired specific activity 
(Wikner et al., 1997). Changing its neighbouring residue from a glycine to an arginine will 
drastically affect the position and pKa of the histidine and thus affect the catalytic activity of 
El. 
Human P217a is conserved in heterotetrameric El. It forms the turn between an a-helix and a 
P-sheet that both contain several residues involved in ThDP binding. Mutating the proline to a 
leucine will drastically effect the positioning of this helix and sheet. Moreover, this P-sheet 
forms part of the hydrophobic core of the enzyme. Site-directed mutagenesis of this residue 
shows that indeed the thermostability of mutants is strongly affected (and thus the structural 
integrity of the enzyme) (Tripatara et al., 1999). 
5 of the El pa mutations listed in Table 1 are responsive to ThDP-treatment (H44R, R88S, 
G89S, R263G and V389fs). Of these 5 residues only R88 and G89 are clearly near the active 
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site. Even though both are not conserved active site residues, they are close to a conserved 
phenylalanine (F105 in P. putida Elb or F90 in human Elp) that is postulated to be involved 
in substrate binding. Thus, alteration of neighbouring residues will affect the catalytic activity 
of the enzyme. Moreover, C91 in human Elp has been identified as an active site residue by 
site directed mutagenesis (Table 2) (Ali et al., 1993; Korotchkina et al., 1999). 
Why the other three mutations are ThDP-responsive is not clear, all are found on the surface 
on the enzyme and not in any direct contact with the active site. As they are more likely 
involved in tetramerisation or interactions with E2, they will be discussed further in this 
section. 
The last mutation that clearly effects the active site is R288fs. This mutation results in a 283 
amino acid truncated protein, of which part of the active site has been deleted. Most likely this 
mutant will not result in any stable folded protein and the residual activity that was measured 
(88%) in the female patient is probably due to the X-chromosome inactivation pattern. 
Regulatory sites in El 
The activity of both PDHC and BCDC are primarily controlled by a phosphorylation-
dephosphorylation cycle. Specific regulatory enzymes carry out this cycle: El-kinase and El-
phosphatase. Pyruvate and ADP inhibit El-kinase. As a result El is activated at high pyruvate 
concentrations and at high ATP demand. Dichloroacetate (DCA) also inhibits El-kinase and 
is therefore used in the treatment of PDHC deficient patients. In human Elp and Elb 3 and 2 
serine residues respectively have been identified that can be phosphorylated (Elp: S232a, 
S293a, S300a and Elb: S337a, S347a) (Table 2) (Zhao et al., 1994; Korotchkina et al., 1995). 
Phosphorylation of the primary sites (S337 for Elb and S293 for Elp) results in inactivation 
of the complexes (Zhao et al., 1994; Hawes et al., 1995). These primary sites are located very 
close to the active site, right next to a conserved histidine that is involved in catalysis (H312ct 
in P. putida). A few mutations are found in the vicinity of the third phosphorylation site 
(S300a): R302C, R302H, R302L, and the insertion mutants E306ins7 and I306insl 1. R302 is 
a conserved surface residue very close to S300a. It is also in proximity of the conserved 
histidine and the primary phosphorylation site. Changing this large charged residue into a 
hydrophobic residue would quite likely affect the surrounding residues or even the stability of 
the entire enzyme. Both insertion mutants will affect the level of phosphorylation and 
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therefore the catalytic activity of the enzyme. Since the insertions are found at the surface of 
Elp, they will probably not be as destructive as if they would have been found in the interior 
of the enzyme. In the last case this would probably lead to complete disruption of the 
structural core. 
The mutation T231A that has already been mentioned above will probably, besides its effects 
on the active site, also influence phosphorylation, because of its position right next to S232a. 
It can be expected though that from both effects the disruption of the active site will have the 
largest effect on catalysis. 
Protein-protein interactions in El 
Human Elb and Elp are heterotetramers formed by two a and two p-subunits (figure 5). In P. 
putida Elb the a-subunit forms a large domain, an extended N-terminal tail and a small C-
terminal domain. The P-subunit is composed of two domains. The interactions between the a 
and P-subunit are mainly between the a-domains and the N-terminal p-domain. The C-
terminal P-domain is not conserved throughout the entire ThDP-family, but it is found in all 
El's, pyruvate:ferredoxin oxidoreductase (PFOR) (Chabriere et al., 1999) and transketolase 
(TK). Its function in TK is unknown but for P. putida Elb a protein-protein (E1-E2) 
interaction function has been proposed (TEvarsson et al., 1999). 
Besides the region responsible for the specific interactions with the lipoyl domain, a second 
region in El is important for protein-protein interactions: the region that binds El to E2. In 
heterotetrameric El's results have been obtained that indicate that the P-subunit is responsible 
for these interactions (^Evarsson et al., 2000; Perham, 1996; Wynn, 1992a; Lessard et al., 
1996). In particular it has been suggested that the C-terminal domain of the P-subunit binds to 
the small El/E3-binding domain. In homodimeric El, on the other hand, limited proteolysis 
(Hengeveld et al., 1997) and mutagenesis experiments (Hengeveld et al., 1999) show that an 
extended N-terminal domain is responsible for the binding to E2. Even more puzzling is the 
fact that the C-terminal domain of the p-subunit of heterotetrameric El is also found in TK 
and PFOR (.flivarsson et al., 1999). Alignment of homodimeric Elp with TK also reveals the 
presence of this C-terminal domain, indicating a common function in all these enzymes. 
Clearly more experiments are necessary to elucidate the binding mode of both kinds of El to 
E2 and to reveal the function of the C-terminal domain. 
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The fact that ThDP binds on the ap-interface does not make it surprising that many mutations 
are found that affect these interactions. Disturbing the subunit interactions will very likely 
affect ThDP binding and therefore catalysis. Three surface residues in El pa were found to be 
responsive to thiamin treatment (Table 1). The H44R mutation is particularly difficult to 
explain, as the N-terminal part of the different El's have a low homology. Using the 
alignment in figure 2, H44 would be analogous to Q61 in P. putida Elb. This residue is an 
exposed surface residue analogous to residues comprising the N-terminal domain of A. 
vinelandii Elp. This domain is involved in the binding of Elp to E2p (Hengeveld et al., 
1997). Removal of this domain also had effect on the catalytic properties of Elp (Hengeveld 
et al., 1999). Therefore, indirect effects of surface mutations on catalysis have to be taken into 
account, and the effect of the mutation H44R may be analogous. Residue R263 is analogous 
to Y283 in P. putida Elb, again a surface residue, now closer to the N-terminal tail of the 
other a-subunit. The mutation R263G is thus possibly involved in disrupting the a-a subunit 
interactions. Since ThDP binds on the a-P interface it is very likely that any disruption of 
subunit interactions can be (partially) compensated by extreme elevation of the ThDP 
concentration and thus it is very likely that ThDP has some effect on all mutations that 
destabilise a-a or a-P interactions. The mutation V389fs results in the elongation of the C-
terminus of the a-subunit, disrupting the a-P interactions. Such a mutation will also be 
sensitive to ThDP-treatment. 
Other mutations that are found on either the a-a or a-P interface are F205L, M210V, W214R, 
Y243N, Y369Q, R378C, R378H and S388X. All of these mutations involve quite drastic 
changes and will for this reason interfere with the tetramerisation of Elp. 
Finally a few mutations (R72C, R127W, D315N, P316L and L329R) are found on the surface 
of the a-subunit of Elp, but not involved in subunit interactions. These exposed residues are 
clearly important for the functioning of Elp considering their effect on catalytic activity or 
stability. They could possibly be involved in binding to the other components of the complex 
(binding to E2 or interaction with the lipoyl domain). On the other hand, the mutations could 
simply be so drastic that the structural integrity of the enzyme is affected. The latter is most 
likely the case for the mutation R127W, where only trace amounts of El pa were found using 
immuno-staining of fibroblasts (Table 1). The mutation D315N, on the other hand, resulted in 
normal amounts of El pa indicating its importance in catalysis. 
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Mutations in Elb causing MSUD 
The crystal structure of human Elb has revealed that it is very alike P. putida Elb. The main 
difference between the two structures is the presence of two structural potassium (K ) ions in 
human Elb that were not found in P. putida Elb. The first K -ion assist a loop close to ThDP 
to adopt its proper conformation, while the second K -ion is found in the P-subunit at the a-p 
interface and is probably necessary for proper tetramerisation. /Evarsson et al. (yEvarsson et 
al., 2000) have discussed recently in detail all known mutations in Elb that cause MSUD. The 
mutations can be divided into three groups based on the effect that they have on the enzyme 
(Table 1). The first group contains mutations that affect ThDP-binding, mutations that were 
discussed above as active site mutants. The second group comprises mutations affecting the 
hydrophobic core or structural integrity of the enzyme. The third (largest) group contains 
mutants that affect the subunit association or protein-protein interactions. In the case of 
MSUD, unlike what has been found for mutations in Elp, the effect of the mutations on 
structure and catalysis correlates very well with the severity of the disease. 
Structure and dysfunctioning of E2 
The E2-component has a multidomain structure in which the independent folding units of 
lipoyl domains, an El and /or E3 binding domain and a catalytic domain are separated by 
flexible linker sequences of about 20-50 amino acids (figure 6). The interdomain fragments 
appear to be extended and highly flexible, as judged from limited proteolysis and NMR 
experiments (Perham & Roberts, 1981; Texter et al., 1988). The high flexibility is essential 
for the mechanism of active site coupling, by which the substrate is transferred between the 
active sites of El, E2 and E3 (figure 1). Within this common architecture the number of lipoyl 
domains differs between the different complexes. Human PDHC has two lipoyl domains, 
human BCDC and OGDC both have only one lipoyl domain. Several structures of lipoyl 
domains have been solved by NMR (Dardel et al., 1993; Green, et al., 1995; Berg et al., 
1996b; Berg et al., 1997; Ricaud et al., 1996), all showing a very similar overall fold. 
Residues in an exposed loop close to the lipoylated lysine residue might be involved in the 
recognition of El. Mutagenesis and NMR studies have shown however that also other parts of 
the lipoyl domain are involved in the interactions with El. The role of the lipoyl domains in 
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multienzyme catalysis was extensively reviewed recently in (Berg & De Kok, 1997). Besides 
its role in catalysis, the inner lipoyl domain of PDHC is also involved in binding the 
regulatory components of the complex, the El-kinase and El-phosphatase. 
The El and/or E3 binding domain is a very small domain of only about 35 amino acids, 
consisting of two almost parallel a-helices. Structures of bacterial PDHC and OGDC E1/E3 
binding domain have been solved by NMR (Kalia et al., 1993; Robien et al., 1992; Mande et 
al., 1996). The structure of a complex between a lipoyl/binding di-domain and the E3-
component from Bacillus stearothermophilus has been solved by X-ray crystallography (Cruts 
et al., 1995). 
Figure 6. Domain structure of E2 and E3BP and the 
interactions of the domains with the other 
components of the mammalian 2-oxoacid 
dehydrogenase complexes. The separately folding 
domains are connected by flexible linker sequences 
shown in wavy lines. Dotted lines indicate 
interactions between different components. K means 
El-kinase, P is E1-phosphatase. The lipoic acid 
covalently attached to the lipyl domain is indicated 
by an asterisk. The C-terminal domain of E2 and 
E3BP do not show sequence identity, therefore the 
C-terminal domain of E2 is indicated as the catalytic 
domain and the domain of E3BP as the C-terminal 
domain. E2 contains either one or two lipoyl 
domains depending on the source (E2p 2 lipoyl 
domains, E2o and E2b one lipoyl domain). 
K + P E 1 o r E 1 * E 3 
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The site of interaction between E3 and the binding domain is so close to the E3 twofold 
symmetry axis that it is impossible for two molecules of the binding domain to bind 
simultaneously to one E3 dimer. The interactions between E3 and the binding domain are 
dominated by an electrostatic zipper formed by basic residues of the binding domain and 
acidic residues of one of the subunits of E3. The binding domain behaves like a Janus-face 
protein: while E3 interacts with the N-terminal helix, mutagenesis experiments in Azotobacter 
vinelandii E2p indicate that El interacts with the C-terminal part of the binding domain 
(Schulze et al., 1991a). Considerable homology between binding domain sequences of many 
organisms indicates a similar structure and binding mode in complexes from other sources. 
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Surprisingly E2o of higher organisms seems to lack a binding domain (Rice et al., 1992). In 
mammalian OGDC sequences related to the E3-BP are integrated into the N-terminal region 
of the El-component. This region is responsible for its interaction with the E2 core and for 
directing E3 binding to the complex. Thus uniquely to the mammalian OGDC, E3 interacts 
via the El component and directly via the binding domain in E2 (Rice et al., 1992). 
The structural core of all 2-oxoacid dehydrogenase complexes is formed by aggregation of the 
C-terminal catalytic domain of E2. Trimeric E2 units form a cubic or dodecahedral core. 
Crystal structures are now available for both the 24-meric cubic structure and the 60-meric 
dodecahedral structure (Mattevi et al., 1992c; Knapp et al., 1998; Izard et al., 1999). Both the 
cube and the dodecahedron have a hollow interior and contain large pores at their faces. While 
the intratrimer interactions are extensive and strong, the intertrimer interactions are much 
weaker. 
The active site of E2 is located at the interface of two E2-subunits in a trimer, forming a 3 nm 
long channel with two entrances. Lipoamide enters this channel from the outside while CoA 
enters from the inside of the core. A high sequence and structural similarity between trimers 
of E2 and chloramphenicol acetyltransferase (CAT) was revealed by the determination of the 
crystal structure of E2. From sequence alignments of 13 known E2-sequences (Russell & 
Guest, 1991b) and the similarity to CAT (Guest, 1987) two highly conserved residues, a 
histidine and an aspartic acid, were predicted to be involved in the catalytic reaction of E2. 
Mutagenesis studies and the crystal structures of E2 have confirmed the proposed mechanism 
(Mattevi, A. et al., 1993c). The involvement of a third conserved residue, a serine or 
threonine, was revealed by the crystal structure of A. vinelandii E2p and has been confirmed 
by mutagenesis studies on E2 from several organisms (Mattevi et al., 1993c; Hendle et al., 
1995). The histidine acts as a general base in the proposed mechanism, while the serine acts as 
a hydrogen bond donor to the putative negatively charged transition state. The acyl transfer is 
completed by rearrangements resulting in the formation of acylated CoA and 
dihydrolipoamide, which then dissociate from the active site. 
Even though the amino acid sequences of various E2's are highly homologous, PDHC OGDC 
and BCDC each have their own substrate specificity. Mutagenesis studies by (Meng & 
Chuang, 1994) suggest that substrate specificity is sensitive to alterations in the size of residue 
348 of human BCDC. In BCDC this residue is either an alanine or serine, in PDHC a 
phenylalanine and in OGDC it is either a glycine or serine. The inability to convert BCDC 
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specificity to PDHC specificity indicates however, that also other elements are important for 
creating the optimal environment within the active site of E2. 
Defects of the E2 component of the 2-oxoacid dehydrogenase complexes have been reported 
for BCDC and OGDC. Up to now no defects were found in the E2 component of PDHC. 
Even though no molecular evidence was found up to now to link the OGDC with inborn 
errors several reports have been published that show a correlation between the activity of this 
complex and for example Alzheimer's disease (AD) (Kish, 1997; Cruts et al., 1995), 
Parkinson's disease (Mizuno et al., 1994), Wernicke-Korsakoff (Butterworth et al., 1993) or 
FAD-bindingdomain 
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Figure 7 Ribbon representation of 
the structure of P. fluorescens 
lipoamide dehydrogenase (E3). 
Subunit one is indicated in dark 
grey shading, the other in light 
grey. The NAD-binding domain, 
the FAD-binding domain and the 
central and interface domain are 
shown. FAD is drawn in ball-and-
stick representation. 
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Freidrich's ataxia (Mastrogiacomo et al., 1996). There is extensive evidence of mitochondrial 
abnormalities in AD, specifically of the activity and levels of OGDC (Gibson et al., 1998). 
Moreover, polymorphisms of the OGDC gene have been associated with AD (Sheu et al., 
1999). On the other hand, the extracellular deposition in the brain of amyloid beta peptide (a 
characteristic of AD) has recently been suggested to have a direct toxic effect via activation of 
transcription factors. In particular a strong upregulation of gadd45 was found, indicating DNA 
damage. (Santiard-Baron et al., 1999). The polymorphisms in the OGDC gene might therefore 
be a result of this neurotoxic effect of amyloid beta peptide and thus be a secondary effect. 
Several mutations in the E2b gene of MSUD patients have been described including 
insertions, substitutions and deletions in both intronic and exonic sequences. Most mutations 
described were found in introns, resulting in splicing problems. A number of these mutations 
involve rare deletions of intronic segments leading to secondary insertions/deletions in the 
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transcript through utilisation of cryptic or new splice sites (Chuang et al., 1997). Other 
mutations include small deletions in exon 2 and 3 (Chuang et al., 1991) or intronic mutations 
resulting in the entire skipping of exons (Fisher et al., 1991; Mitsubuchi et al., 1991; Herring 
et al., 1992). Point mutations were up to now found in exon 6,7, and 8. The first point 
mutation resulted in the substitution of El 63 for a stop codon, yielding a truncated protein that 
only includes the lipoyl and binding domains (Fisher et al., 1993). The other two mutations 
are F215C and R230G (Chuang et al., 1997). F215 is conserved in all E2 as a hydrophobic 
residue, in contact with the active site histidine. Replacing it for a cysteine will certainly affect 
the catalytic activity of E2. R230 is completely conserved in all E2 sequences. It is also 
present in the active site, in contact with CoA. Replacing the positively charged arginine for 
the small and uncharged glycine will affect the binding of CoA and thus the activity of E2. 
Structure and dysfunctioning of E3 
Lipoamide dehydrogenase (E3) belongs to a family of FAD-dependent disulphide 
oxidoreductases. 3-D structures of E3 from multiple sources have been solved by X-ray 
crystallography (figure 7) (Toyoda et al., 1998; De la Sierra et al., 1997; Mattevi et al., 1991; 
Mattevi et al., 1992b; Mattevi, 1993b.). Jentoft et al. (Jentoft et al., 1992) have constructed a 
model structure for human E3 Since recent review articles describe the enzyme in depth 
(Williams, 1992; De Kok & Van Berkel, 1996) we will only give a short description of the 
enzyme. E3 is usually shared by all of the 2-oxoacid dehydrogenase complexes, although 
exceptions were found where different E3's were found for the different complexes (Palmer et 
al., 1991; Claiborn et al., 1994). E3 is a dimer of identical subunits, each comprising of three 
domains: the FAD-binding domain, the NAD-binding domain and the interface domain. The 
catalytic site is located at the subunit interface in an 11 A deep cleft (figure (8). The enzyme 
catalyses the oxidation of the dihydrolipoamide group attached to one of the lipoyl domains of 
E2. In the first step of this ping-pong mechanism the electrons are transferred from the 
reduced lipoyl group to a reactive disulphide group. Secondly, the electrons are transferred via 
the FAD to NAD , the final electron acceptor. All important active site residues, as indicated 
by structural comparison with other disulphide reductases and mutagenesis are conserved 
within all E3's (De Kok et al., 1996). 
E3-deficiency presents itself in two clinical forms, either in infancy with severe mental 
retardation and lactic acidemia or later in life with episodes of liver failure and myoglobinuria. 
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Seven mutations were identified to have the first phenotype (Table 1) and recently one new 
mutation was associated with the second phenotype (G229C). As all of these mutations have 
been discussed extensively we will only give a summary of the proposed functions. The 
mutations K72E and P488L are always found combined in one patient. K72 is an exposed 
residue that likely has negligible effect. P488 is in the cis conformation and positions the 
backbone containing the his-glu diad of the active site. G136D and E375K are also found 
together, G136 is part of an a-helix in the FAD domain and deletion of this residue affects 
FAD binding. E375 is part of the central domain of E3. Mutation of this residue results in 
drastic reduction of the enzyme activity. Mutating either G229 to a C or D479 to a V affects 
protein stability and possibly the dimerisation of E3. R495 is conserved in all E3 as a bulky 
hydrophilic residue, mutating it to a glycine results in disruption of dimer formation. Finally 
one mutation of E3 results in the replacement of the last amino acid of the leader peptide 
(Y35) into a stop codon and a frameshift. This mutation results in complete loss of E3. 
Function and dysfunctioning of E3BP 
So far we have considered the three major catalytic components of the complexes. A fourth 
component has been identified in mammalian PDHC's: the E3BP (De Marcucci & Lindsay, 
1985). The E3BP has a similar domain structure to that of E2 (figure 6): a lipoyl domain, an 
E3 binding domain and a C-terminal domain. The C-terminal domain has no acetyltransferase 
activity or sequence similarity to any other known protein (Reed & Hackert, 1990). A few 
copies of E3BP associate with the catalytic core of E2p, facilitating the proper binding of the 
E3-component (Sanderson et al., 1996). In Yeast PDHC 12 subunits of the E3BP bind to E2, 
probably on the inside of the dodecahedral E2-core structure (Stoops et al., 1997). It has been 
shown that the lipoyl domain of the E3BP can participate in the reaction mechanism (Yang et 
al., 1997). 
Five cases of E3BP deficiency have been reported so far (Aral et al., 1997; De Meirleir et al., 
1998a; Geoffroy et al., 1996; Ling et al., 1998; Marsac et al., 1993). All cases show neonatal 
lactic acidemia. The deficiencies were demonstrated by Western blot analysis, in which the 
E3BP protein was either altered or completely absent. Analysis on a molecular level showed 
that only in one case a small deletion was causing the deficiency. A four bp deletion was 
found in the leader peptide sequence resulting in a premature stop codon (Ling et al., 1998). In 
two other cases large deletions lead to truncated E3BP of only 25 or 321 amino acids, instead 
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of the 501 amino acid long wild type protein (Aral et al., 1997). It is clear from these results 
that the absence of E3BP leads to heavily impaired PDHC. 
Assembly of the complexes 
So far we have discussed the different components of the 2-oxoacid dehydrogenase complexes 
and the effect of mutations on these components. The assembly of the components into the 
functional multi-enzyme complexes is of vital importance for the complexes. All components 
of the mitochondrial complexes are encoded by nuclear genes. The cytosolic precursors of the 
components have to be actively imported into the mitochondrion. For BCDC the relative rates 
of entry were shown to be Elba > E2 > Elbp. This makes the import rate of Elbp the limiting 
factor in the amount of complex formed (Sittler et al., 1998). Point mutations in the leader 
sequence (or mitochondrial targeting sequence) have been found in El pa and E3, both 
strongly affecting the activity of the activity of the entire complex. This shows not only the 
importance of these sequences but also the effect the partial or total absence of one component 
of the complex has on the total activity. 
The mature form of E2 is formed in the mitochondrial matrix through lipoylation of the lipoyl 
domain by lipoyltransferases (Motokawa, 1996). The two lipoyltransferases found in bovine 
liver were able to lipoylate lipoyl domains from several origins (rat E2p and E2o and bovine 
E2b). In the mitochondrial lipoylation system a third enzyme is required for lipoic acid 
activation. 
Chuang et al. (Chuang et al., 1999) have shown in in vitro experiments that Elb requires 
molecular chaperones (GroEL/GroEs) for the reconstitution of the a2|52 tetramers. The 
reconstitution proceeds via the formation of an aP intermediate. 
The assembly of the different 2-oxoacid dehydrogenase complexes can result in aggregates 
ranging in size from only 700 kDa (the smallest PDHC as found in A. vinelandii) up to 10 
MDa in mammalian PDHC. Mammalian complexes all contain the three catalytic components 
(El, E2 and E3), both PDHC and BCDC contain two regulatory enzymes (El kinase and El 
phosphatase) and PDHC also contains the E3BP. The association of the 6 components of 
PDHC, with the emphasis on the association of the regulatory enzymes to E2 has been 
reviewed by Roche et al. (Roche al., 1996) (figure 6). Typical bovine PDHC contains about 
20-30 El tetramers bound to the dodecahedral assembly of E2, and only about one kinase 
molecule. Both El-kinase and El-phosphatase bind to the inner lipoyl domain of E2. Hand 
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over hand movement, from one lipoyl domain to another, of the kinase or phosphatase is 
necessary to reach all bound El's. 
From the number of mutations found on the El and E3 components that affect the subunit 
interactions it is clear that disturbance of the assembly of the components of the complex has 
a drastic effect on the functioning of the complex. It would therefore not be surprising if some 
of the mutations found on the surface of Elp, to which at this moment no definite function 
could be assigned, are involved in the association of this component to the other components 
of the complex. Since the assembly of the complex and the interactions between the different 
NAD+ 
Figure 8 Schematic drawing of the active site 
and reaction mechanism of E3. For an 
explanation see text. 
pro'451 
C-terminus 
components of the complex is still quite unclear, it would be very useful to investigate the 
function of the residues in more detail in in vitro experiments. 
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Concluding remarks 
Dysfunctioning of any of the components of the 2-oxoacid dehydrogenase complexes leads to 
severe disorders in humans. In this paper we have tried to relate mutations in these 
components, that were found by molecular analysis of patients, to a more definite function of 
the affected residues. Especially in the case of PDHC deficiency, the need for uniform kinetic 
data has become obvious from our inventarisation. Because of, for example, the variable 
expression pattern of the X-chromosome linked El pa kinetic data from tissues result in large 
variations in the measured activities. The use of a uniform model system using site directed 
mutants for analysis of mutations identified in patients would certainly improve the 
understanding of the structure-function relationship of these complicated systems. Such an 
analysis can help to improve our understanding of the mechanism of deficiency and might 
lead to new or more effective treatments. 
Table 1. Mutations in human El, 
complexes. 
E3 and E3BP that cause the dysfunctioning of the 2-oxoacid dehydrogenase 
Mutat. " 
Point mutatio 
R10P 
H44R 
R72C 
R88S 
G89S 
H113D 
R127W 
R141Q 
G162R 
N164S 
Sex2> 
ns in human E 
8 
8 
4c? 
8 
9 
$ 
?,3(J 
8 
$ 
3c? 
Act.3> 
Ipa 
28 
0-17 
20-30 
18 
100 
12 
59,7-15 
32 
40 
26 
Blot4' 
R a 
N 
Ra|3 
T 
Km 
ThDP 
Km Location 
* 
-r 
Mitochondrial 
targeting peptide 
Protein 
interaction? 
Protein interaction 
Active site 
Active site 
? 
Protein interaction 
Protein interaction 
Active site 
Active site 
Comments Reference 
Defective import 
E l a 
Defective activation 
by phosphorylation, 
ThDP responsive 
ThDP responsive 
DCA + ThDP 
responsive 
Takakubo et 
al., 1995 
Naito et al., 
1994 
Lissens et al., 
2000; Dahl 
etal., 1992; 
Lissens et al., 
1996 
Lissens et al., 
1997 
Matsuda et 
al., 1994; 
Naito et al., 
1999 
Lissens et al., 
1996 
Lissens et al., 
2000; Fujii et 
al., 1994 
Lissens et al., 
200; Morten 
etal., 1999 
Lissens et al., 
1996 
Lissens et al., 
2000 
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Mutat. '• 
V167M 
A175P 
A199T 
F205L 
M210V 
W214R 
P217L 
T231A 
Y243N 
D258A 
R263G 
R263Q 
M282L 
R288H 
G291R 
H292L 
R302L 
R302H 
R302C 
Sex2> 
2$ 
$ 
s 
26 
3 
3 
3 
3 
3 
3 
9,12c? 
2c? 
? 
$ 
$ 
9 
$ 
$ 
8? 
Act.31 
1-7 
51 
17 
25-36 
6 
47 
12 
2 
32 
10 
16-168 
38 
115 
25 
100 
2 
40 
5-89 
Blot4) 
N 
R 
R a 
R 
R a p 
AL 
N/Ra|3 
Km 
ThDP 
* 
Km 
* 
Location 
Active site 
Subunit 
interaction 
Active site 
Subunit 
interaction 
Subunit 
interaction 
Subunit 
interaction 
Active site, 
structural integrity 
Active site, 
phosphorylation 
Subunit 
interaction 
Protein interaction 
Subunit 
interaction 
Subunit 
interaction 
7 
Protein interaction 
Active site 
Active site 
Phosphorylation 
Phosphorylation 
Phosphorylation 
Comments 
Kcat 38% 
Kcat 24%, 
Structural integrity 
Unstable El 
ThDP responsive, 
unstable El 
Reference 
Chun et al., 
1993 
Takakubo et 
al., 1993b 
Chun et al., 
1993 
Chun et al., 
1995;Dahlet 
al., 1994 
Tripatara et 
al., 1999; 
Triptara et al., 
1996 
Lissens et al., 
2000 
Triptara et al., 
1999; 
Triptara et al., 
1996 
Chun et al., 
1993 
Matthews et 
al., 1994 
Matthews et 
al, 1993b 
Lissens et al, 
2000; Chun 
etal, 1995; 
Lissens et al, 
1996; Marsac 
etal, 1997; 
Chun et al, 
1993; Wexler 
etal, 1992; 
Wexler et al, 
1997;Naito 
etal, 1997; 
Briones et 
al,, 1996 
Awata et al, 
1994 
Matthews et 
al, 1994 
Lissens et al, 
2000 
Matsuda et 
al, 1994 
Chun et al, 
1993 
Lissens et al, 
2000 
Otero et al, 
1998 
Lissens et al, 
2000; Dahl et 
al, 1992; 
Lissens et al, 
1996; Morten 
etal, 1999; 
Otero et al, 
1998; Morten 
etal, 1998; 
Fujii et al, 
1996; De 
Meirleir et 
al, 1993 
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Mutat." 
D315N 
P316L 
L329R 
Y369Q 
R378C 
R378H 
S388X 
Sex2' 
3 
2 
3 
3 
9 
9, 7c? 
3 
Act.3' 
26-40 
53 
50 
30 
13-50 
15 
Blot4 | 
N 
Ra(3 
N/Rap 
Km 
ThDP 
Km 
pyr 
Location 
Protein interaction 
Protein interaction 
Protein interaction 
Subunit 
interaction 
Subunit 
interaction 
Subunit 
interaction 
Subunit 
interaction 
Comments 
PDHC-act. 1.2% 
Reference 
Matthews et 
al., 1994 
Takakubo et 
al., 1995 
Lissens et al., 
2000 
Lissens et al., 
2000 
Lissens et al., 
2000 
Lissens et al., 
2000; 
ripatara et al., 
1999; Chun 
etal., 1995; 
Morten et al., 
1999; 
Matthews et 
al., 1994; 
Wexler et al., 
1997; Hansen 
etal., 1991; 
Wexler et al., 
1995 
Linssen et al., 
2000 
Insertions and fusions in human El pa 
V171A31 
Y243A 
R288fs 
S300fs 
R302fs 
E306ins7 
I307insll 
R311A 
S312fs 
K313A 
P316fs 
321ins5 
N326ins5 
S327fs 
?,2c? 
$ 
9 
9 
$ 
3 
9 
23 
79 
9 
9 
3 
3 
9 
4/40 
88 
16 
5 
10 
15 
11/0 
8-31 
40 
1 
15 
18 
61 
A 
A 
A 
N 
N 
N/RaP 
AL 
SR 
Rap 
SR 
Subunit 
interaction 
Protein interaction 
Protein interaction 
Truncated at 283 aa 
Truncated at 276 aa, 
unstable E1 
Truncated at 297 aa 
Truncated at 293 aa 
Truncated at 308 aa 
Truncated at 313 aa 
Dahl etal., 
1992; Chun 
etal., 1995 
Lissens et al., 
2000 
Matthews et 
al., 1994 
Matthews et 
al., 1993a 
Hansen et al., 
1993 
De Meirleir et 
al., 1992 
Hansen et al., 
1994 
Chun et al., 
1995,Triptara 
etal., 1996 
Lissens et al., 
2000; Green 
etal., 1995; 
Chun et al., 
1993; Fujii et 
al., 1996; 
Dahl et al., 
1990; Lissens 
et al., 1995 
Hansen et al., 
1991 
Chun et al., 
1993 
Lissens et al., 
1996 
Fujii et al., 
1996 
Chun et al., 
1995 
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Mutat. " 
L335insl2 
E358fs 
P360fs 
E362+6 
G365+3 
E376fs 
Q382fs 
K387fs 
K387fs 
K387fs 
S388fs 
S388ins2 
V389fs 
Point mutatio 
M109T 
R159W 
Q190K 
T211M 
G249S 
A253T 
A254D 
R265W 
N267S 
A285P 
G290R 
R297H 
T310R 
Sex2 ' 
8 
? 
9 
$ 
8 
$ 
6$ 
8 
8 
8 
9,4c? 
8 
8 
ns in human 1 
Act.3' 
26 
100 
36 
20 
6-46 
41 
25 
8-14 
25 
lba 
6 
1.4 
0 
0 
0 
27 
0 
1.3 
0 
4 
27 
0 
Blot4) 
S 
S 
Ra(5 
Ra 
R 
T 
Ta,Rp 
Ra|3 
Rap 
R 
Km 
ThDP 
Km 
pyr 
Location 
Structural 
integrity 
Hydrophobic core 
ThDP-binding 
Subunit 
association 
ThDP-binding 
Hydrophobic core 
Hydrophobic core 
Subunit 
association 
ThDP-binding 
ThDP-binding 
Subunit 
association 
Subunit 
association 
Subunit 
association 
Hydrophobic core 
Comments 
Truncated at 339 aa 
Truncated at 332 aa 
Elongated to 394 aa 
Truncated at 358 aa 
Elongated to 362 aa 
Elongated to 400 aa 
Elongated to 431 aa 
Truncated at 358 aa 
ThDP responsive, 
elongated to 392 aa 
Intermediate 
Classic 
Intermediate 
Classic 
Classic 
Classic 
Intermediate 
Classic 
Classic 
Classic 
Intermediate 
Intermediate 
Classic 
Reference 
De Meileir et 
al., 1998 
Chun et al., 
1991 
Chun et al., 
1995 
Ito et al., 
1995 
Fujii et al., 
1996 
Chun et al., 
1993 
Lissens et al., 
2000; Chun 
etal., 1993; 
Endo et al., 
1991; Ito et 
al, 1992; 
Takakubo et 
al., 1993a 
Tripatara et 
al, 1996 
Hansen et al, 
1991 
Morten et al, 
1999 
Lissens etal, 
2000; Naito 
etal, 1994; 
Chun et al, 
1995 
Marsac et al, 
1997; Fujii et 
al, 1996 
Endo et al, 
1989 
^varssonet 
al, 2000 
Nobukino et 
al, 1993 
Nobukino et 
al, 1993 
^Evarsson et 
al, 2000 
Wynn et al, 
1998 
Nobukino et 
al, 1993 
iEvarsson et 
al, 2000 
Wynn et al, 
1998 
Chuang et al, 
1995 
Wynn et al, 
1998 
Chuang et al, 
1990 
,-Evarsson et 
al, 2000 
Wynn et al, 
1998 
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Mutat. ° 
I326T 
F409C 
Y413C 
Y438N 
Sex2) Act.3 | 
1.4 
0 
0 
0 
Blot4) Km 
ThDP 
Km 
pyr 
Location 
Hydrophobic core 
Subunit 
association 
Subunit 
association 
Subunit 
association 
Comments 
Intermediate 
Classic 
Intermediate 
Classic 
Reference 
Nobukino et 
al., 1993 
Chuang et al., 
1995 
Chuang et al., 
1990 
Matsuda et 
al., 1990; 
Fisher etal., 
1991 
Point mutations in human Elbp 
N176Y 
H206R 
<1 
0 
Subunit 
association 
Subunit 
association 
Classic 
Classic 
^varsson et 
al., 2000 
Nobukino et 
al., 
Point mutations in human E3 
Y35X 
K72E 
G136A 
G229C 
E375K 
D479V 
P488L 
R495G 
s 
3 
?.<? 
3 
$ 
$ 
8-20 
6 
3 
9-21 
3 
15 
6 
14 
20% 
R 
N 
25-60% 
N 
8% 
R 
53% 
Leader peptide 
Exposed, solvent 
FAD binding 
Protein stability, 
dimerisation 
9 
Stability, dimer 
interface 
Positioning active 
site 
Dimer formation 
Hong et al., 
1996;Elpeleg 
etal., 1997; 
Shaag et al., 
1999 
Liu et al., 
1993; Liu et 
al., 1995; 
Lanterman et 
al., 1996 
Hong et al., 
1997 
Shaag etal., 
1999 
Hong et al., 
1997 
Shany et al., 
1999 
Liu et al., 
1993; Liu et 
al., 1995; 
Lanterman et 
al., 1996 
Hong et al., 
1996 
' Mutat. means mutation. Amino acid numberings include leader peptide sequences. 
2)
 $ is female, S is male 
3)
 Activity was measured in fibroblast. 
4)
 Blot means Western blot. R is reduced, N is normal, T is trace, AL is altered, A is absent, SR is slightly 
reduced, S is smaller molecular weight. 
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8 Summary and concluding remarks 
Pyruvate dehydrogenase multi-enzyme complex (PDHC) is member of a family of multi-
enzyme complexes that catalyse the irreversible decarboxylation of various 2-oxoacid 
substrates to their corresponding acyl-CoA derivatives, NADH and CO2. 2-oxoacid 
dehydrogenase complexes hold key points in primary energy metabolism: PDHC in 
glycolysis, the oxoglutarate dehydrogenase complex (OGDC) in the citric acid cycle, the 
branched-chain oxoacid dehydrogenase complex (BCDC) in amino acid catabolism, the 
glycine dehydrogenase complex (GDHC) in the glycine cleavage system and acetoin 
dehydrogenase complex (ADHC) in acetoin metabolism. Malfunctioning of a 2-oxo acid 
dehydrogenase complex in man leads to a broad variety of clinical manifestations, e.g. lactic 
acidosis (PDHC-deficiency) or maple syrup urine disease (BCDC-deficiency). 
PDHC consists of multiple copies of three enzymes: 2-oxoacid dehydrogenase or Elp-
component, dihydrolipoyl acyltransferase (E2p) and dihydrolipoamide dehydrogenase (E3). 
The E2 component plays a central role in the complex, both catalytically and structurally. It 
consists of multiple domains (from N- to C-terminus, 1-3 lipoyl domains, an El/E3-binding 
domain and a catalytic domain) connected by flexible linkers, allowing a high degree of 
flexibility of the individual domains. In gram-negative bacteria, the C-terminal catalytic 
domain forms a cubic core of 24 subunits. Multiple copies of the peripheral components Elp 
and E3 are non-covalently attached to this core. Three-dimensional structures of the different 
components and domains of PDHC have been solved by X-ray crystallography or NMR. 
El catalyses the rate limiting step in the overall complex reaction; the reductive acylation of 
the lipoyl groups of E2 utilising thiamin diphosphate (ThDP). The El-component exists either 
as a homodimer (012) or heterotetramer (012P2), depending on the type and source of the 
complex. There is strikingly little sequence similarity between homodimeric and 
heterotetrameric El or even between homodimeric Elo and homodimeric Elp. An exception 
to this is the so-called "ThDP-binding motif, that has so far been found in all known ThDP 
dependent enzymes. Until quite recently El was by far the least characterised component of 
the complex. This lack of (structural) information was largely due to the lack of a stable form 
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of the enzyme: when resolved from the complex, El is unstable. To obtain a better insight into 
the structure and functioning of the El-component of the pyruvate dehydrogenase multi-
enzyme complex from A. vinelandii and its interactions within the complex, a PhD project 
was started in 1995. The results of this project are presented in this thesis. 
Chapter 2 describes the cloning and sequencing of the gene encoding Elp from Azotobacter 
vinelandii and, for the first time, the expression and purification of a homodimeric El. The 
cloned Elp shows a kinetic behaviour exactly as the wild-type complex-bound enzyme with 
respect to its substrate (pyruvate), its allosteric properties and its effectors. Moreover, it can be 
used to fully reconstitute complex activity. The enzyme is stable in high ionic strength buffers, 
but is irreversibly inactivated when incubated at high pH, which presumably is caused by its 
inability to redimerise correctly. This explains the previously found low stability of the wild-
type Elp component after resolution from the complex at high pH. Kinetic experiments show 
that acetyl coenzyme A acts as a feedback inhibitor by binding to the Elp component. 
Limited proteolysis experiments show that the N-terminal region of Elp is easily removed. 
The resulting protein fragment is still active with artificial electron acceptors but has lost its 
ability to bind to the core component (E2p) and thus reconstitute complex activity, indicating 
that the N-terminal region of Elp is involved in the binding of Elp to E2p. 
To further investigate this hypothesis N-terminal deletion mutants of Elp were constructed 
and characterised (Chapter 3). 
Up to 9 N-terminal amino acids could be removed from Elp without affecting the properties 
of the enzyme. Truncation of up to 48 amino acids did not effect the expression or folding 
abilities of the enzyme, but these truncated enzymes could no longer interact with E2p, 
confirming the involvement of the N-terminal region in the binding of Elp to E2p. The 48 
amino acids deletion mutant (ElpA48) was characterised in detail: it is catalytically fully 
functional, it has a Vmax identical to that of wild type Elp, it can reductively acetylate the 
lipoamide group attached to the lipoyl domain of the core enzyme (E2p) and it forms a 
dimeric molecule. On the other hand, the S0.5 for pyruvate is significantly decreased. 
A heterodimer was constructed containing one subunit of wild type Elp and one subunit of 
ElpA48. As the heterodimer is not able to bind to E2p therefore both N-terminal domains are 
needed for the binding of Elp to E2p. 
Based on sequence alignments and mutagenesis experiments on E2p the interactions between 
the N-terminal region of Elp and E2p are thought to be mainly of electrostatic nature 
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involving negatively charged residues on the N-terminal domains of Elp and previously 
identified positively charged residues on both the binding and catalytic domain of E2p. These 
mutagenesis experiments show that Elp, unlike E3, interacts with both the binding- and the 
catalytic-domain of E2p. 
In chapter 4 we use a synthetic peptide (Nterm-Elp) to characterise the structure and function 
of the N-terminal region (amino acid residues 4-45) of Elp. Activity and binding studies 
establish that Nterm-Elp specifically competes with Elp for binding to the E2p component. 
Moreover, the experiments show that the N-terminal region of Elp forms an independent 
folding domain that functions as a binding domain. CD measurements, 2D-'H NMR analysis 
and secondary structure prediction all indicate that Nterm-Elp has a high a-helical content. 
Chapter 5 describes the construction of point mutations in the N-terminal domain (D17Q, 
D17R, E20Q, E20R, D24Q and D24R) to identify the specific residues involved in the 
interactions between Elp and E2p. Kinetic and binding studies show that D17 is essential for 
the binding of Elp to E2p. D24 is involved in the binding, but not essential, whereas E20 is 
not involved. None of the mutations affects the folding or dimerisation of Elp 
We have refined the model of the binding mode of Elp and E2p proposed in chapter 4: in the 
"helix-turn-helix" motif residues D17, E20 and D24 are on one side of the helix, whereas on 
the opposite side W15, LI 9 and V22 form a hydrophobic "patch". Helix II also has a 
hydrophobic side, which can form a hydrophobic "pocket" with the residues of helix I. None 
of the mutations result in complete abolishment of the binding capacity of Elp to E2p; neither 
do point mutations in E2p. Apparently the binding interface is composed of more than one 
region both on E2p (binding domain and catalytic domain) and on Elp. 
Finally, it was shown before that the binding of Elp to E2p is highly species specific: E. coli 
Elp binds very poorly to A. vinelandii E2p. The fact that the mutations D17Q and D24R both 
have such a strong effect on the binding abilities of Elp correlates well with this observation. 
Spectroscopic measurements in chapter 4 show that the peptide is present in two 
conformations, the population of which depends on the sample conditions. The two 
conformations are designated "unfolded" at a pH above 6 and "folded" at a pH below 5. The 
2D-'H TOCSY spectrum of a mixture of folded and unfolded Nterm-Elp shows exchange 
cross peaks that "link" the folded and unfolded state of Nterm-Elp. We suggest that the 
exchange rate between the two species is in the range of 0.5 to 5 seconds'. Sharp resonances 
in the NMR-spectra of wild type Elp demonstrate that this 200 kDa enzyme contains highly 
flexible regions that partly originate from its N-terminal region. The observed dynamic 
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character of Elp and of Nterm-Elp is likely required for the binding of the Elp dimer to the 
two different binding sites on E2p. Moreover, the flexibility might be essential to sustain the 
allosteric properties of the enzyme when bound in the complex. 
In summary, chapter 2-5 describe in detail the elucidation of the binding mode of Elp to E2p. 
Only in the final stages of this PhD project detailed structural information came available for 
El. Therefore, in chapter 6 we combined primary and secondary structural information to 
obtain a sequence alignment of homodimeric and heterotetrameric 2-oxoacid dehydrogenases 
and transketolase. In striking contradiction with their structural similarity is the apparent lack 
of sequence similarity between these enzymes. The alignment consists of two parts, 
corresponding to the a- and P-strand of heterotetrameric 2-oxoacid dehydrogenase. Aligning 
the sequences of homodimeric pyruvate dehydrogenase (Elp) (Azotobacter vinelandii and 
Escherichia coli), transketolase (TK) (Saccharomyces cerevisiae), branched-chain oxoacid 
dehydrogenase (Elb) (Pseudomonas putida and human) and heterotetrameric Elp (Bacillus 
stearothermophilus and human), 36 residues are identical while 32 residues are highly 
conserved. These residues are evenly spread throughout the sequence, although multiple gaps 
and/or insertions had to be introduced. The most likely candidates for ThDP binding and 
active site residues were identified. Furthermore, a common function was suggested for 
regions shared by TK and the 2-oxoacid dehydrogenases. A few conserved regions remain that 
no definite function could be assigned to. It would be very valuable to study the function of 
these regions by for example mutagenesis experiments. In addition, puzzling differences 
between the binding mode of homodimeric El and heterotetrameric El are found and clearly 
need more detailed study. This new alignment opens possibilities to construct model 
structures for El. Especially for the homodimeric Elp, that up to now has resisted 
crystallisation attempts, this will be of great value. 
Finally, chapter 7 reviews the structural basis of the dysfunctioning of human 2-oxoacid 
dehydrogenase complexes. As was mentioned before, malfunctioning of any of these 
complexes leads to a broad variety of clinical manifestations. Deficiency of the PDHC 
predominantly leads to lactic acidosis combined with impairment of neurological function 
and/or delayed growth and development. Maple urine disease is an inborn metabolic error 
caused by dysfunction of the BCDC. An association between both Alzheimer disease and 
Parkinson's disease and the OGDC gene has been reported. In this chapter the wealth of both 
genetic and structural information available is combined to gain more insight into the 
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structural basis of the dysfunctioning of the 2-oxoacid dehydrogenase complexes. Known 
mutations in the components of human complexes were explained based on their putative 
function in the enzyme. 
Even though this thesis sheds light onto the structure and binding mode of homodimeric Elp, 
many questions remain. For example, the differences between homodimeric and 
heterotetrameric El; why does heterotetrameric El lack an N-terminal domain? Putative 
active site residues were identified based on sequence alignments and homology models, but 
their function has to be experimentally verified; what residues form the lipoamide binding 
channel; which residues bind ThDP or what residues bind pyruvate, either in a pre-catalytic 
complex or in a catalytic complex. Finally, our experiments show the presence of several 
highly flexible regions in Elp. Removal of these regions could be an important step in 
obtaining suitable crystals that will ultimately lead to a high-resolution structure of 
homodimeric E1. 
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Samenvatting 
Het pyruvaat dehydrogenase multienzym complex (PDHC) behoort tot een familie van 
multienzym complexen die de irreversibele oxidatieve decarboxylatie katalyseert van 
verschillende 2-oxozuur substraten naar hun corresponderende acyl-CoA derivaten, NADH 
and CO2. 2-oxozuur dehydrogenase complexen bezetten strategische punten in het primaire 
energie metabolisme: PDHC in de glycolyse, het oxoglutaraat dehydrogenase complex 
(OGDC) in de citroenzuur cyclus, het branched-chain oxozuur dehydrogenase complex 
(BCDC) in aminozuur katabolisme, het glycine dehydrogenase complex (GDHC) in het 
glycine splitsingsysteem en het acetoine dehydrogenase complex (ADHC) in acetoine 
metabolisme. Het slecht, of niet functioneren, van een 2-oxozuur dehydrogenase complex in 
de mens resulteert in een grote verscheidenheid aan klinische verschijnselen, zoals 
bijvoorbeeld melkzuur acidose (PDHC-deficientie) of de 'maple syrup urine' ziekte (BCDC-
deficientie). 
Het PDHC bestaat uit meerdere kopieen van drie enzymen: het 2-oxozuur dehydrogenase of 
de Elp component, het dihydrolipoyl acyltransferase (de E2p component) en het 
dihydrolipoamide dehydrogenase (de E3 component). In de afkorting Elp verwijst de "p" naar 
het bijbehorende complex; PDHC, "o" verwijst naar OGDC en "b" verwijst naar BCDC. De 
E2 component speelt zowel katalytisch als structureel een centrale rol in het complex. Het 
bestaat uit meerdere domeinen: van N- naar C-terminus, 1 tot 3 lipoyl domeinen, een E1/E3-
bindingsdomein en een katalytisch domein. De domeinen zijn met flexibele 'linkers' aan 
elkaar verbonden. Deze architectuur zorgt voor de hoge mate van flexibiliteit van de 
individuele domeinen die essentieel is voor het voor het complex zo belangrijke 'active site 
coupling' mechanisme. In Gram-negatieve bacterien vormt het C-terminale katalytisch 
domein een kern die bestaat uit 24 subeenheden; een kubus gevormd uit 8 trimeren (op elk 
hoekpunt een trimeer). Meerdere kopieen van Elp en E3 binden, niet covalent, aan de 
buitenzijde van deze kern. Van al deze verschillende enzymen of domeinen van enzymen van 
PDHC zijn inmiddels drie dimensionale structuren opgelost met behulp van Rontgen 
kristallografie of NMR. 
Om een beter inzicht te krijgen in de structuur en in het functioneren van de Elp component 
van het PDHC uit A. vinelandii en van zijn interacties binnen het complex, is in 1992 een 
SON/NWO OIO project gestart. De resultaten van dit onderzoek zijn beschreven in dit 
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proefschrift. El katalyseert de snelheidslimiterende stap van het reactiemechanisme; de 
reductieve acylering van de lipoyl groepen van E2, waarbij het gebruik maakt van thiamine 
difosfaat (ThDP). El bestaat of als een homodimeer (02), of als een heterotetrameer (012P2), 
afhankelijk van het soort en de oorsprong van het complex. Er zijn verrassend weinig 
overeenkomsten tussen de sequenties van homodimeer en heterotetrameer El, of zelfs maar 
tussen homodimeer Elo en homodimeer El p. Een uitzondering hierop is het zogenaamde 
'ThDP-bindingsmotief. Dit motief is gevonden in alle tot nu toe bekende ThDP afhankelijke 
enzymen. Tot zeer recent was El verreweg de slechtst gekarakteriseerde component van het 
complex. Dit gebrek aan (structurele) informatie werd grotendeels veroorzaakt door het 
gebrek aan een stabiele vorm van het eiwit: wanneer El niet gebonden is aan het complex is 
het instabiel. 
Hoofdstuk 2 beschrijft de klonering en het sequensen van het gen dat codeert voor Elp uit 
Azotobacter vinelandii en, voor de eerste maal, de expressie en zuivering van een homodimeer 
El. Het beschikbaar komen van een stabiel El maakte het mogelijk om dit enzym in meer 
detail te bestuderen. Het katalytisch mechanisme van het gekloneerde Elp is exact hetzelfde 
als dat van het wildtype complexgebonden enzym; wat betreft de substraatbinding (pyruvaat) 
en het allostere gedrag werden geen verschillen waargenomen. Bovendien resulteert het 
combineren van E2 en E3 met het gekloneerde El in volledige complex activiteit. El is 
stabiel in buffers met een hoge zoutsterkte, maar het wordt irreversibel gei'nactiveerd bij een 
hoge pH. Waarschijnlijk wordt dit veroorzaakt door het onvermogen van El om na 
monomeriseren correct dimeren te vormen. Dit verklaart de eerder gevonden instabiliteit van 
het wildtype Elp nadat het van het complex verwijderd is door incubatie bij hoge pH. 
Experimenten laten zien dat acetyl coenzym A zich gedraagt als een 'feedback inhibitor' via 
binding aan de Elp component. 
Gelimiteerde proteolyse experimenten laten zien dat het N-terminale gebied van Elp 
makkelijk kan worden verwijderd. De ontstane eiwitfragmenten zijn actief wanneer een 
artificiele elektronenacceptor wordt gebruikt, maar hebben hun vermogen verloren om aan de 
centrale component (E2p) te binden en op die manier complex activiteit te herstellen. Dit wijst 
er op dat het N-terminale gebied van Elp betrokken is bij de binding van Elp aan E2p. 
Om deze hypothese verder te onderzoeken zijn er N-terminale deletiemutanten van Elp 
gemaakt en gekarakteriseerd. Deze experimenten worden beschreven in hoofdstuk 3. 
Maximaal 9 N-terminale aminozuren kunnen verwijderd worden zonder effect te hebben op 
de eigenschappen van het enzym. Het inkorten van Elp tot en met 48 aminozuren heeft geen 
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effect op de expressie of de vouwing van het enzym, maar deze ingekorte enzymen zijn niet 
langer instaat om aan E2p te binden. Dit bevestigt de betrokkenheid van het N-terminale 
gebied bij de binding van Elp aan E2p. De mutant waarvan 48 aminozuren zijn verwijderd 
(ElpA48) is in detail gekarakteriseerd: Het is katalytisch volledig functioneel, het heeft een 
Vmax welke gelijk is aan die van het wildtype Elp, het kan de lipoamide groep gebonden aan 
het lipoyl domein reductief acetyleren en het vormt dimeren. Aan de andere kant is de S0.5 
voor pyruvaat significant afgenomen. 
Om te bestuderen of een of twee N-termini van Elp betrokken zijn bij de binding aan E2p is 
er een heterodimeer gemaakt met een subunit van het wildtype Elp en een subunit van 
ElpA48. Uit het feit dat de heterodimeer niet in staat is om aan E2p te binden volgt dat beide 
N-terminale domeinen in een Elp dimeer nodig zijn voor de binding van Elp aan E2p. 
Verschillende experimenten (sequentievergelijkingen en mutagenese) aan E2p wijzen er op 
dat de interacties tussen Elp en E2p hoofdzakelijk elektrostatisch van karakter zullen zijn. De 
interacties vinden plaats tussen negatief geladen residuen in het N-terminale domein van Elp 
en positief geladen residuen in zowel het bindingsdomein als het katalytisch domein van E2p. 
De bovengenoemde mutagenese experimenten demonstreren dat Elp, anders dan E3, bindt 
aan zowel het bindingsdomein als het katalytisch domein van E2p. 
Hoofdstuk 4 beschrijft in detail de karakterisering van de structuur en van de functie van een 
synthetisch peptide (Nterm-Elp) dat het N-terminale gebied (aminozuur 4-45) van Elp 
vertegenwoordigd. Activiteitsmetingen en bindingsstudies bevestigen dat Nterm-Elp 
specifiek met Elp concurreert voor de binding aan E2p. Bovendien tonen deze experimenten 
aan dat het N-terminale gebied van Elp een zelfstandig vouwend domein vormt dat 
functioneert als een bindingsdomein. Zowel CD metingen, 2D-'H NMR analyse en secondaire 
structuurvoorspellingen geven aan dat Nterm-Elp voornamelijk uit a-helix bestaat. 
Hoofdstuk 5 beschrijft de constructie van puntmutaties in het N-terminale domein (D17Q, 
D17R, E20Q, E20R, D24Q en D24R) met als doel de specifieke residuen te identificeren 
welke betrokken zijn bij de binding van Elp aan E2p. Analyse van het katalytisch gedrag en 
bindingsstudies tonen aan dat aminozuur D17 essentieel is voor de binding van Elp aan E2p. 
Aminozuur D24 is betrokken bij de binding, maar lijkt niet essentieel. Aminozuur E20 is niet 
betrokken bij de binding van Elp aan E2p. Geen van de mutaties hebben invloed op de 
vouwing of op de dimeer vorming van Elp, wat aantoont dat het effect van de mutaties op de 
binding niet veroorzaakt wordt door slechte vouwing van het eiwit. 
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We hebben het model van de interacties tussen Elp en E2p zoals dat is voorgesteld in 
hoofdstuk 4 in hoofdstuk 5 verder verfijnt: in het 'helix-turn-helix' motief van het N-
terminale domein zitten de residuen D17, E20 en D24 aan een kant van de helix. Aan de 
tegenoverliggende zijde van deze helix bevinden zich W15, L19 en V22 die samen een 
hydrofoob gebiedje vormen. Helix II bevat ook een hydrofobe kant, welke een hydrofobe 
'pocket' kan vormen met de residuen uit helix I. Geen van de mutaties resulteert in totale 
vernietiging van de bindingscapaciteit van Elp; hetzelfde geldt voor de puntmutaties gemaakt 
in E2p. Het raakvlak tussen Elp en E2p is schijnbaar opgebouwd uit meer dan een regio in 
zowel E2p (het bindingsdomein en het katalytisch domein) alsmede in Elp. 
Al eerder werd aangetoond dat de binding tussen Elp en E2p soort specifiek is: E. coli Elp 
bind vrijwel niet aan A. vinelandii E2p. Het feit dat de mutaties D17Q en D24R (A. vinelandii 
aminozuren naar E. coli aminozuren) beiden zo'n sterk effect hebben op het 
bindingsvermogen van Elp correleert goed met deze observatie. 
De spectroscopische metingen in hoofdstuk 4 tonen aan dat het peptide Nterm-Elp aanwezig 
is in twee toestanden, de populatie van de twee vormen hangt af van de condities van het 
monster. De twee gevonden strucruren zijn respectievelijk "ontvouwen" bij een pH boven de 
6 en "gevouwen" bij een pH beneden de 5 genoemd. Het 2D-'H TOCSY spectrum van 
"gevouwen" Nterm-Elp laat zien dat er hier eigenlijk sprake is van een mengsel van 
gevouwen en ontvouwen Nterm-Elp. Bovendien zijn er uitwisselingskruispieken tussen de 
twee toestanden te zien. De uitwisselingssnelheid tussen de twee populaties valt in het gebied 
van 0.5 tot 5 seconden" . De geobserveerde scherpe resonanties in de NMR spectra van 
wildtype Elp tonen aan dat dit 200 kDa grote enzym zeer flexibele gebieden bevat. Deels 
vinden deze scherpe resonanties hun oorsprong in de N-terminus van Elp. Het geobserveerde 
dynamische karakter van Elp en van Nterm-Elp is waarschijnlijk nodig voor de binding van 
de Elp dimeer aan de twee verschillende bindinggebieden in E2p. De flexibiliteit kan ook 
nodig zijn voor het behoud van het allostere karakter van het enzym wanneer het gebonden is 
aan het complex. 
Samenvattend beschrijven de hoofdstukken 2-5 tot in detail de opheldering van de binding 
tussen Elp en E2p. 
Pas aan het einde van dit project is gedetailleerde structurele informatie beschikbaar gekomen 
over El. Om deze reden hebben we in hoofdstuk 6 primaire en secondaire structurele 
informatie gecombineerd met als doel het verkrijgen van een sequentievergelijking van 
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homodimeer en heterotetrameer 2-oxozuur dehydrogenase en van transketolase. Het is 
opvallend dat in tegenstelling tot hun structurele overeenkomsten, er een totaal gebrek aan 
sequentie identiteit lijkt te bestaan tussen deze eiwitten. De gemaakte sequentievergelijking 
bestaat uit twee delen, overeenkomstig met de a- en de P- keten van het heterotetramere 2-
oxozuur dehydrogenase. Vergelijken van de sequenties van homodimeer pyruvaat 
dehydrogenase (Elp) (Azotobacter vinelandii en Escherichia coli), transketolase (TK) 
{Saccharomyces cerevisiae), branched-chain oxozuur dehydrogenase (Elb) (Pseudomonas 
putida en de mens) en heterotetrameer Elp {Bacillus stearothermophilus en de mens) laat zien 
dat 36 aminozuren identiek zijn terwijl 32 residuen zeer sterk geconserveerd zijn. Deze 
residuen zijn gelijkmatig verspreid over de sequentie, alhoewel meerdere tussenruimtes 
('deletions') en/of invoegingen ('insertions') geintroduceerd moesten worden. De meest 
aannemelijke kandidaten voor ThDP binding en voor de 'active site' aminozuren zijn in dit 
hoofdstuk gei'dentificeerd. Daarnaast is er een gemeenschappelijke functie voorgesteld voor 
gebieden die aanwezig zijn in zowel TK als in beide soorten 2-oxozuur dehydrogenase. 
Enkele geconserveerde gebieden blijven over, waarvoor geen duidelijke functie kon worden 
toegekend op basis van de gemaakte vergelijking tussen de verschillende sequenties. Het zou 
zeer waardevol zijn om de functie van deze gebieden te bestuderen bijvoorbeeld met behulp 
van mutagenese experimenten. Daarnaast zijn er verschillen gevonden tussen de manier van 
binden van homodimeer El en van heterotetrameer El aan E2p welke oproepen tot vragen en 
dus nader dienen te worden bestudeerd. Deze nieuwe sequentievergelijking opent, samen met 
de nu beschikbare drie dimensionale informatie, de mogelijkheid tot het maken van zeer 
bruikbare model structuren van El. Speciaal voor homodimeer Elp, welke tot nu toe niet 
gekristalliseerd kon worden, zal dit van zeer grote waarde zijn. 
Als laatste, wordt in hoofdstuk 7 een overzicht gegeven van het structurele grondvlak van de 
verstoorde of verdwenen functie van humane 2-oxozuur dehydrogenase complexen. Zoals al 
eerder vermeld, resulteert het slecht of niet functioneren van elk van deze complexen in een 
brede variatie aan klinische verschijnselen. Slecht functioneren of gebrek aan PDHC leidt met 
name tot melkzuur acidose gecombineerd met verminderde neurologische functie en/of een 
vertraagde groei en ontwikkeling. Maple syrup urine ziekte is een aangeboren 
stofwisselingsstoornis veroorzaakt door het slecht functioneren van het BCDC. Daarnaast zijn 
er verbanden gevonden tussen de ziekte van Alzheimer en de ziekte van Parkinson en het gen 
dat OGDC codeert. In dit laatste hoofdstuk wordt de overvloed aan zowel genetische alsook 
aan structurele informatie die nu beschikbaar is gecombineerd om op deze manier een beter 
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inzicht te verkrijgen in het structurele grondvlak van de verstoorde fiinctie van de 2-oxozuur 
dehydrogenase complexen als gevolg van mutaties. De effecten van mutaties in de 
verschillende componenten van de humane complexen worden verklaard gebaseerd op hun 
vermoedelijke functie. 
Alhoewel dit proefschrift licht werpt op de bindingswijze van homodimeer Elp in het 
complex en op de structuur van dit enzym, blijven er vele vragen open met betrekking tot dit 
enzym. Bijvoorbeeld, de verschillen tussen homodimeer en heterotetrameer El; waarom heeft 
heterotetrameer El geen N-terminaal domein? We hebben, gebaseerd op sequentie 
vergelijkingen en homologie modellen, de hypothetische aminozuren in de 'active site' 
gei'dentificeerd, maar hun functie moet experimenteel geverifieerd worden; welke aminozuren 
vormen het lipoamide bindingkanaal; welke residuen binden ThDP en welke aminozuren 
binden pyruvaat, hetzij in een pre-katalytisch complex, hetzij in een katalytisch complex. 
Tenslotte hebben onze experimenten het bestaan van verschillende zeer flexibele gebieden in 
Elp aangetoond. Het verwijderen van deze gebieden zou een belangrijke stap kunnen zijn in 
de richting van het verkrijgen van geschikte eiwitkristallen. Uiteindelijk zou dit kunnen leiden 
tot het oplossen van de hoge resolutie structuur van een homodimeer El, wat weer hele 
nieuwe wegen zal openen in het onderzoek naar 2-oxozuur dehydrogenase complexen. 
Nawoord 
Eindelijk: Het is af!! 
Eigenlijk zegt dit genoeg, toch wil ik op deze plek iedereen bedanken die heeft bijgedragen 
aan het tot stand komen van dit proefschrift. 
Bedankt allemaal!! 
Een paar mensen wil ik speciaal noemen: Aart bedankt voor je interesse, begeleiding en steun 
in de afgelopen jaren. Adrie, kamer en labgenoot die altijd klaar stond om te helpen: 
ontzettend bedankt!! 
Prof. Veeger en Prof. Laane voor het mogelijk maken van mijn promotie. 
En dan natuurlijk alle labgenoten die door de jaren heen biochemie bevolkt hebben; het was 
altijd enorm gezellig. 
Petra, kom op meid nu jij nog!! 
Bart, je hebt van al die tekst een boekje gemaakt, dat hebben we mooi voor mekaar! 
Mam, zonder al het oppassen was het niet gelukt. 
Polleke en Loes, nu gaan we weer wat leuks doen.... 
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